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Epigenetics (epi- from the Greek word επί meaning “over” or “above”) refers to heritable 
meiotic and mitotic changes in gene expression that occur without a change in the DNA 
sequence. The best understood mechanisms that account for this form of expression 
regulation are DNA methylation and covalent modifications of histones. 
DNA methylation
DNA methylation is a covalent modification of the fifth carbon within the cytosine DNA 
base; the resulting base is often referred to as the ‘fifth base’ in the human genome (Figure 
1). In adult mammalian somatic cells, this modification occurs only on the cytosine in a 
CpG dinucleotide pair. The CpG notation is used to distinguish the linear sequence of 
a cytosine preceding a guanine bound by a phosphate from the complementary base 
pairing between a cytosine and guanine residue (Figure 2). The methylation of these CpGs 
is facilitated by the DNA methyltransferases DNMT1, DNMT3A and DNMT3B1-4. DNMT1 
resides at the replication fork and methylates CpG dinucleotides in the newly synthesized 
strand, making this enzyme essential for maintaining DNA methylation patterns in 
proliferating cells5-8. DNMT3A and DNMT3B are required for de novo methylation during 
embryonic development5-7.
Figure 1 - Chemical structure of a cytosine nucleotide and 5-methylcytosine.
Due to spontaneous de-amination in the germ-line during evolution, CpG dinucleotides 
are rare within the genome1. However, CpG dinucleotides are enriched in DNA stretches 
ranging from 500 bp to several kb, and these regions are called CpG islands (GCIs)1, 2, 
4. In contrast to the sparse CpG dinucleotides that occur throughout the genome, the 
majority of CGIs are hypomethylated. Approximately 60% of all genes contain a CGI within 
their promoter region that often expands to the first exon or intron and -regardless of 
the expression status of the associated geneare primarily unmethylated4. Although most 
CGIs reside in the 5’ regions of genes, a large proportion of CGIs are located in inter-genic 
regions. 
Hypermethylation of the promoter CGI is believed to down-regulate gene expression in 
two ways. First, DNA methylation may form a direct physical barrier against binding of 
the basic transcription complex or transcription enhancers (i.e., steric hindrance), thereby 
preventing downstream genes from being transcribed. Secondly, DNA methylation may 
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recruit methylation-specific proteins to the region, thus resulting in a cascade of silencing 
effects. Evidence for both hypotheses can be found in the literature9. CGI methylation is 
normally involved in allele-specific inactivation of imprinted genes and/or genes located 
on the inactive X chromosome, and aberrant CGI methylation has been found in numerous 
cancers2, 10, 11. 
Figure 2 - Chemical structure of a CpG dinucleotide. The phosphate group (the p in CpG) indicates a 
deoxyribose bond between both nucleotides and thereby the 5’-3’locations of the cytosine and guanine. This 
annotation is used to prevent confusion with the hydrogen bonds between cytosine and guanine bases in 
complementary strands of DNA.
Histone modifications and chromatin state
In eukaryotes, genomic DNA is packaged with histone proteins into nucleosomes. 
A nucleosome consists of an octamer of histone proteins -comprised of two H2A-H2B 
heterodimers and two H3-H4 heterotetramers- that wrap ~146 bp of DNA around itself in 
1.67 turns of a left-handed superhelix. Subsequently, these nucleosomes are themselves 
packed into chromatin, thus compacting DNA by approximately 10,000-fold. This ‘packing’ 
of two meters of DNA into a 1.7-µm cell nucleus is a considerable obstacle to replication, 
transcription and DNA repair complexes in reaching the DNA (Figure 3). To overcome this 
obstacle, dynamic changes in the chromatin state permit localized de-condensation from 
heterochromatin to euchromatin, thereby providing the nuclear machinery access to the 
DNA12-16. 
Condensed and de-condensed chromatin states coincide with a variety of post-
translational covalent modifications of the core histone amino termini. A large number 
of histone modifications have been reported, among which acetylation, methylation, 
phosphorylation and -to a lesser extent- ubiquitination are the best characterized12-17. 
For all modifications (with the exception of arginine methylation), enzymes exist to 
either attach or remove the histone modification. An overview of histone modifications 
is presented in Table 1. The complexity of histone modifications -and our increasing 
understanding of their consequences- have led to the ‘histone code’ hypothesis. According 
to this hypothesis, histone modifications provide a platform for the binding of chromatin-
associated regulators of gene expression12-16.
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Figure 3 - Schematic representation of the sequential packaging of human DNA in the nucleus (adapted from 
www.epitron.eu)
interaction between DNA methylation and histone modifications
Since epigenetic communication between DNA methylation and the chromatin state was 
initially described, the precise sequence of events that underlie this communication has 
been a subject of debate18. Currently, two progression models are considered to be plausible. 
The first model starts with initial DNA methylation that causes histone modifications via 
the recruitment of proteins that have methyl-DNA binding activity such as methyl-CpG-
binding protein 2 (MeCP2), methyl-CpG-binding domain protein 1 (MDB1) and Kaiso 
(also known as the Zinc finger and BTB domain containing protein 33, or ZBTB 33). The 
subsequent recruitment of histone methyltransferases (HMTs) and histone deacetylases 
(HDACs) attach and detach histone modifications that are associated with transcriptional 
silencing and activation, respectively19-25. Finally, DNA methylation can inhibit active 
histone modification H3K4 methylation (H3K4me)26, 27. 
Studies that support a model in which DNA methylation is initiated by histone modifications 
are increasing in number. These studies report that targets of the inactive histone 
modification H3K27me3 and the enrichment of polycomb group 2 (PRC2) proteins in both 
embryonic (ES) and adult stem cells are pre-marked for de novo methylation in cancer28-31. 
Additional functional insights allowed the linking of PCR2 proteins, the presence of the 
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inactive histone mark H3K27me3 and absence of H3K4me3 to the recruitment of DNMTs 
and subsequent DNA methylation (Figure 4)32-36. The aforementioned studies led to a 
developmental model in which the balance between binding the mediators of inactivating 
histone mark H3K27me3, PRC2 and the mediators of the activating histone mark H3K4me3, 
the trithorax-group proteins, determine the DNA methylation and expression states of the 
regions to which they bind (Figure 4)28-31, 37-40.
Although studies addressing this subject have not yielded conclusive evidence to support 
this model, they have revealed a high level of synergy between histone modifications and 
DNA methylation in regulating gene expression. Histone modifications are believed to act 
either sequentially or in combination with DNA methylation to generate the proposed 
histone code, which in turn conveys information to the nuclear machinery15.
Figure 4 - Model of epigenetic regulation of gene expression in differentiation and tumorigenesis. Three 
nucleosomes that are composed of an H3-H4 hetero-tetramer (blue), two H2A-H2B dimers (red), the DNA 
(black line) with CpG dinucleotides (open circles attached to the DNA) and a histone tail with H3K4 (purple 
circle) and H3K27 (green circle) methylation are represented. A loss of PCR2 (yellow crescent) association 
during differentiation results in the loss of repressive H3K27 methylation, thereby allowing the binding of 
transcriptional complexes (light brown). The disassociation of trx family proteins (red) results in the loss of H3K4 
methylation-mediated protection against DNMT (orange) recruitment. The remaining H3K27 methylation 
actively recruits the DNMT complexes, thereby resulting in methylation of the associated CpG dinucleotides 
(black circles attached to the DNA). The association of the trx or PCR2 complexes during differentiation can 
determine both the transcription of genes and downstream DNA methylation in somatic or cancer cells.
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table 1 - Histone modifications, locations and modifiers
Histone modification site enzyme Proposed function
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chromatin state, activity and nuclear position
As mentioned above, chromatin status coincides with specific histone modifications (and 
thus to DNA methylation). These modifications are believed to regulate chromatin density 
either directly or by providing a surface substrate for interactions with other proteins12, 
16, 41. Gene-rich and transcriptionally active regions can therefore be maintained as 
euchromatin, whereas gene-poor and transcriptionally inactive regions can be condensed 
to form heterochromatin.
Chromatin density -and thus transcriptional activity- is associated with specific 
interphase locations within the nucleus’ volume. Heterochromatin generally clusters into 
condensed chromocenters that are located in the vicinity of the nucleolus, whereas active 
euchromatin is located in the central region and nuclear border42. This organization is 
not random, as differences have been reported based on cell type, shape, quiescence, 
commitment, functional status or transformation43. The availability of euchromatin to 
the interchromatin compartment -a channel network that is connected to the nuclear 
pores- has been postulated to facilitate transcription by the nuclear machinery that is 
located within this interchromatin compartment44, 45. Chromatin domains that contain 
transcriptionally active genes form euchromatic chromatin loops that migrate from the 
chromocenters to -or into- the interchromatin compartment46-48. 
Because histone modifications determine transcriptional activity and chromatin 
condensation, a reciprocal impact on nuclear architecture would be expected. Cremer et 
al. studied the relation between histone methylation and nuclear location in breast cancer 
interphase nuclei and reported clustering of histone methylation in close proximity to 
the nucleoli and -to a lesser extent- in the nuclear periphery49. Studies that investigated 
the relation between nuclear location and specific histone modifications for active (i.e., 
H3K4me3, H4K20me1 and H4K20me3) and inactive (i.e., H3K9me1, H3K9me3 and H3K27me3) 
chromatin revealed that methylation patterns are arranged in distinct nuclear layers, with 
a certain degree of overlap that depends on the type of epigenetic modification50, 51.
Although the relations between gene activity, chromatic condensation and spatial 
location in the nucleus are less pronounced in quiescent cells than in proliferating cells, 
genomic loci that are found in the same chromosome territories during S phase are likely 
to be replicated at the same time and come into contact with the same chromatin factors 
following replication52. This provides a means to re-establish a given transcriptional and/
or spatial pattern of organization in the daughter cells, as the factors that mediate the 
chromatin state are proposed to act coordinately on newly replicated loci52. As such, 
subnuclear compartments may not be critical for immediate biological events but may 
provide a mechanism for an accurate heritable transmission of the chromatin state and 
transcription patterns52. 
lamina binding
A mechanism for anchoring chromatin to subnuclear compartments -and more specifically, 
to the nuclear envelope- occurs via binding of chromatin to the nuclear lamina (NL). The 
core of the NL consists of nucleus-specific, type V intermediate filament lamin proteins. 
These lamin proteins can be divided into A-type lamins, which are found predominately 
in differentiated cells, and B-type lamins, which are essential for cell viability52, 53. Stable 
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interactions between lamins and lamin-associated polypeptides (LAPs) are integral for 
both maintaining mechanical integrity of the nuclear envelope and providing anchor 
points for the aforementioned chromatin binding to the NL53, 54. The interaction between 
the NL and chromatin-associated proteins is mediated through LAPs, which bind to both 
the NL and to chromatin-associated proteins such as BAF, HP1 and Rb (see references 52, 
54, and 55 for an overview). 
Both genomic and proteomic experimental approaches have identified an association 
between the NL and heterochromatin. Although a putative role for the NL in the formation 
and/or maintenance of heterochromatin remains unclear, the NL is believed to anchor 
heterochromatin to the nuclear periphery, thereby providing structure and associated 
replication timing (Figure 5). A genetic approach to the study of B1-type lamin-associated 
DNA in human fibroblasts has identified 1,344 sharply defined DNA domains of 0.1-10 
Mb each56. These lamina-associated domains (LADs) are characterized by hallmarks of 
heterochromatin such as a low level of gene expression, low gene density, high levels of 
H3K27me3 and low levels of H3K4me2. Interestingly, these LADs are demarcated (Figure 5) by 
CpG islands, promoter regions driving transcription away from LADs and binding regions 
of the insulator protein CCCTC-binding factor (CTCF)56. 
Figure 5 – Model of chromatin binding to the nuclear lamina. Large chromatin domains (green line) are 
dynamically associated (depicted as black lines) with the nuclear lamina (dark blue) adjacent to the nuclear 
envelope (gray). The LAD regions are demarcated by putative insulator elements, including CTCF binding sites 
(light blue), CpG islands (pink) and promoters that are orientated away from the lamina (orange arrows)56. 
Adapted from de Wit et al.192.
the insulator protein ctcF
In vertebrates, CTCF is a ubiquitously expressed, 11-zinc finger protein that has been shown 
to bind to a larger number of binding sites in the genome; the number of binding sites 
ranges from 13,804 to 26,814 sites, depending on the cell type, technique and method of 
analysis57-61. This ‘Jack-of-all–trades’ protein has been implicated in diverse roles in gene 
regulation, including promoter activation/repression, enhancer blocking and/or barrier 
insulation, hormone-responsive silencing, genomic imprinting and -most recently- long-
range chromatin interactions62. In addition to the aforementioned correlation between 
LAD boundaries and CTCF, a recent genome-wide mapping study uncovered a significant 
proportion of CTCF binding sites that are localized to the boundaries between euchromatic 
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and heterochromatic domains that are marked by H2AK5Ac and H3K27me3, respectively61.
 The discovery of CTCF-mediated intra- and inter-chromosome loop formation at 
the IGF2/H1963, 64 and β-globin loci65, 66 gives insight into how CTCF might form loops of 
condensed chromatin. Although the variability of CTCF loop formation by either homo- or 
hetero-dimerization with one of the many suggested protein partners makes it difficult to 
portray CTCF in a universal model, the high number and high variation of CTCF binding 
sites throughout the genome suggest a key role for CTCF in nuclear architecture. It has 
been reported recently that CTCF binding sites are generally located in chromatin linker 
regions that are flanked by at least 20 symmetrically distributed nucleosomes, thus 
revealing both a genome-wide role for CTCF in nucleosome positioning and a link to the 
regulation of chromatin structure67. Among CTCF’s many protein partners, the recruitment 
of the Polycomb Repressor Complex 2 member Suz12 by DNA-bound CTCF is associated 
with the subsequent acquisition of H3K27me3, indicating that CTCF binding might initiate 
local heterochromatin formation68. 
Studies of CTCF binding to the imprinting control region of IGF2/H19 have shown that 
CTCF binding is DNA methylation sensitive69, 70. Additionally, methylation of a single 
CpG dinucleotide within the CTCF consensus sequence of the chicken β-globin gene is 
sufficient to block CTCF binding. This finding has led to the classification of CTCF binding 
sites into the following three groups: sites without CpG dinucleotides, sites that contain 
DNA methylation and unmethylated sites. A small-scale comparison between pre-B and 
thymocyte cell lines found that sites with unchanged CTCF occupancy are generally 
unmethylated, whereas sites that display differential binding between lineages may 
acquire CpG methylation69, 71. Not only does the binding of CTCF appear to be DNA 
methylation sensitive, but the recruitment and activation of the DNMT1 inhibitor PARP-1 
by DNA-bound CTCF seem to indicate a protective function against methylation of CTCF 
binding sites that contain CpG dinucleotides72, 73. Interestingly, a specific subset of CTCF 
remains associated with chromosomes during mitosis, suggesting a possible role in the 
maintenance of epigenetic marks throughout cell division74, 75. Together with its insulator 
function, the protection of CTCF’s own binding sites throughout cell division could 
link epigenetic transcriptional regulation and nuclear architecture and could explain 
epigenetic heritability through cell division in differentiated cells. Naturally occurring 
DNA sequence variations can also influence CTCF binding. For example, a polymorphism 
in a CTCF binding site downstream of MMP-7 that leads to differential CTCF binding is a 
possible genetic factor in breast cancer76.   
DNA methylation in cancer
Aberrant methylation of CpG dinucleotides is commonly seen in cancer and -shown by 
studies of this phenomenon- is recognized as an important step in tumorigenesis4, 77. In 
carcinomas, hypomethylation of the genome is accompanied by regional hypermethylation 
of CGIs compared to the normal epithelium cells from which they arise2, 4, 77. Global 
hypomethylation has been linked to both genomic instability and increasing mutation 
rates, whereas hypermethylation of promoter CGIs can lead to transcriptional inactivation 
of the associated gene78, 79. This aberrant CGI hypermethylation is accompanied by the 
recruitment of methyl-CpG binding domain (MBD) proteins and histone deacetylases 
(HDACs) and is associated with histone modifications that are associated with expressional 
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down-regulation80. In various types of cancers, promoter hypermethylation of tumor 
suppressor genes (TSGs) such as p16INK4a81-83, MLH184-87, BRCA188, 89 and Rb90 have been 
described. 
Hypermethylation of CGIs in tumors is part of a cascade that can lead to the down-
regulation of expression through changes in the histone code and possibly even via the 
nuclear location of the associated DNA. Due to the robust nature of DNA methylation, 
changes in the DNA methylome can be detected using various techniques, and there 
exists a huge potential for the use of DNA methylation as a diagnostic and/or prognostic 
marker91. Additionally, the identification of aberrancies in epigenetic regulation might 
provide new insights into tumorigenesis and perhaps pave the way for the development 
and application of new cancer treatments that reverse DNA methylation.
The initiation of cancer-related DNA methylation has been a focus for researchers since it 
was first discovered. The aforementioned complex interplay between DNA methylation 
with histone modifications and their mediators yields a large group of epigenetic machinery 
proteins that can play a role in epigenetic tumorigenesis. A complete understanding of 
the initiation and impact of DNA methylation in tumorigenesis is needed to distinguish 
between randomly accumulated DNA methylation and the methylation of targets that are 
important in the development of cancer.
colorectal cancer: clinical context
Colorectal cancer (CRC) is the third and second most common type of cancer in males and 
females, respectively, and one of the leading causes of cancer-related deaths in both Europe 
and the US92, 93. In the Netherlands, the lifetime risk for developing CRC is 6% (an incidence 
of approximately one in 17) among both genders. In recent years, the number of new CRC 
cases and associated deaths has seemingly decreased in developed countries, and this is 
possibly due to improved screening methods and early diagnosis92, 93. However, in Japan 
and other developing countries, the incidence of CRC is increasing, and this is believed to 
reflect a combination of factors that are related to a Western lifestyle, including changes 
in dietary patterns, obesity and an increased prevalence of smoking92-96. Worldwide, it is 
estimated that approximately one million new cases are diagnosed annually92, 93, 96. Over 
95% of colorectal cancers are adenocarcinomas, and approximately half of these patients 
develop a local recurrence or a distant metastasis during the course of the disease. Survival 
depends greatly on early detection, particularly before the tumor has metastasized97. The 
five-year survival rate ranges from 93.2 to 82.5% for the early stages in which no lymph 
node metastasis has occurred yet98. In cases of lymph node metastasis (stage III; see www.
UICC.org) or distant metastasis (stage IV), the survival rates are 59.5 and 8.1%, respectively. 
Stage III and stage IV tumors are typically treated with chemotherapy consisting of 
5-fluorouracil compounds either with or without oxaliplatin or irinotecan97, 99. In recent 
years, insights into the molecular pathogenesis of colorectal cancer have led to the use 
of targeted therapeutics that are specific for the epidermal growth factor receptor (EGFR) 
and vascular endothelial growth factor (VEGF)97, 99. Although the success of these therapies 
in CRC is limited, these examples illustrate how molecular biological research contributes 
to the development of promising new therapies.
19







The accumulation of genetic and epigenetic changes results in the progressive 
transformation of normal colon epithelium to hyperplasia, dysplasia and eventually 
adenocarcinoma. This stepwise progression of tumorigenesis in colorectal cancer 
has served as an example of other types of tumors. The recently updated yet classic 
Vogelgram100 shows that colorectal neoplasias can be characterized based on molecular 
features. The predilection for specific molecular alterations at different sites in the colon is 
remarkable. Right-sided (proximal) and left-sided (distal) CRC100-103 can be seen grossly as 
the following two classic and distinct genetic pathways (Figure 6): tumors with high levels 
of chromosomal instability (CIN) or microsatellite instability (MSI or MSI high/MSI-H). The 
CIN pathway (which comprises 50-70% of sporadic colon cancers) is characterized by a 
change in chromosomal copy number such as a chromosomal gain, loss or a copy-neutral 
loss of heterozygosity (cnLOH)104. Tumors that arise via this pathway are often located in 
the left-sided colon (i.e., distal to the splenic flexure) and are often aneuploid. Although 
these CIN colon tumors progress through the adenoma-carcinoma progression pathway, 
the facilitating mechanism is not completely understood. Specific mutations in genes 
that are involved in mitotic spindle checkpoints and DNA replication checkpoints (e.g., 
hBUB1 and hBUBR1) have been proposed to underlie CIN, and self-propagating genomic 
instability can occur in the absence of genetic mutations104-108. To date, no data have been 
provided compelling evidence that mutations in any of these genes provide more than a 
permissive role for CIN, despite the tight association between CIN and mutant APC and 
p53106. 
Tumors that arise via the MSI pathway (comprising ~15% of sporadic colon cancers) are 
typically diploid, right-sided (i.e., before the splenic flexure) and carry small deletions and/
or insertions in short repetitive sequences (An or CAn, where n is the number of repeats) as 
a result of a loss of function of any of the DNA mismatch repair (MMR) genes106. In colon 
cancer, MSI is found in the context of Lynch syndrome (previously known as hereditary 
non-polyposis colorectal cancer, or HNPCC) with germline mutations in one of four MMR 
genes, primarily in MLH1 or MSH2109 and -to a lesser extent- in MSH6110 or PMS2111. Deletions 
in EPCAM/TACSTD1, which is upstream of MSH2, cause sequential MSH2 methylation112, 113. 
Although rare, several studies have described inherited and de novo germline methylation 
of MLH1 in patients with Lynch-like colon cancer114-120. Approximately 15% of all sporadic 
colon cancers are due to somatic biallelic or hemiallelic methylation of the MLH1 
promoter121. 
A growing understanding of the impact and level of promoter, inter- and intra-gene CGI 
methylation that is described as aberrantly methylated in MSI colon cancer has led to 
the classification of colon cancers into the following CpG island methylator phenotypes 
(CIMP), regardless of MSI status: CIMP1 (CIMP-high), CIMP2 (CIMP-low) and CIMP0 (CIMP-
negative)4, 122-124. Although the definition of CIMP has been debated in the literature, an 
integrated genetic and epigenetic analysis provided definitions for each of these three 
phenotypes124. The phenotype with the highest frequency of aberrant methylation, 
CIMP1, is associated with sporadic MSI, somatic BRAF mutations and the methylation of 
a debated set of methylation markers. The methylation status of the second phenotype, 
CIMP2, has also been the subject of debate. Methylation has been found among cancers 
in this group, albeit to a lesser extent than among CIMP1 tumors. Although methylation 
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markers have been suggested for both groups, indecisiveness regarding a defined marker 
set has led to MLH1 methylation (and thereby sporadic MSI) and BRAF mutations as being 
the best indicators for CIMP1, whereas KRAS and TP53 mutations are often found in CIMP2 
and CIMP0 tumors, respectively122-126.
Figure 6 – A model of the CIN and MSI tumorigenesis pathways
the cause of aberrant DNA methylation in crc
The underlying causes of aberrant methylation and subsequent sporadic MSI colon 
cancer remain largely unknown. Both BRAF and KRAS mutations have been observed in 
the earliest identified colonic neoplasms, and recent studies have provided evidence that 
induction of the ras oncogenic pathway results in DNA hypermethylation127-132. Although 
activating KRAS and BRAF mutations are present in early colonic neoplasia, they give rise 
to different types of polyps. KRAS mutations are primarily found in adenomatous polyps, 
whereas BRAF mutations occur primarily in polyps that have a serrated architecture and 
have been suggested as precursor lesions for MSI carcinomas129, 130, 132-135. In early neoplasia, 
BRAF mutation was are associated with CIMP, which has been suggested to precede MSI by 
MLH1 promoter methylation128-130, 132, 136. This association of BRAF mutations with sporadic 
MSI colon cancer, their precursor lesions and CIMP (in contrast to KRAS mutations) 
suggests that the two mutations (BRAF and KRAS) follow distinct tumorigenesis pathways 
despite being members of the same signaling pathway128, 130, 132, 136.
Although KRAS and BRAF mutations are observed in early colonic neoplasia, the 
sequence of events regarding DNA methylation remains unclear. Promoter methylation 
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of O6-methylguanine DNA methyltransferase (MGMT) often occurs in many tumor types, 
including colon cancer137-139. Additionally, epigenetic down-regulation of MGMT expression 
is often seen in tumor-adjacent normal colon mucosa140. MGMT is a DNA base excision 
repair protein that removes mutagenic and cytotoxic adducts from the O6 position of 
guanine. O6-methylguanide often mispairs with thymine during replication, resulting in 
the conversion from a GC pair to an AT pair if the adduct is not removed. Inactivation 
of the MGMT gene via promoter hypermethylation can result in G-to-A transitions in the 
mutational hotspots within codons 12 and 13 of the KRAS oncogene, as well as in TP53137, 
139, 140. Therefore, methylation of the MGMT promoter might initiate tumor progression 
through secondary KRAS and/or TP53 mutations, a theory that might argue against the 
initiation of aberrant DNA methylation via the occurrence of activating KRAS mutations. 
Although BRAF mutations cannot be explained by MGMT inactivation, methylation of the 
IGFBP7 promoter has been shown to facilitate the oncogenic potency of activated BRAF. 
Active IGFBP7 is required for oncogene-induced cellular senescence (OIS), an important 
tumor suppressor mechanism141-143. Escaping the OIS pathway could favor selection for 
activating BRAF mutations. The accumulation of aberrant promoter hypermethylation 
might provide a favorable environment for the oncogenicity of mutated BRAF, which 
could explain the association between BRAF mutations and CIMP. However, the association 
between BRAF mutations and MSI remains a molecular puzzle. More research is needed to 
determine the initiating factor and the role of MLH1 methylation in this model.
MLL-rearranged B-lineage leukemia
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children under 
the age of 15 and accounts for 26.8% of all childhood cancers144, 145. This lymphoid leukemia 
can be divided into B and T cell leukemia depending on the cancer cell lineage. Over past 
few decades, treatment with a combination of chemotherapies has led to a considerable 
decrease in childhood cancer-related deaths and a 5-year survival rate that is currently 
between 78 and 83% in developed countries144, 145.
However, upon age stratification of childhood ALL, a subgroup of infants who are younger 
than one year of age at diagnosis only attains a 5-year survival rate of approximately 
50%146, 147. Although complete remission is achieved in most of these patients, a high 
relapse rate is the principal cause of this decrease in survival odds146, 147. Approximately 
80% of infants with ALL carry chromosomal translocations that involve the mixed 
lineage leukemia (MLL) gene and typically exhibit an immature CD10-negative precursor 
B-lineage immunophenotype146-148. Within this infant ALL subgroup, the presence of 
MLL rearrangements and an age of younger than six months are described as the most 
important factors for predicting poor outcome146, 147. 
The most prevalent chromosomal translocations in infant ALL patients are t(4;11), t(11;19) 
and t(9;11), which fuse the N terminus of MLL to the C-terminal regions of AF4, ENL and 
AF9146, 149. Interestingly, these different translocations are characterized by distinct mRNA 
levels150, 151 and DNA methylation patterns152. Genome-wide studies of DNA methylation 
levels as well as studies into the functions of MLL and fusion partner proteins have 
indicated that epigenetic changes play a major role in MLL-rearranged ALL and might be 
the driving force behind the expression differences between the translocation-stratified 
groups and control samples.
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Chapter 1
the normal function of mll
The human MLL gene was discovered in the early 1990s by isolating the chromosomal 
breakpoints at chromosome 11q, cytoband 23153-156. A sequence comparison revealed 
three regions of sequence similarity with the Drosophila melanogaster gene trithorax 
(trx); thus, both are members of the trithorax group, an evolutionarily conserved family 
of proteins157. Similar to the function of trx in Drosophila, in mammals MLL acts as a 
transcriptional regulator of the class I homeodomain (Hox) genes and counters the 
repressive effects of the Polycomb group (PcG) proteins (Figure 4)158-161. The Hox genes, in 
turn, are transcription factors that direct cell fate during development. MLL is ubiquitously 
expressed both during development and in most adult tissues, including myeloid and 
lymphoid cells, and is required for definitive hematopoiesis162-164. In both Mll-/- mice and trx-
/- flies, Hox gene expression is initiated correctly but deteriorates during embryogenesis, 
suggesting an essential role in maintaining expression patterns following initiation by 
other factors157. 
Identification of the different active domains of the large (3,968 amino acids) MLL 
protein has provided much insight into how MLL-mediated transcriptional regulation 
is facilitated (Figure 7). The MLL protein is cleaved by the protease taspase I into 320-
kDa N-terminal and 180-kDa C-terminal fragments, both of which are core components 
of the MLL complex165-168. Two N-terminal domains -a region of three AT-hook domains 
and a region containing a CXXC zinc-finger domain- are believed to be involved in DNA 
binding169-172. The AT hook domain is a minor groove DNA binding motif that preferentially 
recognizes DNA that is distorted with bends or kinks, whereas the CXXC domain is the 
major determinant of subnuclear localization and target gene selection and recognizes 
and binds specifically to unmethylated CpG dinucleotides173-175. Although MLL can bind 
directly to DNA, MLL recruitment to chromatin can be mediated by DNA-binding protein 
partners such as menin (encoded by the MEN1 gene)176. In addition to the CXXC, another 
domain targets MLL to sites that are associated with active chromatin. A central region 
between the third and fourth fingers contains three cysteine-rich plant homeodomain 
(PHD) zinc fingers and a fourth divergent PHD finger. This bromodomain has been shown 
to bind lysine-acetylated histone-derived peptides, thus suggesting preferential binding 
to acetylated histones by MLL170, 172, 177-179. 
Although the MLL protein has been associated with proteins that suppress gene expression, 
the recruitment of MLL to chromatin is most often associated with transcriptional 
activation. Both of the activating domains -namely, the transcription activation (TA) 
domain and the SET [Su(var)3-9, enhancer of zeste, and trithorax] domain- are located 
on the protein’s C terminus169-171. The activating functions of both of these domains are 
mediated through epigenetics; the SET domain is directly responsible for methylating 
H3K4, and the TA domain recruits the histone acetyltransferases CREB-binding protein 
(CBP) and p300180-183.
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Figure 7 – Schematic representation of the MLL protein. The 89-kb MLL gene consists of 37 exons and encodes 
a 3,969-amino acid nuclear protein. MLL is cleaved at two cleavage sites (CS1 at amino acid 2666 and CS2 
at amino acid 2718), resulting in two non-covalently associated subunits (N-terminal MLL (300 kDa) and 
C-terminal MLL (180 kDa)). The DNA-interacting domains (AT-hooks and the DNA methyltransferase homology 
domain (DMT) containing the zinc finger) are located in the N-terminal cleavage fragment. The PHD zinc-finger 
motifs facilitate the binding of proteins that are suggested to regulate MLL protein activity. This domain can be 
either present in an MLL fusion protein or completely absent, depending on the precise site of translocation 
in the breakpoint cluster region (BCR) spanning exons 8-13. Located on the C-terminal MLL domains are the 
transcriptional activation site (TA) and the SET domain (SET), both of which are involved in transferring marks 
of transcriptional activation to histone tails. The C-terminal parts of the fusion partners are shown beneath the 
MLL protein.
mll fusion proteins: what do they add?
Given that MLL functions as an epigenetic transcriptional activator, a disruption in 
normal MLL function can be linked directly to the differences found in expression and 
DNA methylation between MLL-rearranged ALL groups and controls. All of the MLL 
rearrangements that have been found in ALL are believed to arise from a failure of DNA 
double-strand break repair during hematopoiesis. Most of the MLL rearrangements target 
the breakpoint cluster region that is located between exons 8 and 13, resulting in a fusion 
protein that contains N-terminal MLL and the C terminus of a fusion partner184, 185. Mouse 
studies have revealed that a truncation of MLL after exon 8 is not sufficient to induce 
leukemia but requires a functional C-terminal portion of a fusion protein186. The perturbed 
H3K4 methylation of one MLL copy is therefore not sufficient to initiate leukemogenesis. 
The aforementioned translocations with fusion partners AF4, AF9 or ENL account for more 
than 80% of all MLL-rearranged leukemias, and all three resulting fusion partners contain a 
C-terminal transcriptional activation domain. These activation domains are associated with 
the H3K79 histone methyltransferase DOT1L187-191. H3K79 methylation levels are increased 
in targets that are crucial for MLL-rearranged leukemogenesis187-191. Given that the various 
methylation marks regulate transcription in unique ways12, 14-16, 41, the addition of H3K79 
methylation to normal H3K4 methylation at MLL-associated promoters could account for 
the aberrant over-expression and DNA methylation differences in MLL-rearranged leukemia. 
However, the high levels of DNA hypermethylation observed in patients with MLL-AF4 and 
MLL-ENL translocations cannot currently be explained with the current understanding of 
MLL rearrangements in infant B-ALL. 
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Chapter 1
scoPe AND oUtliNe oF tHis tHesis
Tumor formation is the result of either DNA mutations in the genetic code, of chromosomal 
alterations or of epigenetic changes, the latter with DNA hyper- and hypomethylation. 
DNA mutations comprise base substitutions (point mutations) as well as relatively small 
insertions and deletions. Chromosomal alterations can occur as copy number variations, 
translocations and inversion of chromosomes. Often these alterations occur in parallel to 
ploidy changes of the whole genome of the cells. 
Epigenetics, comprising DNA and histone modifications, is a relatively new field of study 
and recent technical possibilities have fuelled a growing interest in the role of epigenetics 
in tumorigenesis. Although the causes and effects of DNA hyper- and hypo-methylation in 
cancer are still being investigated, cancer-specific methylation profiles can be potentially 
used for clinical purposes such as pre-symptomatic screening for colorectal cancer in 
serum and faeces. In this thesis DNA methylation was studied in colon cancer and infant 
acute lymphoblastic leukemia. 
In chapter 1 an introduction is given on this topic. In chapter 2, using the differential 
methylation hybridization (DMH) technique, home-spotted CpG island microarrays were 
employed on right-sided colon cancer samples and compared with normal colon mucosa. 
High frequent methylation of the PTPRGint1 sequence different types of colon cancer was 
seen. The PTPRGint1 sequence turned out to be a binding site for CTCF, a protein that is 
involved in regulation of chromatin modifications. In chapter 3 a relatively young cohort 
of colon cancer patients with MLH1 promoter hypermethylation was studied. Interestingly, 
this epigenetic down-regulation of MLH1 is mostly seen in elderly colon cancer patients 
above 70 years of age. In chapter 4 we used the DMH technique in combination with a 
high density oligonucleotide CpG island microarray to obtain methylation profiles of colon 
cancer samples and matching normal colonic mucosa. As DNA methylation is suggested to 
be a consequence of pre-existing histone modifications we filtered BRAF mutation-specific 
methylation profiles for such pre-marking and identified promoter methylation of FOX 
genes involved in oncogene induced senescence.  
Finally, the CpG Island microarrays were employed to study cancer-specific DNA methylation 
in MLL-rearranged B-ALL (chapter 5). Infant ALL-specific as well as MLL-translocation-
specific promoter methylation patterns were identified. These promoter methylation 
patterns correlated strongly with expression and outcome.
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tUmoUr-sPeciFic metHylAtioN oF PTPRG iNtroN 
1 locUs iN sPorADic AND lyNcH syNDrome 
colorectAl cANcer
Abstract
DNA methylation is a hallmark in a subset of right-sided colorectal cancers. Methylation-
based screening may improve prevention and survival rate for this type of cancer, which 
is often clinically asymptomatic in the early stages. We aimed to discover prognostic or 
diagnostic biomarkers for colon cancer by comparing DNA methylation profiles of right-
sided colon tumours and paired normal colon mucosa using an 8.5k CpG island microarray. 
We identified a diagnostic CpG-rich region, located in the first intron of the PTPRG gene, with 
altered methylation already in the adenoma stage, i.e. prior to the carcinoma transition. 
Validation of this region in an additional cohort of 103 sporadic colorectal tumours and 
58 paired normal mucosa tissue samples showed 94% sensitivity and 96% specificity. 
Interestingly, comparable results were obtained when screening a cohort of Lynch 
syndrome-associated cancers. Functional studies showed that PTPRG intron 1 methylation 
did not directly affect PTPRG expression, however, the methylated region overlapped with 
a binding site of the insulator protein CTCF. Chromatin immunoprecipitation (ChIP) showed 
that methylation of the locus was associated with absence of CTCF binding. Methylation-
associated changes in CTCF binding to PTPRG intron 1 could have implications on tumour 
gene expression by enhancer blocking, chromosome loop formation or abrogation of its 
insulator function. The high sensitivity and specificity for the PTPRG intron 1 methylation in 
both sporadic and hereditary colon cancers support biomarker potential for early detection 
of colon cancer. 
introduction
DNA methylation is a common mechanism in colorectal tumorigenesis1, 2. Over the last 
decade, several genome-wide array-based methods have been developed, allowing the 
discovery of novel tumour-specific methylated loci. Enzymatic (HELP3, MMASS4, DMH5, 
CHARM6) and ChIP methods7 are most commonly used for genome-wide screening of 
DNA methylation, in combination with CpG island or promoter microarrays. An alternative 
genome-wide approach to identify genes silenced by DNA methylation detects expression 
differences in cell lines treated with DNA demethylating agents8, 9. More recently, captured 
methylated DNA10 and bisulphite-converted reduced representations11 are analyzed by 
high-throughput sequencing strategies. The unbiased approaches have indicated that 
transcription regulation associated with CpG methylation is not restricted to promoter 
CpG islands12, 13. Conserved regions up to 2kb distant from the promoter, annotated as CpG 
island shores12, and promoter CpG islands of lesser density, annotated as intermediate-CpG 
islands13, undergo cancer-specific methylation more often than traditional promoter CpG 
islands. The methylation status of these regions is strongly related to gene expression and 
might have been underestimated in previous studies. 
The aim of this study was to discover novel tumour-specific DNA methylation markers 
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in right-sided colon cancer. These tumours have a higher frequency of the CpG island 
methylator phenotype (CIMP). Additionally, right-sided tumours are often clinically 
asymptomatic at early stages, thus, patients would greatly benefit from a reliable screening 
method. We employed differential methylation hybridization (DMH) combined with a 
8.5k CpG clone library microarray for the initial identification of differential methylation 
in a cohort of colon cancers14. This library is enriched for CG-rich areas throughout the 
genome, encompassing promoter CpG islands as well as CpG-rich island shores and 
intermediate-CpG islands15. We report tumour-specific methylation of the first intron of 
the receptor protein-tyrosine phosphatase gamma gene (PTPRG), in both sporadic and 
Lynch syndrome colorectal cancers. Additionally we demonstrate that methylation of this 
region affects its binding to the CCCTC-binding factor (zinc finger protein, CTCF).
materials and methods
Tissue
Anonymized samples were obtained from patients who underwent surgery between 
1988 and 2006 at the Leiden University Medical Center (Leiden, The Netherlands) or 
at the Rijnland Hospital (Leiderdorp, The Netherlands). Tumour sections were micro-
dissected to minimize normal epithelium and stromal cells. DNA was isolated from fresh-
frozen tissue using a previously described method16, and from formalin-fixed paraffin-
embedded (FFPE) tissue using the Wizard Genomic DNA Purification kit (Promega, 
Madison, WI, USA). We used available normal mucosa from the same individuals as control 
to correct for age-dependent methylation. Age, location and microsatellite instability 
(MSI) status for the sporadic tumours are listed in Supplementary Table S1, and for the 
Lynch syndrome-associated tumours in Supplementary Table S2. The colorectal cancer 
cell lines SW48, RKO, SW480, Caco2, SW837, and LS411 were obtained from the American 
Type Culture Collection (Manassas, VA, USA). DNA was isolated from these cell lines as 
described previously16. RNA was isolated using TRIZOL (Invitrogen, Carlsbad, CA, USA) and 
subsequently purified with Qiagen RNeasy columns combined with the RNase-free DNase 
kit (Qiagen Sciences, Germantown, MD, USA). The present study was approved by the 
Medical Ethics committee of the LUMC (protocol P01-019). Cases were analyzed following 
the medical ethical guidelines described in the Code Proper Secondary Use of Human 
Tissue established by the Dutch Federation of Medical Sciences.
CpG island microarrays
CpG island clone inserts (8544) were amplified using vector-based primers as described 
previously14, 17. The CpG island clone library was originally generated by the Sanger Centre 
from affinity-purified in vitro methylated DNA fragments15. Clone sequence information 
was downloaded from the Toronto Microarray Facility. PCR products were spotted onto 
CodeLink (GE Healthcare, Munich, Germany) slides using an OmniGrid arrayer (Genomic 
Solutions, Ann Arbor, MI, USA) at the Leiden Genome Technology Center (www.lgtc.nl) as 
described18.
Differential methylation hybridization
DMH was performed according to Yan et al.14. Cy5-labeled amplicons, representing 
methylated DNA fragments derived from tumours and paired normal mucosa samples, 
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were co-hybridized to the CpG island microarrays with a Cy3-labeled common reference 
amplicon consisting of a pool of DNA from the six colorectal cancer cell lines described 
above. Detection was done on a G2565BA scanner (Agilent Technologies, Santa Clara, CA, 
USA) and image analysis using GenePix6.0 (Molecular Devices, Union City, CA, USA). Pre-
processing, including normalization, was performed using the GenePix error model in 
Rosetta Resolver version 5.0 (Rosetta Biosoftware, Seattle, WA, USA). Microarray data for 
the tumour and normal samples were compared using an error-weighted ANOVA model 
and corrected for multiple testing19 in Rosetta Resolver. Microarray data are available on 
Gene Expression Omnibus with accession number GSE21181.
Bisulphite sequence analysis (BSA)
DNA samples (500 ng) were converted using the EZ DNA methylation Gold bisulphite kit 
(Zymo Research). Primers (Supplementary Table S3) for BSA of ten CpGs in the PTPRGint1 
locus (Supplementary Figure S1) were designed using MethPrimer.20 Amplification was 
carried out in a DNA Engine Dyad Peltier Thermal Cycler (Bio-Rad, Hercules, CA, USA) using 
AmpliTaq Gold PCR buffer and enzyme (Applied Biosystems, Foster City, USA). For the direct 
BSA, PCR products were sequenced using the right primer, resulting in nine interpretable 
CpGs (CpG2-10). For additional clonal BSA, PTPRGint1 PCR fragments were cloned into 
TOP10 E. coli bacteria using a TOPO TA cloning kit (Invitrogen, Carlsbad, CA, USA). Sequence 
alignment analysis was performed using ClustalW21 and BioEdit.22 CpG dinucleotides in the 
direct BSA were scored as being methylated when the ratio of the cytosine/thymine peaks 
was above 0.4. The BiQ analyzer software was used for visualization.23
MS-MLPA assay
Custom MS-MLPA probes (Supplementary Table S3) for the PTPRGint1 locus were designed 
in Primer324 and included the HhaI site in CpG9 (see Figure 1B). As a control we used a 
BRCA2 probe set from the SALSA MS-MLPA KIT ME001B Tumour suppressor-1 kit (MRC-
Holland, Amsterdam, The Netherlands). Fragment analysis was performed on an ABI 3130 
(Applied Biosystems, Foster City, US). The MS-MPLA was performed as described using 50 
ng of genomic DNA25. A negative, unmethylated control (human semen DNA) and a 100% 
methylated DNA control (CpGenome Universal methylated DNA, Chemicon, Millipore, 
Billerica, MA, USA), were included in every experiment to asses HhaI cleavage and PCR. 
Fragment analysis was performed in GeneMapper (Applied Biosystems). PTPRGint1 peak 
heights were normalized by comparison with the BRCA2 peak height from the same run. 
Subsequently, the PTPRGint1/BRCA2 ratio from the digested reaction was divided by the 
PTPRGint1/BRCA2 ratio from the undigested reaction resulting in one ratio per sample that 
represented the fraction of methylated CpG9. Ten independent measurements provided 
a ratio distribution for unmethylated (mean 0.108, sd 0.037) and fully methylated (mean 
0.833, sd 0.148) control DNA. Samples were typed as being unmethylated or methylated 
when they were within three standard deviations of the mean of the unmethylated and 
methylated reference samples, respectively. Samples with ratios in between these standard 
deviation boundaries were scored as partially methylated. For specificity and sensitivity 
calculations, partially methylated samples were considered methylated. Determination of 
specificity between normal and tumour tissue was performed by a Chi-square test. 
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Real-time RT-PCR
cDNA was generated using the random primer protocol from the Transcriptor First Strand 
cDNA Synthesis Kit (Roche Applied Science, Indianapolis, IN, USA) using 1 µg of RNA. 
Intron-spanning primers (Supplementary Table S3) were designed to target exon 1 and 
2 of the main PTPRG transcript in Primer324. Reactions were performed in duplicate on a 
Light Cycler 480 (Roche Applied Science) using IQ SYBR Green SuperMix (Biorad). High 
resolution melting curve analysis was performed to check primer specificity. Reactions 
with more than one peak in the melting curve were discarded, as were samples where 
the standard deviation between technical replicates was above one Ct value. A standard 
curve was generated using five 1:10 dilutions of pooled cDNA from colon cancer cell lines 
(SW48, RKO, SW480, Caco2, SW837, and LS411), showing an efficiency of 100%. The Ct 
values that were used for analysis were between 23 and 33. Relative mRNA concentrations 
were calculated from this standard curve. Stably expressed control genes for normalization 
were selected with the GeNorm applet; the two most stably expressed genes were used 
for normalization of each tumour cDNA (CPSF6 and EEF1)26.
CTCF ChIP and quantitative PCR
The primary colon cancer cell line KP7038t, established at the Department of Pathology 
at the LUMC, was grown in GIBCO RPMI 1640 with glutamax (Invitrogen, Carlsbad, CA, 
USA), 10% foetal calf serum, and penicillin/streptomycin (50µg/ml). Tumour-associated 
fibroblasts (KP7038f ), collected from the primary tumour, as well as cell lines RKO and 
SW480 were grown under identical conditions. Cells at approximately 80% confluency 
were fixed with 1% formaldehyde for 10 minutes at room temperature. The formaldehyde 
was quenched with glycine (0.125 M) and the cells were harvested by scraping. Chromatin 
immunoprecipitations were performed using the SimpleChIP Enzymatic Chromatin IP kit 
(Cell Signaling Technology, Danvers, MA, US) with 10 µl anti-CTCF antibody (D31H2 XP; Cell 
Signaling Technology). Normal colon mucosa was collected from a patient who underwent 
a colon colonoscopy unrelated to colon cancer. Twenty 50µm sections, cut from macro-
dissected frozen tissue, were fixed in PBS with 1% formaldehyde. After quenching, the 
tissue was micro-dissected and processed for ChIP followed by duplicate PCR reactions 
as above. Primers (Supplementary Table S3) targeting control regions were selected from 
Kim et al.27. The Ct values that were used for analysis were between 25 and 40. Standard 
curves were generated using four consecutive 1:5 dilutions of input DNA for both cultures 
(non-immunoprecipitated, cross-linked DNA) to determine relative DNA concentrations. 
For comparison between pull-downs, relative DNA concentrations of the CTCF and IgG 
antibody pull-downs were normalized with the corresponding relative concentration 




Locus PTPRGint1 is methylated in colorectal adenomas and carcinomas
Methylation profile comparison by ANOVA of 15 carcinomas, three adenomas and eight 
paired normal mucosa samples identified 20 differentially methylated loci for the three 
tissue groups (false discovery rate < 0.01%). For all but one of these loci methylation in the 
adenomas was comparable to the normal samples while carcinomas showed increased 
methylation (Figure 1A). The most significant CpG island clone was 47B02 that showed 
increased methylation in both adenomas and carcinomas compared to normal mucosa. 
Therefore, we performed validation experiments for the corresponding locus, which 
mapped to the first intron of the PTPRG gene (chr3: 61524993-61525363, UCSC assembly: 
March 2006, see Supplementary Figure S1), referred to as PTPRGint1. 
Analysis at single CpG resolution using direct BSA showed that 17 out of 18 tumour samples 
were fully methylated in the PTPRGint1 region, while one carcinoma was unmethylated 
for CpG dinucleotides 8-10 (Figure 1B, bottom panel). In contrast, normal colon samples 
were mostly unmethylated (Figure 1B, upper panel). CpGs 7-10 were most informative 
to distinguish between tumour and normal in this set of samples. These results were 
confirmed at the single chromosome level using clonal BSA (Supplementary Figure S2). In 
summary, the microarray-based finding of differential PTPRGint1 methylation in right-sided 
tumours was confirmed, and extended to left-sided adenomas and carcinomas.
      
Figure 1- Identification and validation of the differentially methylated locus PTPRGint1. (A) Trend plot of the 
top-20 differentially methylated microarray clones (FDR ≤ 0.01%) showing the average log10 ratios in the 
normal, adenoma and carcinoma samples compared to the colorectal cancer cell line reference panel. Clone 
47B02, corresponding to PTPRGint1, had a similarly increased log ratio in adenomas and carcinomas compared 
to normals (red solid line). (B) BiQ summary of direct BSA of PTPRGint1 (CpG dinucleotides 1-10) in paired 
normal colon mucosa (n=19, upper panel) and colon tumours (n = 18, 12 right- and left-sided carcinomas and 6 
adenomas, lower panel) showed highest specificity and sensitivity in the four most 3’ CpGs measured. Each box 
corresponds to one CpG position in the genomic sequence, while colours summarize the methylation states of 
all sequenced samples at that position.
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Methylation of PTPRGint1 CpG9 has high sensitivity and specificity
To assess the sensitivity and specificity of PTPRGint1 methylation to discriminate between 
cancer and normal tissue, we developed a high-throughput MS-MLPA assay (Figure 2A, 
2B). We tested an FFPE cohort of 103 tumours and 58 corresponding normal tissues, 
which allowed us to assess the possibility of age-related methylation often seen in aging 
mucosa. Of the 67 carcinoma samples 94% showed methylation of the targeted CpG 
dinucleotide (61 fully, two partially methylated), while 46 (95.8%) of the 48 corresponding 
normal samples were unmethylated, and the remaining two partially methylated (Figure 
2C, Table 1). Comparing the methylation numbers between normal and tumour tissue by 
Chi-square test provided a highly significant p-value of 9.8x10-110. PTPRGint1 methylation 
was independent of MSI status in the sporadic carcinomas, as both MSI-High and stable 
cases were methylated. A relatively small group of 18 sporadic adenomas (13 low grade 
dysplastic and five high grade dysplastic) and neighbouring normal mucosa of 10 of these 
showed PTPRGint1 methylation in all adenomas, but not in the available normal mucosa 
(Figure 2C, Table 1). To assess whether PTPRGint1 methylation is an early event in colorectal 
carcinogenesis, several colon lesions preceding the adenoma/carcinoma stages were 
studied. All six hyperplastic polyps and 11 out of 12 serrated adenomas tested showed 
PTPRGint1 methylation (Figure 2C).
table 1: Sensitivity and specificity of the PTPRGint1 locus CpG9 methylation in sporadic tumours and tumours 
associated with a specific MMR mutation
cpG9 sensitivitymethylated tumours / total tumours
specificity I
Unmethylated normals / total normals
Sporadic adenomas 100%    (18/18) 100%    (10/10)
 Sporadic carcinomas 94%    (63/67) 95.8%    (46/48)
MLH1 mutated 100%    (14/14) 87%    (20/23)
MSH2 mutated 96%    (18/19) 100%    (24/24)
MSH6 mutated 86.7%    (26/30) 100%    (14/14)
Total Lynch 92.1%    (58/63) 95.4%    (62/65)
1The mutational analysis of the MMR genes was incomplete for four unpaired normal samples in the Lynch 
syndrome cohort. Therefore, these were only included in the total specificity calculations.
PTPRGint1 CpG9 methylation in Lynch syndrome associated colorectal cancer
The initial cohort for MS-MLPA validation contained two Lynch syndrome associated 
colorectal carcinomas that were both methylated. Therefore, we further investigated 
PTPRGint1 methylation in 63 carcinomas from patients with a DNA mismatch repair 
(MMR) gene mutation (14 MLH1 mutations, 19 MSH2 mutations and 30 MSH6 mutations). 
Of these 92.1% showed methylation (58 fully, 3 partially methylated), while 62 of the 
65 (95.7%) corresponding normal samples were unmethylated (Figure 2C, Table 1; Chi-
square p-value 3.3x10-153). In conclusion, methylation of PTPRGint1 CpG9 has similarly 




Figure 2 - PTPRGint1 methylation detected by MS-MLPA. (a) GeneMapper output of the custom MS-MLPA 
to analyze PTPRGint1 CpG9 methylation in a normal mucosa sample. Upper panel: The PTPRGint1 peak was 
located at ~84 bp, the control peak was located at ~110 bp. Lower panel: Loss of PTPRGint1 signal after HhaI 
digestion indicated an unmethylated CpG9. (b) GeneMapper output of the custom PTPRGint1 MS-MLPA in 
the corresponding colon cancer sample. Upper panel: Undigested. Lower panel: HhaI digestion. Retention of 
the PTPRGint1 marker signal indicated protection against HhaI digestion by CpG9 methylation. (c) Frequency 
of PTPRGint1 CpG9 methylation in precursor lesions (hyperplastic polyps and serrated adenoma), early- and 
advanced adenomas, carcinomas, and corresponding normal mucosal tissue for the latter three groups. The 
number of samples typed as methylated (dark), partially methylated (striped) and unmethylated (white) in the 
MS-MLPA assay is indicated on the y-axis.
No silencing of PTPRG gene expression in methylated samples
To assess if hypermethylation of PTPRGint1 affected expression of the gene, relative mRNA 
levels of PTPRG were studied in 15 right-sided colon carcinomas, three adenomas and 18 
corresponding normal mucosa samples. The PTPRG gene encodes four protein coding 
isoforms (Source: HGNC Symbol; Acc:9671, aligned to Ensembl GRCh37). Using intron 1 
spanning primers the full length transcripts ENST00000474889 and ENST00000295874 
(missing one cassette exon) were analyzed (Figure 3). Two additional transcripts, 
ENST00000383711 and ENST00000394462 both starting at exon 3, were analyzed using 
intron 26 spanning primers and gave comparable results (data not shown). Expression of 
the PTPRG gene was detected in all samples. To assess the effects of PTPRGint1 methylation 
on PTPRG expression, we compared the MS-MLPA methylation ratio with the PTPRG relative 
expression (Figure 3). We found that PTPRG was expressed at similar levels in the tumour 
and normal samples independent of methylation status. One patient (No. 28) showed 
increased PTPRG expression in both normal and tumour samples, thought to reflect 
individual expression differences and a possible copy number effect in the tumour.





























Figure 3 - Scatter plot of the relative PTPRG expression against the PTPRGint1 methylation ratio according to 
the MS-MLPA. The dotted vertical line at 0.22 indicates the cut-off for unmethylated samples. Plotted data is 
representative of two independent experiments.
PTPRGint1 is a methylation-dependent CTCF binding site
The PTPRGint1 locus overlapped with an experimentally defined CTCF binding site from a 
CTCF ChIP-chip study in fibroblasts27 displayed in the genome web browsers USCS28 and 
Ensembl29. This CTCF binding region of 750bp (OREG0015647; chr3: 61525101-61525851, 
UCSC assembly: March 2006) has a 262 bp overlap with the 3’ part of the PTPRGint1 locus 
( Supplementary Figure S1). We studied CTCF binding by ChIP in the primary tumour 
culture KP7038t that carried PTPRGint1 methylation (MS-MLPA ratio 0.97, data not shown), 
unmethylated tumour-derived fibroblasts KP7038f from the same patient (MS-MLPA ratio 
0.07, data not shown), as well as normal colon mucosa. We detected CTCF binding to 
PTPRGint1 in the normal mucosa and KP7038f fibroblasts, but little binding to the primary 
tumour cells (Figure 4A). 
To control for possible differences in the amount of CTCF protein between the samples, 
we compared the qPCR results for the PTPRGint1 region with a positive control locus 7.9 
Mb distant from PTPRGint1 that was shown to bind CTCF and does not contain a CpG in its 
putative 20 bp consensus sequence27. This locus was enriched in pull-downs of all samples, 
including the primary tumour cells, indicating that lack of CTCF binding to PTPRGint1 was 
not due to lack of CTCF protein. CTCF binding to PTPRGint1 was comparable to the positive 
control in both KP7038f fibroblasts (ratio 1.2) and normal colon mucosa (ratio 1.1). However, 
the PTPRGint1/positive control ratio was 0.06 in the primary tumour culture KP7038t (Figure 
4B). CTCF binding to PTPRGint1 was similarly decreased in colorectal cancer cell lines RKO 
and SW480 (Figure 4B). These results indicate a significant decrease of bound CTCF to the 
methylated PTPRGint1 region in tumour cells.
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Figure 4 - (a) CTCF binding to PTPRGint1, positive- and negative control regions in normal colon mucosa (light 
grey), KP7038f (black) and KP7038t (dotted). The histone H3 normalized values of the CTCF antibody and 
IgG negative control antibody pull downs are given per primer pair. Standard errors represent the variability 
of duplicate PCR reactions. This is a representative experiment of three ChIPs. (b) The PTPRGint1/positive 
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Discussion
We describe colorectal tumour-specific methylation of a locus in the first intron of the 
putative tumour suppressor gene PTPRG in both proximal and distal carcinomas and 
adenomas, including Lynch syndrome tumours. For these high-risk individuals, who are 
advised to undergo regular colonoscopies, no molecular markers have been described 
so far30. Assuming that a successful faecal or blood DNA test for PTPRGint1 methylation 
could be developed, this is a promising discovery that would aid the early detection of 
colorectal tumours, independent of their aetiology.
PTPRGint1 is not located in a promoter CpG island but in the first intron, about 3kb from 
the transcriptional start site. We did not find a relation between the methylation status 
of PTPRGint1 and PTPRG expression, indicating that PTPRGint1 methylation does not lead 
to loss of function of PTPRG as has been observed for mutations in colon cancer, and 
deletions in lung carcinomas and renal carcinoma cell lines31,32. However, the identification 
of a methylation-sensitive CTCF binding site overlapping with PTPRGint1 suggests that 
tumour-specific methylation may have a more distant effect. Differential binding of 
the insulator protein CTCF could have a major influence on expression of distant genes 
through alternative loop formation, as has been observed in β-globin expression in 
mouse models33. A recent study has shown that loss of CTCF binding to a boundary region 
upstream of CDKN2A resulted in spreading of repressed chromatin and DNA methylation 
into the p16 promoter with sequential down-regulation of p16 expression34. The same 
study described that loss of upstream CTCF binding resulted in promoter DNA methylation 
of RASSF1 and CDH134. Contradictory to the finding that CTCF binding abrogation was 
shown to be causative of heterochromatin spreading and DNA methylation34,35, is the 
observation that DNA methylation of CTCF binding sites is suggested to regulate CTCF 
binding36, 37. Interestingly, aberrant DNA methylation that excludes CTCF binding to 
intronic regulatory DNA was shown to promote expression of an oncogene, BCL6, in B 
cell lymphomas38. Although the sequence of events is unknown, the age-related aberrant 
hypermethylation often seen in colon cancer hints towards the latter. 
We excluded differential peptidic abundance of CTCF between tumour and normal samples 
by successfully amplifying a positive control CTCF binding site on all samples. It remains to 
be demonstrated if CTCF protein modifications and its cellular and nuclear distribution are 
maintained in all tumour cells, both of which can influence CTCF activity and the binding 
to specific regions. More insight into the role of aberrant DNA methylation of PTPRGint1 in 
the aetiology of cancer requires a better understanding of whether aberrant CTCF binding 
is caused by inhibition of protein activity or by initial aberrant methylation of the CTCF 
binding site.
Hypermethylation of the CpG island in the PTPRG gene promoter has been previously 
described in cutaneous T-cell lymphomas, melanoma cell lines, and gastric cancer39-41. 
Transcriptional down-regulation was shown to be associated with PTPRG promoter 
methylation in the cutaneous T-cell lymphomas study39. This study used a similar microarray 
for identification of differential methylation as the present study. We did not find differential 
methylation of the PTPRG promoter region between normal and colon tumour samples 
on the microarray. Moreover, BSA of colorectal cancer cell lines showed that the PTPRG 
promoter region was unmethylated (R. van Doorn, personal communication). Therefore, 
we have no indication for upstream spreading of DNA methylation from the CTCF binding 
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region at PTPRGint1 towards the promoter.
In conclusion, this study provided evidence for tumour-specific hypermethylation of a 
CTCF binding site located in the first intron of PTPRG. The high specificity and sensitivity 
imply a possible utility for PTPRGint1 methylation in new or existing colon-specific 
methylation marker panels. Especially the high level of PTPRGint1 methylation in Lynch 
syndrome associated colorectal tumours is unique and could prove to be a valuable 
addition. Methylation-dependent absence of CTCF binding to the PTPRGint1 locus 
suggests a possible effect on chromatin density or conformation that could play a role in 
colon tumorigenesis42.
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supplementary data
supplementary Figure s1 - Visual representation of the PTPRGint1 region. The PTPRG exon 1 (grey) and 
beginning of intron 1 (thick black line) are shown, with the transcription start site indicated with an arrow. 
Relative to the PTPRG start site, the following genomic features are shown: Promoter CpG island and intron 1 
CpG island (green), ORegAnno CTCF fragment OREG0015647 (adapted from UCSC genome browser, light blue), 
CpG island microarray clone 47B02 (dark blue), amplified region by direct BSA (yellow). The black arrowhead 
indicates the approximate location of MS-MLPA probe hybridization. Visualization based on UCSC assembly: 
March 2006.
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supplementary Figure s2 - Clonal BSA of PTPRGint1 in three paired tumour-normal tissues. Visual 
representation of the clonal BSA results of ten CpG dinucleotides of PTPRGint1 in carcinomas ID503 and 
ID127 and adenoma ID180. Black dot: methylated CpG. White dot: unmethylated CpG. Grey dot: sequence not 
readable. In a partially methylated normal sample (ID127) not more than three out of ten alleles were found 
methylated for several CpGs. In addition, complete methylation of 9/9, 8/10 and 4/7 sequenced tumour alleles 
was found respectively, roughly corresponding to the estimated percentage of tumour cells observed in HE-
stained tissue sections.
supplementary table s1 - Overview of the sporadic colorectal tumour samples and paired controls used in 
this study. Location, histology, age, sex and microsatellite instability status are listed, as well as the different 
techniques used on each sample. A gray box behind a sample in one of the last five columns indicates that the 
sample was tested with the technique listed in the header. Available at: http://www.nature.com/ejhg/journal/
v19/n3/suppinfo/ejhg2010187s1.html?url=/ejhg/journal/v19/n3/full/ejhg2010187a.html
supplementary table s2 - Overview of Lynch cohort used. Location, histology, mismatch repair gene 
mutation, age and sex are listed for each sample as well as the different techniques used in this study. A gray 
box in the last column indicates that the sample was tested with the technique listed in the header. Available 
at: http://www.nature.com/ejhg/journal/v19/n3/suppinfo/ejhg2010187s1.html?url=/ejhg/journal/v19/n3/full/
ejhg2010187a.html
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eArly oNset msi-H coloN cANcer witH MLH1 Promoter 
metHylAtioN, is tHere A GeNetic PreDisPositioN?
Abstract
Background: To investigate the etiology of MLH1 promoter methylation in mismatch repair 
(MMR) mutation-negative early onset MSI-H colon cancer. As this type of colon cancer is 
associated with high ages, young patients bearing this type of malignancy are rare and 
could provide additional insight into the etiology of sporadic MSI-H colon cancer.
methods: We studied a set of 46 MSI-H colon tumors cases with MLH1 promoter 
methylation which was enriched for patients with an age of onset below 50 years (n=13). 
Tumors were tested for CIMP marker methylation and mutations linked to methylation: 
BRAF, KRAS, GADD45A and the MLH1 -93G>A polymorphism. When available, normal colon 
and leukocyte DNA was tested for GADD45A mutations and germline MLH1 methylation. 
SNP array analysis was performed on a subset of tumors.
results: We identified two cases (33 and 60 years) with MLH1 germline promoter 
methylation. BRAF mutations were less frequent in colon cancer patients below 50 years 
relative to patients above 50 years (p-value: 0.044). CIMP-high was infrequent and related 
to BRAF mutations in patients below 50 years. In comparison with published controls the 
G>A polymorphism was associated with our cohort. Although similar distribution of the 
pathogenic A allele was observed in the patients with an age of onset above and below 50 
years, the significance for the association was lost for the group under 50 years. GADD45A 
sequencing yielded an unclassified variant. Tumors from both age groups showed 
infrequent copy number changes and loss-of-heterozygosity.
conclusion: Somatic or germline GADD45A mutations did not explain sporadic MSI-H 
colon cancer. Although germline MLH1 methylation was found in two individuals, locus-
specific somatic MLH1 hypermethylation explained the majority of sporadic early onset 
MSI-H colon cancer cases. Our data do not suggest an intrinsic tendency for CpG island 
hypermethylation in these early onset MSI-H tumors other than through somatic mutation 
of BRAF.
Background
High frequency of microsatellite instability (MSI-H) is the hallmark of tumors with a 
mismatch DNA repair (MMR) deficiency. This deficiency leads to an accumulation of somatic 
mutations, especially in repetitive coding or non-coding DNA sequences (microsatellites) 
in the genome. MSI-H in colon cancer is found in the context of Lynch syndrome, previously 
known as hereditary non-polyposis colorectal cancer (HNPCC), in which germline mutations 
in one of four mismatch repair genes (primarily in MLH1 and MSH2 1 and to a lesser extent in 
MSH62, PMS23 or deletions in EPCAM/TACSTD1 (leading to MSH2 methylation)4, 5 are found. 
Approximately 15% of cases are due to somatic biallelic or hemiallelic DNA methylation 
of the CpG-rich MLH1 promoter sequence, which is associated with gene silencing6. Colon 
cancers with sporadic MSI-H are observed more frequently in females and are often located 
proximal to the splenic flexure7. 
A clear association between increased age and occurrence of sporadic MSI-H colon 
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cancer was described in 2002 by Young et al.8. The combination of age at diagnosis 
and three pathological features (tumor heterogeneity, peritumoral lymphocytes and 
tumor-infiltrating lymphocytes) allowed positive identification of 94.5% of MSI-H 
cancers as either Lynch syndrome or sporadic8. As normal aging colon mucosa shows 
global hypomethylation and specific hypermethylation of tumor associated genes, this 
epigenetic accumulation can explain the association between sporadic MSI-H colon 
cancer and older age9-11. The rare sporadic cases diagnosed at a relatively young age can 
provide insight into the etiology of sporadic MSI-H. As young patients with sporadic MSI-H 
colon cancer are subjected to MLH1 methylation without this age-associated epigenetic 
accumulation, a defect of DNA methylation maintenance or direct targeting of MLH1 for 
methylation could be expected.
MLH1 methylation has been one of the hallmarks of the CpG island methylator phenotype 
(CIMP) since the phenotype was first described in 199912. The high levels of methylation 
found in CIMP–high colon tumors suggest that a causative genetic or epigenetic defect 
influences the spread and initiation of methylation13. Somatic BRAF mutations, MLH1 
methylation and sporadic MSI-H are associated with CIMP-positive (CIMP-high and 
CIMP-low combined) colon tumors in which the bulk of aberrant methylation can be 
found13, 14. Aberrant methylation in CIMP-high tumors is thought to arise through an 
increase in de novo methylation. KRAS mutations have also been associated with elevated 
levels of aberrant DNA methylation, although discrepancies between marker panels 
and techniques showed variable levels of methylation. In general, KRAS mutations are 
associated with CIMP-low (also annotated CIMP2) colon tumors, in which increased levels 
of aberrant methylation can be detected to some extent, but at lower levels than in the 
CIMP-high tumors13, 14. 
The underlying causes leading to MLH1 promoter hypermethylation and subsequently 
to sporadic MSI-H colon cancer are still largely unknown. A relatively new concept in the 
field of genetics is germline epimutation. Although rare, multiple studies have described 
inherited and de novo germline methylation of MLH1 in patients with Lynch-like colon 
cancer15-21. Cases with confirmed or probable MLH1 epimutations are documented to have 
the same range of tumors as described in Lynch syndrome patients, predominantly early-
onset MSI colorectal cancer and endometrial cancer. Although possible, inheritance of the 
MLH1 epimutation is described as very weak, as the MLH1 epimutation is unstable in the 
germline17, 18, 20, 21. Paradoxically, patients suspected of having a genetic disorder based on 
a strong family history may be less likely to carry an epimutation18. Germline epimutations 
are thus highly suspected in young patients presenting with an MSI tumor without a clear 
family history. Increased risk of MSI-H tumors22 and tumor-specific MLH1 methylation23 
might also be associated with a single-nucleotide polymorphism (SNP) -93 bp from the 
MLH1 transcription start site (rs1800734). This MLH1 G>A polymorphism is associated with 
increased age of onset and CIMP and BRAF mutations in individuals with MSI-H tumors24.
Another possible factor contributing to aberrant DNA methylation is inactivation of 
GADD45A25, although this finding was later disputed26, 27. GADD45A (growth arrest and 
DNA-damage inducible protein 45 alpha) is a nuclear protein involved in maintenance of 
genomic stability, DNA repair and cell growth suppression28, 29. A recent publication has 
found GADD45A to be a key regulator of active DNA demethylation in Xenopus oocytes 
and cell lines through a DNA repair-induced mechanism25. Specific short interfering RNA 
(siRNA)-mediated knockdown of GADD45A and GADD45B in the colon cancer cell line RKO 
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induced hypermethylation of MLH1, THBS1 and p16, three genes known to be involved in 
carcinogenesis of different types of tumors by DNA methylation25. 
In contrast to MSI-H colon cancer, chromosomal instability (CIN) is enhanced and more 
pronounced in tumors with a low frequency of microsatellite instability (MSS or MSI-L 
tumors). This relationship can also be deduced from the observation that MSS/MSI-L tumors 
often are aneuploid, whereas MSI-H tumors mostly are peri-diploid. Lynch syndrome-
associated MSI-H colon cancer hardly shows chromosomal copy number alterations, and 
the few alterations are mainly restricted to copy neutral LOH (cnLOH) at the mutated locus, 
especially in MLH1 mutated cases30. However, sporadic MSI-H colon cancer and MSI-H from 
patients with unclassified variants in MMR genes seem to show an enhanced (although 
subtle) number of chromosomal aberrations30-33. 
We studied 46 MSI-H colon tumors showing loss of MLH1 expression and its heterodimer 
PMS2 and methylation of the MLH1 promoter. Pathogenic germline MMR mutation were 
excluded. We have primarily focused on comparing relatively young patients with patients 
of older ages to identify a possible cause for MLH1 methylation in young individuals with 
colon cancer. Tumors were characterized for somatic BRAF, KRAS, GADD45A and the MLH1 
-93G>A polymorphism (rs1800734), as these genetic factors could play a causative role in 
MLH1 promoter methylation. Whenever material was available, germline MLH1 methylation 
status was studied and DNA sequencing for germline GADD45A mutations was performed. 
In order to analyze whether the younger patients exhibit an intrinsic higher methylation 
tendency in their genome, the methylation status of eight CIMP markers was determined 
in the tumors. In a selected subset of young patients, whole genome SNP array analysis 
was performed on formalin-fixed, paraffin-embedded (FFPE) tumor tissue and compared 




Tumor tissues were obtained from 46 sporadic right sided colon cancer patients analyzed 
between 1997 and 2006 at the Leiden University Medical Center (Leiden, The Netherlands). 
MSI analysis, additional MMR immunohistochemistry (IHC) and MMR germline mutation 
analysis were performed due to a relatively young age of onset and/or a suspected family 
history of Lynch syndrome. As we mainly focused on comparing relatively young patients 
with patients of older ages, our sample set was enriched for young patients with MLH1 
methylation. Our sample set contained a high percentage of MLH1 methylated colon cancer 
patients with an age of onset below 50 years (28%, 13 cases) which is not a reflection the 
general age distribution of this of type colon cancer. The present study falls under approval 
by the Medical Ethical Committee of the LUMC (protocol P01-019). Informed consent was 
obtained according to protocols approved by the LUMC Medical Ethical Committee (02–
2004). Patient samples were handled according to the medical ethics guidelines described 
in the Code Proper Secondary Use of Human Tissue established by the Dutch Federation of 
Medical Sciences (www.federa.org).
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DNA isolation and MSI analysis
DNA was isolated from 0.6 mm FFPE punches after assessment of corresponding 
hematoxylin-eosin stained slides by a pathologist (HM). Standard deparaffination 
preceded DNA isolation using the Wizard Genomic DNA Purification kit (Promega, Madison, 
WI, US). The microsatellite instability status of each of the tumors was determined using 
the Promega MSI analysis system (Version 1.2, Promega, Madison, WI, US) following the 
recommendations of the National Cancer Institute/ICG-HNPCC34-36. Tumors with at least 
two out of five mononucleotide markers unstable were classified as MSI-H. 
IHC of MMR proteins
Standard three-step, indirect IHC was performed on 4-μm tissue sections that had been 
transferred to glass slides, including citrate antigen retrieval, blockage of endogenous 
peroxidase and endogenous avidin-binding activity and di-aminobenzidine development. 
The following antibodies were used: anti-MLH1 (clone G168-728; BD Biosciences, San Jose, 
CA), anti-PMS2 (clone A16-4; BD Biosciences), anti-MSH2 (clone GB-12; 1:100; Oncogene 
Research Products, San Diego, CA) and anti-MSH6 (clone 44; 1:400; BD Biosciences). The 
utilized secondary antibodies were biotinylated rabbit anti-mouse IgG antibodies (DAKO, 
Glostrup, Denmark), goat anti-rabbit IgG antibodies (DAKO, Glostrup, Denmark) and 
biotinylated-peroxidase streptavidin complex (SABC; DAKO, Glostrup, Denmark). Loss 
of expression was assessed by a complete lack of staining in the tumor cell nuclei with 
concurrent staining in normal epithelium, stroma or infiltrating leukocytes. 
Mutation analysis
BRAF V600E mutations were detected using flanking primers that have been previously 
described37. DNA sequence analysis of codons 12 and 13 of KRAS was performed as 
previously described38. For direct sequencing of GADD45A, six exon primer pairs were 
designed (encompassing 100 bp of intronic sequence) using the Primer3 web-tool 
for the amplification of the four exons of GADD45A39. The utilized primers are listed in 
Additional file 1. Primers utilized for sequence analysis of the MLH1 -93G>A polymorphism 
were designed to amplify the region spanning from -231 bp to -51 bp from the MLH1 
transcription start site39. PCR products were purified with the QIAquick PCR Purification kit 
(Qiagen, Hilden, Germany). Sequencing was performed at the Leiden Genome Technology 
Center (LGTC, Leiden, The Netherlands) using an ABI 3730 XL (Applied Biosystems, Foster 
City, CA). Mutational analysis was performed using mutational surveyor (SoftGenetics LLC., 
State College, PA). Results of all mutational analyses are summarized in Table 1 (extended 
in Additional file 2).
table 1: Occurrence of BRAF mutations, SNP rs1800734 in relation to age and MLH1 methylation status.
MLH1 methylation BRAF MLH1 -93G>A
type n m pm mut G/G G/A A/A NA
Adenoma 2 2 0 1 0 1 1 0
Carcinoma 44 33 11 24 12 20 7 5
Age
Total <50 13 9 4 4 4 7 2 0
Total ≥50 33 26 7 21 8 14 6 5




Methylation of the 5’ regulatory MLH1 region at -200 bp (from the transcription start site) 
was analyzed by using Methylation-Specific PCR (MSP) primers that have been previously 
described40. Sample DNA (100 ng) was mixed with carrier DNA (salmon sperm DNA, 
400 ng) followed by bisulfite conversion using the EZ DNA Methylation Gold kit (Zymo 
Research, Orange, US) and the standard protocol provided by the manufacturer. Amplified 
fragments were analyzed by electrophoresis through a 2% agarose gel and on an Agilent 
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). The utilized primers are listed in 
Additional file 1. 
Contamination of the carcinoma tissue by stromal or inflammatory cells was unavoidable 
in some cases, despite use of micro-dissection, and tumors with a partially methylated 
phenotype were scored as methylated.
Methylation of MINT1, MINT2, MINT12, MINT31, RIZ1 and TIMP3 was determined by MSP 14. 
Primers and conditions are listed in Additional file 1. MINT27 and Megalin methylation was 
determined by Combined Bisulfite Restriction Analysis (COBRA)41. Tumors were determined 
to be CIMP-high when four or more markers besides MLH1 showed methylation, and 
tumors were determined to be CIMP-low when containing three or fewer methylated 
markers besides MLH1. For validation of our CIMP marker set, methylation of IGF2, SOCS1, 
NEUROG1, RUNX3, CACNA1G was determined by MSP in the cases with an age of onset less 
than 50 years42, 43. 
SNP array analysis, copy number changes and loss of heterozygosity (LOH) 
assessment
Single nucleotide polymorphism array analysis, copy number change and loss of 
heterozygosity (LOH) assessment were performed as previously described30. For each 
sample, four SNP panels (linkage panel, LP), LP1-4, were tested. All LP panels were 
combined for testing of the entire genome. LP1 covers chromosomes 1 to 3 and 22, LP2 
covers chromosomes 5 to 9, LP3 covers 10 to 15 and 21, and LP4 covers chromosomes 4, 
16 to 20, X and Y. Each panel was separately analyzed on a bead array. Due to the limited 
availability of archival tumor tissue, some of the LPs could not be analyzed. In two cases 
two LPs and in one case one LP could not be analyzed. To assess the fraction of the genome 
altered, the number of chromosome cytobands that were altered was divided by the total 
number of cytobands tested.  
Statistical analysis
Differences in mutation and MSI frequencies between groups were analyzed using Fisher’s 
exact and Chi-Square tests. A p-value below 0.05 was considered to indicate statistical 
significance. Yates’ correction was used whenever a value lower than 5 was used in the Chi-
Square test. 
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results
We characterized 13 MSI-H colon cancer cases with MLH1 promoter methylation from 
patients with an age of onset below 50 years and compared these data with those obtained 
from 33 MSI-H cases of patients over 50 years of age. Based on the Bethesda guidelines, 
which recommend MSI testing for all colorectal cancers in patients diagnosed before 50 
years of age, we used the cutoff age of 50 for our comparisons36. The mean age of the study 
cohort was 61 years (SD is 31 years). The majority of tumors originated from the proximal 
colon (n=36, 78% of total), while a low percentage (n=5, 11%) of MSI-H tumors originated 
distal from the splenic flexure. All tumors showed loss of expression of nuclear MLH1 and 
its heterodimer PMS2, confirming the deleterious effect of MLH1 promoter methylation. 
Both MSH2 and MSH6 stained positive and pathogenic germline mutations in any of the 
four mismatch repair genes were identified in none of the patients. 
Two patients identified with germline MLH1 epimutation
For seven MSI-H patients with an age of onset below 50 years and 13 patients aged above 
50 years, normal colonic epithelium and/or leukocyte DNA was available for germline 
methylation analysis of MLH1. Two female patients were identified as having germline 
MLH1 promoter methylation as both normal colonic epithelium and leukocyte DNA 
tested positive. The first patient (ID60, Figure 1) presented with a right sided colon cancer 
at the age of 33 and endometrial cancer at age 52. Her family history showed a sister with 
endometrial cancer at the age of 37. Apart from a maternal grandfather with colon cancer 
at the age of 90 years and a maternal niece with duodenum cancer at 39 years, no other 
tumors from within the Lynch syndrome spectrum were seen. The second patient with 
germline methylation (ID36) does not have a family history with characteristics of Lynch 
syndrome. She was diagnosed with colon cancer at age 60 (MSI-H with a BRAF V600E 
somatic mutation) and pancreatic cancer at age 62 (scored as MSS).
Figure 1 - Lab-on-chip results of a MLH1 MSP performed on normal tissue and peripheral blood from patient 
ID60. Lane one contains the lab-on-chip DNA marker. Partial methylation of both normal colon mucosa 
(ID60N) and peripheral blood (ID60P) was observed as they show products produced by the primer pairs 
amplifying unmethylated (UM) and methylated (M) template DNA. Negative (Neg) and Positive (Pos) controls 
represent unmethylated (Neg) and methylated (Pos) controls, respectively. The first lane is a visualization of 
the Agilent DNA 1000 Marker 15/1500 in base pairs (bp) 
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BRAF mutation shows an age-dependent trend in MSI-H tumors
Somatic BRAF V600E mutations were found in 25 out of the 44 tested tumors, whereas no 
KRAS codon 12/13 mutations were found (Table 1; extended information in Additional file 
2). The majority of the BRAF mutations were identified in patients over 50 years of age 
(n=21, 65.6% of patients over 50). Comparison with the patient group under 50 years of age 
(n=4, 31% of patients under 50) showed a significant difference between the two groups 
(p-value: 0.044).
GADD45A somatic and germline DNA mutation analysis
GADD45A was successfully sequenced for 38 samples (17 normal epithelium samples and 
21 tumor samples). Exon 1 was successfully studied for 37 samples and did not reveal 
any alterations. We identified 5 cases with an SNP (rs3783466, c.45-23C>T) present in the 
first intron. Exon 2 was studied for 38 samples and did not reveal any alterations. Exon 3 
was sequenced for 38 samples and revealed a variant that was not previously described 
(in ID70). This heterozygous C>T transition resulted in a neutral amino acid change from 
proline to serine (p. Pro119Ser) and was predicted by the Sorting Intolerant From Tolerant 
(SIFT) prediction software to be a tolerated mutation44. Exon 4 was studied for 37 samples 
and did not reveal any alterations.
No association between age, BRAF and GADD45A mutation status or the MLH1 -93G>A 
polymorphism was observed. An overview of the GADD45A mutation data is given in 
extended information in Additional file 2. 
MLH1 -93G>A polymorphism analysis
We screened 41 out of 46 (13 below 50, 28 above) samples successfully for the MLH1 
-93G>A polymorphism (rs1800734), by sequence analysis. The G/G genotype was found 
in 12 samples (29.3%), G/A in 21 (51.2%) and the A/A genotype in 8 (19.5%). No significant 
differences between tumors grouped by age (with either 50 or 60 years as a cutoff for early 
onset colon cancer), BRAF or GADD45A mutational status were observed in our patients. An 
association between the G>A polymorphism and ages of onset above 50 years (p=3.5x10-5) 
was found in comparison with published control samples (Table 2)24. This association was 
lost (p=0.19) when comparing younger patients with corresponding published control 
samples (Table 2)24. However, grouping of the A/A and G/A genotypes provided lower 
p-values when comparing both age groups to controls. A similar distribution of the A allele 
was found in the young age group as for the patients above 50 years. In this comparison 
the association between the A allele and the group with an age of onset below 50 years was 
significant (p=0.035), although the significance was lost after the required Yates’ correction 
(p=0.068, Table 2). A numeric overview of the MLH1 -93G>A polymorphism sequence data 
is given in Table 1 (extended information in Additional file 2 and Table 2).
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table 2: Genotype frequencies of MLH1 -93G>A polymorphism in sporadic MSI-H colon cancer with an age of 
onset below and above 50 years. 
Genotype frequency (%)




diagnosis <50 13 4(31) 7(54) 2(15)
      
controls 1 929 554(59.5) 331(35.5) 44(5) 6.0 2 0.19427123*
controls 2<60 501 287(57) 175(35) 39(8) 3.8 2 0.34061584*
Age at 
diagnosis ≥50 28 8(29) 14(50) 6(21)
controls 1 929 554(59.5) 331(35.5) 44(5) 20.5 2 0.00003502
controls 2 >60 1462 883(60) 513(35) 66(5) 22.6 2 0.00001209
GG GA+AA chi-square DF P-value
Age at 
diagnosis <50 13 4(31) 9(69)
controls 1 929 554(60) 375(40) 4.4 1 0.06890141*
controls 2<60 501 287(57) 214(43) 3.6 1 0.10499389*
Age at 
diagnosis ≥50 28 8(29) 20(71)
controls 1 929 554(60) 375(40) 10.8 1 0.00100409
controls 2 >60 1462 883(60) 579(40) 11.6 1 0.00066844
n: Total number
Chi-square: Value of the chi-square test
DF: Degrees of freedom
Control samples are adapted from literature. Percentages are given in brackets. (Raptis et al., for controls 1 and 
Samowitz et al. for controls 236,38). P-values with a * are Yates corrected.
CpG island DNA methylation is more frequent in older patients and is highly 
correlated with BRAF mutation in younger colon carcinoma patients
We examined the methylation status of 31 samples (11 below 50 years, 20 above) using 
six CIMP markers (MINT1, MINT2, MINT12, MINT31, RIZ1 and TIMP3) with MSP and two 
CIMP markers (MINT27 and Megalin) with COBRA. Results of the analysis are presented in 
Table 3. Although all samples in this sub-selection of our MSI-H study group contain MLH1 
methylation, a clear age-related trend of methylation was observed. Out of the 11 tested 
patients that were below 50 years of age and had MLH1 methylated colon cancer, only four 
were shown to be CIMP-high. Remarkably, all of these young CIMP-high cancers showed 
BRAF mutations, whereas such mutations were not detected in samples with less extensive 
methylation. A higher frequency of CIMP-high (20/20 vs. 4/11, p=3.1x10-4 (Yates’ corrected)) 
62
Chapter 3
was observed for colon cancer patients above the age of 50, concomitant with the higher 
number of BRAF mutations found in these patients. 
The methylation status of our early onset cases were validated by use of 5 additional 
CIMP markers (IGF2, SOCS1, NEUROG1, RUNX3, CACNA1G). All validated samples showed 
similar levels of methylation in both marker sets (Table 3). Although sample ID1 showed 
methylation of 3/5 additional markers, the cumulative amount of markers still led us to 
determine this sample as CIMP-low.
Genomic profiling of MSI-H colon carcinomas
For a sub-selection of 15 MSI-H carcinomas (5 below and 10 above 50 years of age) for 
which sufficient DNA was available, genome-wide profiles of copy number abnormalities 
and copy neutral LOHs (cnLOHs) were obtained using SNP arrays suitable for analysis of 
archival FFPE tissue (Additional file 3). Chromosomal copy number changes were observed 
in 7/15 samples. Physical chromosomal loss was a rare event (on average of 0.2% of the 
genome) and was only found in 3/15 carcinomas, in which small telomeric regions on 
chromosomes 1q, 4q, 8p and 18q were deleted. An overview of the events in all tested 
samples is given in Figure 2. Four chromosomal regions showed cnLOH in more than one 
tumor: chr 2q23.1-37.3 (n=2, ID50 and ID59), 3p21.31-26.3 (n=2; ID18 and ID39, containing 
MLH1), 9p21.2-24.3 (n=2; ID3 and ID36) and 11p15.1-15.5 (n=2 ; ID20 and ID59). 
Figure 2: Chromosomal events per chromosome arm in 15 sporadic MSI-H carcinomas. Bars indicate the 
percentage of the tested sporadic MSI-H carcinomas containing a chromosomal aberration or copy neutral 


















































































































1 M 15 Ca NA wt wt C>T G/G pM Lo
3 F 27 Ca R wt wt wt G/A Lo
7 M 36 Ca L wt wt C>T A/A pM Lo
11 M 39 Ca L wt wt wt G/A pM Lo
12 M 41 Ca R wt wt wt G/G NA NA NA NA NA Lo
13 M 42 Ca R V600E wt C>T G/A NA H
17 M 43 Ca R wt wt wt G/G pM Lo
18 F 44 Ca R wt wt wt G/A Lo
20 F 46 Ca R V600E wt wt G/A H
21 M 47 Ca R V600E wt wt G/A H
23 F 48 Ca R V600E wt wt G/G NA H
25 F 52 Ca L V600E wt wt G/G H
27 F 53 Ca L wt wt wt G/G pM H
15 M 55 Ca R V600E wt wt G/A pM NA H
35 M 59 Ca R V600E wt wt G/A H
36 F 60 Ca R V600E wt C>T G/A H
37 F 60 Ca R wt wt wt G/G H
38 F 61 Ca R wt wt wt G/A H
39 M 62 Ca R V600E wt wt G/G H
42 F 62 Ca NA wt wt wt G/A pM H
43 F 62 Ca R V600E wt wt A/A NA H
65 F 64 Ca R V600E wt wt G/G H
47 M 67 Ca NA V600E wt wt A/A H
66 F 69 Ca R V600E wt wt A/A H
67 M 75 Ca R V600E wt wt G/A H
68 F 75 Ca R V600E wt wt G/G pM H
69 F 76 Ca R wt wt wt G/A H
56 F 78 Ca R V600E wt NA G/A pM H
57 F 80 Ca R wt wt wt A/A H
70 F 80 Ca R V600E wt C>T G/G H
59 M 84 Ca R V600E wt wt G/A H
NA: Not available  CIMP: CpG island methylator phenotype
R: Right sided  Lo: CIMP-low
L: Left sided  H: CIMP-high
wt: Wildtype  V600E: BRAF V600E mutation
M: Male   C>T: rs3783466c.45-23C>T
F: Female




Since CpG island hypermethylation (including MLH1) in colon mucosa is considered to be 
age-related9, the finding of hypermethylation of MLH1 at a younger age is unexpected. Since 
2002, several manuscripts pointed to the existence of MLH1germline methylation15-21. More 
recently, MSH2 methylation due to an inherited deletion in the 3’end of EPCAM/TACSTD1 
was also discovered4. Methylation of MLH1 can also be found in addition to a germline MMR 
mutation, as described by Rahner et al.45. We studied 13 MMR germline mutation-negative 
patients with MSI-H colon cancer (mostly right-sided) at ages of onset under 50 years. These 
data were compared with those obtained from a control group of 33 patients with an age 
of onset above 50. The presence of (somatic) promoter methylation of MLH1 in the tumors 
made Lynch syndrome unlikely. We identified two female patients with ages of onset of 
33 and 60 years harboring germline MLH1 methylation. Relatively young patients without 
a strong family history who present a MSI-H tumor with loss of MLH1 and PMS2 protein 
expression are suggested as candidates for MLH1 germline epimutation screening017, 21. 
We identified one patient with germline MLH1 methylation in seven tested cases who 
were less than 50 years of age, giving a frequency of ~14%. Although the low number of 
tested samples in this study makes this percentage not representative, this number is not 
significantly higher than the frequency range of 0.6-13% described in studies screening 
for germline MLH1 methylation in Lynch syndrome-suspected patients5. The discovery of 
germline MLH1 methylation in a patient aged 60 years at diagnosis is surprising, as the 
patients with germline MLH1 methylation described prior to this study (n=25) have a mean 
age of diagnosis of 37 years with a range of 17-465.
In contrast to the group with an age of onset above 50 years, only some (4/11) of the MLH1 
methylated MSI-H tumors from patients below 50 years showed high levels of CIMP marker 
methylation (CIMP-high). For the patient group with an age of onset below 50 years the 
CIMP-high status completely overlapped with BRAF mutations. As both BRAF and KRAS 
mutations have been observed in the earliest identified colonic neoplasms, and recent 
papers have provided evidence that induction of the ras oncogenic pathway will result in 
DNA hypermethylation, a causative effect of BRAF/KRAS mutations is likely24, 46-50. Instead 
of widespread CpG island methylation in non-BRAF mutated tumors in the early onset 
patient group, methylation seems to be largely restricted to the MLH1 locus. Although 
the existence of locus-restricted methylation may be a reflection of the Gaussian curve 
of methylation patterns in relation to age, this finding may suggest a distinct, non-BRAF 
associated mechanism of MLH1 methylation. However, all tumors here were selected upon 
MLH1 promoter methylation which may explain the fact that MLH1 is methylated more 
frequent than all other CIMP genes. As the methylation mechanism is (at least partly) age 
related, and progressive, a similar selection of tumors methylated on one of the other CIMP 
markers would have also shown more frequent methylation on these than other CIMP 
markers including MLH1 and occurring in tumors not reaching the CIMP-high classification 
yet. A progressive methylation and CIMP appearance according to age similar as that 
shown in Table 3 favors the argument that MLH1 methylation in these young patients is a 
reflection of the Gaussian curve of methylation patterns in relation to age. 
An alternative hypothesis concerning the association between BRAF mutation and DNA 
methylation is that promoter methylation and silencing of specific target genes such as 
IGFBP7 by promoter methylation could favor the selection of activating BRAF mutations, 
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since the oncogenic effect of activated BRAF would be enhanced in the absence of 
IGFBP7’s inhibitory function51. Since promoter hypermethylation is partly age related 
the occurrence of  IGFBP7 hypermethylation and BRAF mutation would also explain the 
diminished occurrence in the young sporadic MSI-H patient group50. This role of BRAF in 
aberrant methylation initiation will have to be elucidated in the future. The locus-specific, 
non-BRAF associated mechanism of MLH1 methylation suggested in our study should 
be addressed in a larger group of early onset sporadic colon cancer patients with MLH1 
methylation to provide additional insights. 
In patients of older ages, there is an association between somatic MLH1 methylation and 
the MLH1 -93G>A polymorphism22, 24, 49. Indeed, when we compared our group of patients 
above 50 years of age with the published control groups of Raptis et al., and Samowitz et 
al., we observed an enrichment of the A allele. We explored the possibility that the A allele 
was more prevalent in the sporadic MSI-H at early ages. However a similar distribution in 
both age groups was found, no significant enrichment could be found for the cases under 
50 years. The hypothesis of Samowitz et al., which suggests an increased likeliness of MLH1 
methylation in the presence of a CIMP/BRAF mutation background and a MLH1 -93 G>A 
polymorphism, excludes young onset patients because of low levels of BRAF mutations24. 
Although Samowitz did find a significant difference in A allele distribution between MSI-H 
colon cancer age groups, our cohort of sporadic MSI-H colon cancer patients with MLH1 
methylation excluded patients with a germline MMR gene mutation, which might explain 
the difference found between our studies. 
Knockdown and overexpression experiments of GADD45A in Xenopus laevis led to the 
suggestion that deregulation of GADD45A’s role in active DNA demethylation could 
give rise to aberrant methylation25. The absence of pathogenic somatic and germline 
mutations in human GADD45A observed in our study and data published during this 
study26, 27 suggest that a role for GADD45A mutations in aberrant hypermethylation in 
human colon tumors is unlikely.  
In a subset of tumors (including five with an age of onset under 50 years), whole genome 
SNP array analysis of FFPE tumor tissue was used to assess possible causative loci for MLH1 
methylation. Our copy number and cnLOH analysis identified patterns in agreement with 
literature describing limited chromosomal instability in sporadic MSI-H colon tumors 
with MLH1 methylation. The extent of copy number abnormalities (CNA) identified here 
is in agreement with that found by Trautman et al. and by van Puijenbroek et al.30, 33. In 
patients under 50 years, no specific genomic pattern was identified, although two cases 
showed overlapping alterations at chromosome 4q. The smallest region of overlap (region 
4q35.1-4q35.2) encompasses the cancer associated genes TLR3, CDKN2AIP, ING2, CASP3 
and SORBS2, none of which are thought to cause aberrant DNA methylation. The four 
regions of cnLOH that showed infrequent overlap in the 15 tumors tested are not known 
as such. The cnLOH of 3p21.31-26.3, found in a 44 and a 62 year old, encompasses the 
3p22.2 region where MLH1 is located. Such cnLOH is not typical for sporadic MSI-H colon 
carcinomas, but is more readily found in tumors containing pathogenic MLH1 mutations30. 
We cannot rule out that the identified cnLOH regions may harbor loci involved in MLH1 




Although our study did not identify a cause for MLH1 methylation in sporadic MSI-H 
colon cancer with an age of onset below 50 years, we observed methylation to be almost 
restricted to the MLH1 locus in patients without a BRAF mutation. We show that this early 
onset group consists of two sub-groups: those which are CIMP-high and contain a BRAF 
mutation (resembling sporadic MSI-H in the older age group to a great extend) and those 
with wild-type BRAF and limited methylation in addition to MLH1 methylation. 
Genomic analysis did not provide recurrent aberrations leading to identification of a 
possible cause of MLH1 methylation in the cases under 50 years. Lastly, we excluded a role 
for somatic and germline GADD45A mutations in the tumorigenesis of early onset sporadic 
MSI-H colon cancer. 
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3 F 27 wt wt L 9p21.2-9p24.3 3, 4
12 M 41 wt wt L 4
18 F 44 wt wt L chr:19 3p21.31-3p26.3
20 F 46 V600E wt H 8q11.22-8q24.3 1p36.12-1p36.33
1q21.2-1q32.2 4q35.1-4q35.2
1q42.2-1q44 11p15.1-11p15.5




25 F 52 V600E wt H chr:5 ; chr:8
36 F 60 V600E C>T H chr:7 ; chr:14 9p13.2-9p24.3
39 M 62 V600E wt H 3p21.32-3p26.3
14q31.1-
14q32.33
42 F 62 wt wt H
43 F 62 V600E wt H
47 M 67 V600E wt H
50 M 71 NA wt NA chr:19 2q23.1-2q37.3
5q35.1-5q35.3
chr:13
56 F 78 V600E NA H 5q21.3-5q22.3 3, 4
57 F 80 wt wt H 8q24.21-8q24.3
8p22-8p23.3
59 M 84 V600E wt H 2q14.3-2q37.3
11p12-11p15.5
chr:22
F: Female   NA: Not available
M: Male   LP: Linkage panel
L: CIMP-low  V600E: BRAF V600E mutation
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Abstract
Cancer-specific hypermethylation of (promoter) CpG islands is common during the 
tumorigenesis of colon cancer. Although associations between certain genetic aberrations, 
such as BRAF mutation and microsatellite instability, and the CpG island methylator 
phenotype (CIMP) have been found, the mechanisms by which these associations are 
established are still unclear. 
Using differential methylation hybridization on oligonucleotide microarrays, we generated 
methylation profiles of paired tumor and normal colon. The majority of CpG regions 
found differentially methylated between BRAF mutant and wildtype tumors showed 
hypermethylation in the mutant cases. Enrichment of several cancer-related pathways, 
including the PI3 kinase and Wnt signaling pathways, was found. To focus on genes that are 
silenced in a tumor-specific rather than a lineage-specific manner, we used information on 
an epigenetic silencing mark in embryonic stem (ES) cells. Among the genes showing BRAF 
mutation-specific promoter methylation but no H3K27me3 mark in ES cells were forkhead 
box (FOX) transcription factors associated with the PI3-kinase pathway as well as MLH1, and 
SMO. Epigenetic down-regulation of these targets may contribute to mutationally active 
BRAF-driven tumorigenesis, explaining its association with aberrant DNA methylation.
introduction
The CpG island methylator phenotype (CIMP) was introduced in 1999 by Toyota et al. to 
describe a subset of colorectal tumors with high levels of cancer-specific methylation1. 
Subsequent studies regarding (CIMP) in colon cancer described a strong association 
between this epigenetic phenotype, BRAF mutations and microsatellite instability (MSI)2-
8. As sporadic MSI colon cancer is caused by promoter methylation of a mismatch repair 
gene (MLH1, MSH2 or MSH6) the association between MSI and the high levels of DNA 
methylation in CIMP is considered a causative one9, 10. However, the association between 
activating BRAF mutations and CIMP remains unclear. 
The field of epigenetic research has progressed from a candidate-gene to a genome-
wide approach which not only provided a plethora of new candidate targets of cancer-
specific DNA methylation but a better understanding of transcription regulation by DNA 
methylation as well.11. Using such genome-wide DNA methylation approaches could 
help identify new targets of BRAF mutation-specific promoter methylation. Hinoue et al. 
examined the CIMP- and BRAF mutation-specific methylation status of 1,505 CpG sites, 
located at 807 genes, in 235 primary colorectal tumors and discovered specific methylation 
of genes mediating various signaling pathways involved in colon cancer tumorigenesis2. 
In this study, we screened 32,171 CpG sites located at 10,537 genes in 19 colon cancer 
patients to obtain additional insight into the association between BRAF mutations and 
DNA methylation in colon cancer tumorigenesis.
Recent publications have reported a possible pre-marking of cancer-specific hypermethylated 
genes by the inactivation mark Histone H3 lysine 27 trimethylation (H3K27me3) and binding 
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of polycomb group member SUZ12 in both ES cells and differentiated normal colon 
mucosal tissue12-14. These studies led to the suggestion that colon cancer cells utilize a 
pre-existing repression program to target loci for cancer specific promoter methylation12, 
14-16. However, the presence of such repressive histone modifications at promoters during 
differentiation from ES to normal colon epithelium suggests that the associated genes 
are at a transcriptional silent state prior to tumor formation, reducing the relevance of 
the DNA methylation of pre-marked genes on tumorigenesis. In an attempt to identify 
biologically relevant BRAF mutation-specific promoter methylation, we excluded loci with 
H3K27me3 pre-marking in ES cells from the functional pathway analyses. By both extending 
the number of screened loci and filtering out pre-marked genes we identified new targets 
of BRAF mutation-specific methylation that could either create a favorable setting for the 




Anonymized tumor and normal fresh-frozen colon mucosa samples were obtained 
from patients who underwent surgery between 1988 and 2006 at the Leiden University 
Medical Center (Leiden, The Netherlands) or at the Rijnland Hospital (Leiderdorp, The 
Netherlands). Age, gender, histology, microsatellite instability (MSI), and BRAF V600E 
status for the 19 patients used for the array profiling are listed in Supplementary Table S1. 
Prior to DNA isolation, frozen sections were micro-dissected to minimize the presence of 
normal epithelium and stromal cells. To correct for age-dependent methylation, we used 
normal mucosa, distant from the tumor, from the same individuals. DNA was isolated by 
phenol/chloroform extraction and ethanol precipitation from 10-20 sections of 30 µm and 
yielded 10-50 µg. The present study was approved by the Medical Ethics committee of the 
LUMC (protocol P01-019). Cases were analyzed following the medical ethical guidelines 
described in the Code Proper Secondary Use of Human Tissue established by the Dutch 
Federation of Medical Sciences.
BRAF mutation analysis
BRAF V600E mutations were detected using flanking primers that have been previously 
described17. PCR products were purified with the QIAquick PCR Purification kit (Qiagen, 
Hilden, Germany). Sequencing was performed at the Leiden Genome Technology Center 
(LGTC, Leiden, The Netherlands) using an ABI 3730 XL (Applied Biosystems, Foster City, 
CA). Mutational analysis was performed using mutational surveyor (SoftGenetics LLC., 
State College, PA). Results are summarized in Supplementary Table S1.
Array hybridization
Differential methylation hybridization (DMH) was performed according to Yan et al. 18. 
DNA (500 ng) was digested with MseI, ligated to linkers, and sequentially digested with 
two methylation-sensitive restriction enzymes (HpaII and BstUI, New England Biolabs, 
Ipswich, MA, USA). Digested linker-ligated DNA was used as template for polymerase 
chain reaction (PCR) amplification (20 cycles) and coupled to fluorescent dyes. Cy5- or 
Cy3-labeled amplicons, representing methylated DNA fragments derived from tumor and 
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normal samples, were co-hybridized to the Agilent 244k human CpG island microarrays 
(Agilent Technologies, Santa Clara, CA, USA) in a dye-swap setup. Detection was done on 
a G2565BA scanner (Agilent Technologies) and feature extraction using Feature Extraction 
Software version 9.5.3.1 (Agilent Technologies). 
Array data analysis
Non-background corrected data was preprocessed by within-array loess normalization 
followed by between-array aquantile normalization using limma v3.2.119 in R2.10.020. Data 
was corrected for gene-specific dye bias using R package dyebias v1.4.021. Raw data and 
preprocessed log2 ratios (tumor versus normal) per probe are available via GEO under 
accession number GSExxxxx. Probes mapping to the same MseI fragment were expected to 
show similar hybridization patterns and not be independent. Therefore, we mapped probes 
to the human genome (UCSC assembly March 2006) cut in silico with MseI. Fragments of 
150-3000 bp mapping at least one complete probe and containing at least one BstUI or 
HpaII restriction site (n=32,171) were selected. In total, 195,625 of the 244,000 array probes 
(80.2%) mapped to such informative fragments, mostly with 1-2 probes per fragment, up 
to 33. For statistical analysis and visualization, the median log ratio per fragment was used 
to represent the fragment. Methylation differences between tumor and normal samples 
and tumor subgroups were analyzed using a linear model in limma v3.2.119. The obtained 
P-values were corrected for multiple-testing22 and fragments with a false discovery rate 
(FDR) <= 0.01 were selected as significant. 
MLH1 and cimP marker methylation
DNA samples (500 ng) were converted using the EZ DNA methylation Gold bisulphite kit 
(Zymo Research). For validation of methylation changes we performed a methylation-specific 
PCR (MSP) on the MLH1 promoter using primers previously described23 (Supplementary 
Table S1). Methylation of previously described CIMP markers:MINT1, MINT2, MINT12, 
MINT31, RIZ1 and TIMP3 was determined by MSP, while MINT27 and Megalin methylation 
was determined by Combined Bisulfite Restriction Analysis (COBRA)6, 24. Amplifications were 
carried out in a DNA Engine Dyad Peltier Thermal Cycler (Bio-Rad, Hercules, CA, USA) using 
AmpliTaq Gold PCR buffer and enzyme (Applied Biosystems, Foster City, USA). Amplified 
bands were visualized on a 2% agarose gel. 
Exploratory data analysis
Differentially methylated fragments were compared to publicly available data containing 
chromosomal regions identified in chromatin immunoprecipitation using antibodies 
against H3K27me3, H3K4me3, CTCF and SUZ12 in ES cells followed by high-throughput 
sequencing25-27. By using the sqldf R package (version 0.3-5), we determined overlap of at 
least 20 bp between CpG fragments represented on the array and these regions. Enrichment 
of chromatin domains among the differentially methylated fragments was calculated by 
χ-squared test. Functional annotation clustering was performed in Panther 6.028. Filtering 
of the differential methylation datasets by H3K27me3 in ES cells using the dataset from Zhao 
et al.27 was performed in R using the sqldf package.
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results
Colon cancer-specific CpG island methylation 
We identified 1770 CpG-rich fragments with significant methylation differences between 
tumor and paired normal colon. Of these, 1234 fragments were associated with 816 genes, 
of which 531 were localized to gene promoters (Supplementary Table S2). As expected, 
CpG islands were mostly found hypermethylated in tumors (78.8%)11. 
We compared our results with those of Irizarry et al11 who described 2707 cancer-specific 
differentially methylated regions (cDMRs) based on the comparison of 13 colorectal cancer 
tumor-normal pairs. Of the described cDMRs, 1203 overlapped with our CpG island array 
fragments, of which 282 (23%) were also differentially methylated between tumor and 
normal in our analysis. This overlap is reasonable considering the different, modest sized 
patient groups, and different experimental approaches. 
CIMP-specific methylation
Next, we compared the tumor-normal methylation ratios between different groups of 
patients. Between CIMP-positive (n=11) and CIMP-negative (n=8) patients 749 CpG-rich 
fragments showed methylation changes, of which 85.6% had a higher tumor-normal 
methylation ratio in the CIMP-positive group. Of these fragments, 589 were associated 
with 508 genes, of which 244 were localized to gene promoters (Supplementary Table 
S3). In 8 out of 11 CIMP-positive tumors, promoter methylation of MLH1, the cause 
of microsatellite instability (MSI) in sporadic colon cancer, was observed which was 
consistent with methylation-specific PCR (Supplementary Table S1). We conclude that 
the hypermethylation in specific genomic regions used to define CIMP6 is associated with 
methylation changes throughout the genome.
BRAF mutation-specific methylation 
Activating BRAF mutations have been associated with high levels of CpG island methylation 
and MSI in colon cancer2-8. To investigate this association we compared the tumor-normal 
methylation ratio profiles of BRAF wildtypes (n=11) with those containing the BRAF V600E 
mutation (n=8). We identified 758 fragments with a BRAF mutation-specific methylation 
change, of which 96.3% had a higher tumor-normal methylation ratio in the BRAF mutant 
group. Out of these 758 fragments 579 were associated with 479 genes, of which 229 were 
localized to gene promoters (Supplementary Table S4). 
Since BRAF mutations and CIMP co-occurred in eight samples, there was a high level of 
overlap between CIMP- and BRAF mutation-specific methylation changes (Figure 1A). 











Figure 1- Proportional Venn diagrams showing the overlap between BRAF mutation- (blue) and CIMP-specific 
(yellow) methylation changes for all CpG-rich fragments (A) and promoter fragments filtered for H3K27me3 
binding in ES cells (B).
Regions with tumor, CIMP and BRAF mutation-associated methylation changes 
are enriched for SUZ12 and H3K27me3 while depleted for CTCF and H3K4me3
Regions binding the polycomb repressor complex 2 (PRC2) component SUZ12 in ES cells29 
were found to be enriched among the loci differentially methylated between colon cancer 
and normal colon (Table 1). The histone mark H3K27me3 is mediated by the PRC2 complex29, 
and the two marks have been reported to be highly correlated13. Enrichment of ES cell 
H3K27me3 binding regions among the fragments with colon cancer-associated methylation 
changes was therefore expected and indeed observed. Similarly, fragments with CIMP- and 
BRAF mutation-associated differential methylation changes were also highly enriched for 
regions binding SUZ12 and H3K27me3 in ES cells (Table 1). Additionally, sites binding CTCF 
and the active chromatin mark H3K4me3 were underrepresented among the differentially 
methylated fragments. Interestingly, although all colon cancer-, CIMP- and BRAF mutation-
specific fragments are underrepresented for H3K4me3, this depletion is most evident for 
BRAF mutation-specific fragments.
After exclusion of fragments with H3K27me3 pre-marking in ES cells the overlap between 
CIMP- and BRAF mutation-specific methylation changes for all loci (Figure 1A) and promoters 
(Figure 1B) remained highly significant. Despite this high level of overlap approximately 
50% of BRAF mutation-specific methylation changes showed no overlap with CIMP. In our 
functional analysis we focused on all promoter fragments with BRAF mutation-specific 
methylation changes regardless of overlap with CIMP.













    
    














    
    
    
    
    
    








    
    
    



































   
   














   
   













   
   
   
   
   






























































   
   














   
   














   
































































   
   














   
   














   



















   
   
   
   




































































































































































































































































































































































































































































































































































































BRAF mutation-associated methylation pathway analysis 
To identify biological pathways affected by BRAF mutation-associated gene methylation, 
we used 186 promoter regions that did not bind H3K27me3 in ES cells representing 125 genes 
after exclusion of duplicates and annotation by Panther 6.0. We found five significantly 
enriched pathways (P-val < 0.01, Table 2) containing 13 unique genes (Table 2). 
With seven genes, the WNT pathway contained the most BRAF mutation-specific methylation 
changes (Table 2). However, the tumor-normal log2 ratios (Figure 2) of AXIN1, CREBBP, GSK3A 
and NKD2 in the BRAF wildtype samples were low (-0.26 median, 0.12 standard deviation) 
compared to those in the BRAF mutated samples (-0.02 median, 0.12 standard deviation). 
While this could indicate tumor hypomethylation in BRAF wildtype samples compared to 
normal and BRAF mutated samples, the high level of chromosomal instability among BRAF 
wildtype samples suggests that copy-number loss is the most plausible explanation for this. 
To filter for this phenomenon we excluded fragments with a log2 ratio below one standard 
deviation of the median log2 ratio of all BRAF mutation-specific fragments in the BRAF 
wildtype group. A significant increase in the BRAF mutant log2 ratios compared to those of 
the BRAF wildtypes (approximately 0), indicate BRAF mutation-specific hypermethylation 
in these colon cancer samples (Figure 2). Upon filtering nine of the pathway associated 
genes remained (SMO, FOXB1, FOXB2, FOXD3, CCND1, GNG4, LEF1, MTERF, TAF7) and the 
PI3 kinase pathway was the only statistically significant enriched (P-val: 5.5E-03) pathway. 
Interestingly, besides promoter methylation of PI3 kinase pathway-associated forkhead 
box (FOX) genes we identified promoter methylation of three other FOX transcription 
factors: FOXA1, FOXC1 and FOXF1. However, these promoters were bound by H3K27me3 and 
were excluded from our pathway analysis.     


















































































































































































































































































































































































































































































Figure 2 - Scatter plots for 9 unique genes with BRAF mutation-specific promoter methylation causing 
pathway enrichment. The Y-axis represents the tumor-normal log2 ratio for the median probe per fragment. 
Sample IDs are given below the X-axis with BRAF wildtypes left of the black line and BRAF mutants on the 
right. Median log2 ratios and standard deviations (dotted lines) for the BRAF wt and BRAF mutant groups are 




In this study we extended the number of screened CpG loci compared with previous 
studies performed in context of BRAF mutations to identify new BRAF mutation-specific 
methylation changes. This association between DNA methylation and activating BRAF 
mutations in colon cancer has been identified in multiple studies2-8. Here, we attempted to 
identify additional targets of BRAF mutation-specific DNA methylation that could provide 
a favorable context to either obtain a BRAF mutation or to attain the full potential of RAS-
RAF-MEK induced proliferation provided by this activating mutation. Identified targets 
of promoter methylation showing pre-marking by H3K27me3 in ES cells were excluded to 
filter out methylation changes with minimal expected effects on transcription and thereby 
tumorigenesis13. We showed high levels of overlap between CIMP- and BRAF mutation-
specific methylation changes which remained after filtering out pre-marked loci. Although 
Rada-Iglesias et al. showed a higher pre-marking of colon cancer-specific DNA methylation 
by H3K27me3 binding in normal colon epithelium compared to ES cells, we were restricted 
to using ES cell data due to incompatibility between data formats in our analyses13. 
Interestingly the promoter region of MLH1, found methylated in both a CIMP- and BRAF 
mutation-specific manner, was not filtered out. Therefore, MLH1 promoter methylation, the 
cause of sporadic MSI colon cancer, is not established through utilization of a pre-existing 
repressive program in ES cells.
The study by Hinoue et al.2 described BRAF mutation-specific DNA methylation of 60 genes 
in a comparison of 1505 CpG sites between 33 BRAF mutated tumors and 202 BRAF wildtype 
tumors. The identification of promoter methylation of the mediator of BRAFV600E-induced 
senescence, IGFBP7, led them to suggest that this epigenetic silencing provides a favorable 
context for the acquisition of BRAF mutations2, 30. Despite differences in experimental 
techniques and coverage, ten genes overlapped with our set of BRAF mutation-specific 
methylated fragments, including the RAS-RAF hyperactivation-associated BMP3, receptor 
kinases EPHA3 and FLT3 as well as the Hedgehog (Hh) signaling protein SMO. However, no 
overlap was found for the mediator of RAS-RAF oncogene-induced senescence, IGFBP7, 
possibly due to lack of IGFBP7 promoter area coverage in our assay. Additionally, BMP3 and 
EPHA3 were pre-marked by H3K27me3 in our analysis suggesting minimal impact on gene 
expression and tumorigenesis. 
We initially identified enrichment of five cancer-associated pathways by BRAF mutation-
specific promoter methylation of 9 unique genes. Our analysis took into account copy 
number changes and filtered for this which could improve the reproducibility of DMH 
based assays18, 31. Exclusion of these loci resulted in the PI3-kinase pathway as the only 
pathway enriched in our analysis. 
Among the four genes enriched in this pathway are the FOX transcription factors FOXD3, 
FOXB1 and FOXB2. A recent study described FOXD3 as a p53 and p21cip1-dependent negative 
cell cycle regulator which is suppressed by activated BRAF in melanoma cells32. Down-
regulation of FOXD3 levels by promoter methylation could provide a favorable setting for 
either acquisition of a BRAF mutation or proliferation by RAS-RAF-MEK over-activation in 
colon cancer, similar to IGFBP72. Interestingly, the FOXO transcription factors have been 
described as mediators of p21cip-dependent BRAF induced senescence as well, indicating 
that multiple FOX genes are involved in this process33. We identified additional FOX genes 
with BRAF mutation specific promoter methylation that were not annotated as part of 
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the PI3-kinase pathway in our analysis as they were pre-marked by H3K27me3 in ES cells: 
FOXA1, FOXC1 and FOXF1. However, the promoters of these genes were also pre-marked 
with H3K4me3 indicating possible tissue-specific expression of these genes. All three are 
targets of inactivation in breast cancer and both FOXC1 and FOXF1 subjected to promoter 
methylation34-36. Most intriguing is the description of FOXF1 as an inducer of G1-S and S-G2 
cell cycle arrest, indicating a possible role in oncogene induced senescence35. Additional 
research is required to determine the role of these FOX genes in colon cancer-associated 
oncogene induced senescence and what the impact of their promoter methylation is on 
this mechanism. Finally, research into the sequence of such events is required to provide a 
better insight in the association between activating BRAF mutations and DNA methylation 
in colon cancer.
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supplementary table s1 - Sample information. Gender (indicated by M for male and F for female), Age, 
Histology (indicated by Ad for adenoma and Ca for carcinoma), MLH1 promoter methylation status and BRAF 








































117 M 69 Ad U - wt
180 F 86 Ad U - wt
118 F 69 Ad U - wt
127 F 87 Ad U - wt
577 M 32 Ad U - wt
187 F 61 Ca U - wt
503 F 63 Ca U - wt
97 F 68 Ca U - wt
131 F 71 Ca U + mut
505 F 83 Ca U + wt
63 F 57 Ca U + mut
57 F 75 Ca pM + mut
601 F 83 Ad M + wt
56 M 75 Ca M + mut
499 F 69 Ca M + mut
119 F 76 Ca M + wt
49 F 80 Ca M + mut
179 M 90 Ca M + mut
132 F 64 Ca M + mut
supplementary table s2 - Fragments with tumor-specific methylation changes. Genomic location is 
provided by chromosome number (Chr) and the start (start) and end (end) position in the human genome 
build 18 (UCSC assembly: March 2006) basepair number. Annotation as promoter, divergent promoter or 
otherwise and the associated gene (UniGene and EntrezGene numbers) in case of promoter or intergenic 
(annotated as inside) is given as well as fragments length (length), number of DNA methylation-specific 
restriction sites (BstUI and HpaII), number of probes located in the specific fragment (Probes) and pre-marking 
by H3K27me3 in ES cells. Available upon request
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supplementary table s3 - Fragments with CIMP-specific methylation changes. Genomic location is provided 
by chromosome number (Chr) and the start (start) and end (end) position in the human genome build 18 
(UCSC assembly: March 2006) base pair number. Annotation as promoter, divergent promoter or otherwise 
and the associated gene (UniGene and EntrezGene numbers) in case of promoter or intergenic (annotated as 
inside) is given as well as fragments length (length), number of DNA methylation-specific restriction sites (BstUI 
and HpaII), number of probes located in the specific fragment (Probes) and pre-marking by H3K27me3 in ES 
cells. Available upon request
supplementary table s4 - Fragments with BRAF mutation-specific methylation changes. Genomic location is 
provided by chromosome number (Chr) and the start (start) and end (end) position in the human genome build 
18 (UCSC assembly: March 2006) base pair number. Annotation as promoter, divergent promoter or otherwise 
and the associated gene (UniGene and EntrezGene numbers) is given as well as fragments lengths, number of 
DNA methylation-specific restriction sites (BstUI and HpaII), number of probes located in the specific fragment 
(Probes) and pre-marking by H3K27me3 in ES cells. Available upon request
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         chapter 5
specific promoter methylation identifies different 
subgroups of MLL-rearranged infant Acute lymphoblastic 
leukemia, influences clinical outcome and provides 
therapeutic options
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sPeciFic Promoter metHylAtioN iDeNtiFies DiFFereNt 
sUBGroUPs oF MLL-reArrANGeD iNFANt AcUte 
lymPHoBlAstic leUKemiA, iNFlUeNces cliNicAl oUtcome 
AND ProviDes tHerAPeUtic oPtioNs
Abstract 
MLL-rearranged infant Acute Lymphoblastic Leukemia (ALL) remains the most aggressive 
type of childhood leukemia, displaying a unique gene-expression profile. Here we 
hypothesized that this characteristic gene-expression signature may have been established 
by potentially reversible epigenetic modifications. To test this hypothesis, we used 
Differential Methylation Hybridization (DMH) to explore the DNA methylation patterns 
underlying MLL-rearranged ALL in infants. The obtained results were correlated with 
gene-expression data to confirm gene silencing as a result of promoter hypermethylation. 
Distinct promoter CpG island methylation patterns separated different genetic subtypes 
of MLL-rearranged ALL in infants. MLL translocations t(4;11) and t(11;19) characterized 
extensively hypermethylated leukemias, whereas t(9;11)-positive infant ALL and infant ALL 
carrying wild-type MLL genes epigenetically resembled normal bone marrow. Furthermore, 
the degree of promoter hypermethylation among infant ALL patients carrying t(4;11) or 
t(11;19) appeared to influence relapse-free survival, with patients displaying accentuated 
methylation being at high relapse risk. Finally, we show that the demethylating agent 
zebularine reverses aberrant DNA methylation, and effectively induces apoptosis in MLL-
rearranged ALL cells. Collectively these data suggest that aberrant DNA methylation occurs 
in the majority of MLL-rearranged infant ALL cases and guides clinical outcome. Therefore 
inhibition of aberrant DNA methylation may be an important novel therapeutic strategy 
for MLL-rearranged ALL in infants.
introduction 
While long-term survival rates in childhood Acute Lymphoblastic Leukemia (ALL) exceed 
80%1, the survival chances of infants (<1 year of age) still range between 20-50%2. 
Approximately 80% of infants with ALL carry chromosomal translocations involving the 
MLL gene3, fusing the N-terminal portion of the MLL gene to the C-terminal region of one 
of its translocation partner genes. The most frequent MLL translocations among infant ALL 
patients are t(4;11), t(11;19) and t(9;11)2,4, giving rise to the fusion proteins MLL-AF4, MLL-
ENL and MLL-AF9. These chimeric MLL fusion proteins exhibit pronounced transforming 
capacities5, and independently contribute to an unfavorable prognosis.2, 6
As a member of the trithorax gene family, MLL is involved in transcriptional regulation7. 
Therefore, structural alterations of this gene may be expected to affect its function, 
presumably leading to transcriptional deregulation. Not surprisingly, recent gene 
expression profiling studies characterized MLL-rearranged ALL as a unique type of 
leukemia that is genetically clearly separable from other ALL subtypes8,9. As epigenetic 
modifications affect gene expression patterns10, we hypothesized that the specific gene 
expression profiles associated with MLL-rearranged infant ALL may well be driven by 
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epigenetic changes, which recently have been established to play important roles in the 
development and progression of leukemia11. The most widely studied epigenetic event in 
hematological malignancies constitutes transcriptional gene silencing by promoter CpG 
island hypermethylation11,12. This phenomenon either leads directly to the silencing of 
tumor suppressor genes, or indirectly to up-regulation of other genes, when silencing of 
certain regulatory genes relaxes the suppression on their target genes. Hence, genome-
wide promoter hypermethylation potentially results in abnormal gene expression profiles 
that favor malignant transformation. For example, we recently demonstrated that FHIT, 
a putative tumor suppressor gene, is characteristically silenced in MLL-rearranged infant 
ALL cells by CpG hypermethylation, and that re-expression of this gene induced apoptosis 
in these cells13. 
Here we applied Differential Methylation Hybridization (DMH), an array-based technique that 
allows genome-wide screening of DNA methylation, using two different microarray platforms 
to explore the DNA methylation patterns underlying MLL-rearranged infant ALL. We show that 
different types of MLL translocations are associated with distinct patterns of DNA methylation, and 
we found that the degree of DNA methylation influences clinical outcome, identifying subgroups 




We studied 57 newly diagnosed infant ALL patients, enrolled in the international 
INTERFANT-99 treatment protocol2 (patient characteristics listed in Supplemental table 
1). Forty-four patients (77%) carried MLL translocations, and thirteen (23%) harbored 
untranslocated (wild-type) MLL genes. Among the MLL translocated patients, twenty 
one were positive for t(4;11), seventeen for t(11;19) and six patients carried translocation 
t(9;11). Written informed consent and institutional review-board approval were obtained 
for all patients. Whole normal bone marrow samples obtained from eight non-leukemic 
pediatric patients were included as controls. Leukemic cell isolation and enrichment 
to achieve more than 90% leukemic blasts, as well as DNA and RNA extractions were 
performed as described before14.
Leukemia cell lines 
RS4;11, SEMK2 and BEL-1 represent t(4;11)-positive precursor B-cell ALL cell lines. SEMK2 
was originally derived from a 5-year-old girl at relapse15 and was kindly provided by Dr. 
Scott Armstrong (Dana Farber Cancer Institute, Boston, Massachusetts, USA). BEL-1 was 
a generous gift from Dr. Ruoping Tang (University Laboratory, Paris, France).16 RS4;11 was 
established from the bone marrow of a 32-year-old woman17, and was, like all other cell 
lines used in this study, purchased from the German Collection of Microorganisms and 
Cell Cultures (DSMZ, Braunschweig, Germany). KOPN-8 harbors translocation t(11;19) 
and was derived from a 3-month-old infant girl with B-cell precursor ALL. REH and TOM-1 
represent precursor B-lineage ALL cells exhibiting a TEL-AML1 fusion, and a Philadelphia 
chromosome, respectively. JURKAT and HSB2 both are T-lineage ALL cell lines, and 
Kasumi-1 and MV4;11 are AML cell lines. Kasumi-1 carries the t(8;21) AML1-ETO fusion 
gene, and MV4;11 harbours MLL translocation t(4;11). All cell lines were maintained as 
suspension cultures in RPMI 1640 with L-Alanyl-L-Glutamine (Invitrogen) supplemented 
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with 10% FCS (Integro), 100 IU/ml penicillin, 100 μg/ml streptomycin, and 0.125 μg/ml 
fungizone (Invitrogen) at 37°C in humidified air containing 5% CO2. 
Differential Methylation Hybridization using CpG island microarrays 
Differential Methylation Hybridization (DMH) was performed essentially as described 
by Yan et al. (Supplemental Methods)18,19. DMH was applied on two different CpG island 
microarray platforms with limited overlap in CpG island probes. The first was the custom 
spotted 9K microarray chip developed by Huang and co-workers, containing 8,640 MseI 
fragment probes18. In addition, we also used the first commercially available genome-wide 
CpG island microarrays (Agilent Technologies, Santa Clara, USA). These high-resolution 
microarrays contain 243,497 60-mer oligonucleotide probes, including 67,487 CpG island 
probes located in or near gene promoters. For the present study, only these probes located 
in gene promoters were used. Due to restricted availability of patient material, DNA 
methylation profiling using the Agilent microarrays was performed in 49 of the 57 infant 
ALL patients.
Gene expression profiling using Affymetrix GeneChips 
Gene expression profiles were generated for t(4;11)-positive (n=15) and t(11;19)-positive 
(n=14) infant ALL cases, using the same samples for which DNA methylation profiles were 
already produced on Agilent microarray chips. Expression profiles were also generated 
for whole healthy pediatric bone marrow samples, however, these did not correspond to 
the samples in which the DNA methylation patterns were determined. RNA processing, 
microarray hybridization (HU133 plus 2.0 Affymetrix GeneChips), and washing steps were 
performed according to the manufacturer’s protocol (Affymetrix, Santa Clara, CA, USA). 
The infant ALL gene expression data and DNA methylation data presented in this study 
have been deposited in the NCBI Gene Expression Omnibus and are accessible via the GEO 
Series accession number GSE18400.
In vitro cytotoxicity assay and exposure to zebularine 
In vitro sensitivity of leukemia cell lines to the demethylating agent zebularine20,21 was 
determined by four-day MTT-assays as described previously22. Zebularine was a generous 
gift from Dr. Victor E. Marquez (National Cancer Institute of Frederick, Frederick, Maryland, 
USA). To study the effects of demethylation on MLL-rearranged ALL cells, the cell lines SEMK2 
and RS4;11 were cultured for 10 days in the presence or absence of 100 μM zebularine.
Statistical analyses 
Normalization of the CpG island microarray data was performed using global locally 
weighted scatterplot smoothing (loess) normalization23, and differentially methylated CpG 
islands were identified using the linear models for microarray data (limma) package in 
the R statistical environment (R Development Core Team, 2007) (Supplemental Methods) 
24. The resulting list of p-values was corrected for multiple testing by the false discovery 
rate (FDR) step-up procedure of Benjamini & Hochberg25. An FDR-adjusted p-value <0.01 
was regarded significant. As a measure of internal validation for the subtype-specific 
methylation signatures, permutation testing (global test)26 was applied to evaluate 
whether genes were significantly associated with a certain type of MLL translocation. For 
this, the tendency of repeated re-assignment of individual samples to their original cluster 
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was assessed. (Supplemental Methods)
Relapse-free survival was computed with the Kaplan Meier estimator. The duration of 
relapse-free survival was defined as the time from diagnosis until the date of leukemia 
relapse or the last follow-up. The probability of relapse in complete remission was 
estimated by applying the cumulative incidence estimator. The log-rank test was used 
to compare outcomes between different patient groups, and a one-step Cox model 
was applied to estimate the hazard of relapse for these patients, adjusting for already 
established risk stratification according to the international INTERFANT-06 treatment 
protocol. (Supplemental Methods).
results
Unsupervised analysis based on DNA methylation patterns separates different 
infant ALL subtypes
Using Differential Methylation Hybridization (DMH) on two different microarray platforms, 
genome-wide promoter DNA methylation profiles were generated for infant ALL patients 
carrying MLL translocations t(4;11), t(11;19) or t(9;11), and infant ALL patients bearing wild-
type MLL genes. To explore whether these samples showed leukemia-specific increases in 
promoter CpG island methylation, these profiles were compared with DNA methylation 
patterns obtained from bone marrow samples derived from healthy children. Initially, we 
performed a principal component analysis (PCA), using all CpG island probes present on 
each array without any selection. Based on the first three components of the PCA, which 
explain 41.8% (9K chip) and 32.2% (244K chip) of the total variance, the patient samples 
were visualized (Figure 1). Interestingly, for both microarray platforms, this unsupervised 
analysis separated two major groups. Infant ALL samples that carry t(9;11) or wild-type 
MLL genes clustered together with normal bone marrow samples, whereas infant ALL 
samples carrying t(4;11) or t(11;19) clustered tightly together separately from the other 
samples. Although the cluster comprising t(9;11)-positive, untranslocated infant ALL 
samples and normal bone marrow samples appeared more heterogeneous, it has to be 
taken into account that this cluster consists of three different types of samples. Moreover 
epigenetic heterogeneity is already present among the normal bone marrow samples. 
Finally, we emphasize that this analysis is completely unguided.
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Figure 1 - Unsupervised clustering analysis of DNA methylation in infant ALL. Principal Component Analyses 
(PCA) of the CpG island methylation data from infant ALL patients and normal bone marrows using all probes 
present on each microarray platform. Each case is color-coded indicating the specific infant ALL subgroups. 
a-1. shows data from the custom spotted 9K CpG island microarray. t(4;11) (n=21; red), t(11;19) (n=17; orange), 
t(9;11) (n=6; yellow), MLL wild-type ALL (n=13, green) and normal bone marrow (n=8; blue). a-2. shows data 
from the commercially available 244K CpG island microarray (Agilent). t(4;11) (n=16; red), t(11;19) (n=15; 
orange), t(9;11) (n=6; yellow), MLL wild-type ALL (n=12; green) and normal bone marrow (n=7; blue). Due to 
restricted availability of patient material, Agilent DNA methylation profiles were generated for 49 infant ALL 
patients and 7 normal bone marrow samples.
Specific DNA methylation patterns further separate the different infant ALL 
subtypes
Subsequently, to explore whether specific DNA methylation profiles could define the genetic 
subgroups of infant ALL more accurately, the 20 most discriminative hypermethylated genes 
for each group (as compared with all other relevant subgroups combined) were selected. 
For both microarray platforms the gene names, log-fold changes, and p-values are listed 
in the Supplemental data (tables 2S and 3S). Permutation testing validated the robustness 
of the subtype-specific methylation signatures. Using the selected genes, we generated 
heatmaps in which both the genes and samples were clustered hierarchically (Euclidean 
distance and complete linkage) (Figure 2a). This semi-supervised analysis revealed that 
MLL t(4;11) and t(11;19)-positive patients could clearly be separated from one another 
and from the other samples. In contrast, hypermethylated genes that unambiguously 
separate t(9;11)-positive samples from MLL wild-type (untranslocated) infant ALL samples, 
could not be identified. Moreover, the most significantly hypermethylated genes shared 
by t(9;11)-positive and wild-type MLL samples were also methylated in healthy bone 
marrow samples (Supplemental figure 1S), and therefore likely reflect normal methylation 
in healthy hematopoietic cells. Importantly, these genes are hypomethylated in infant ALL 
harbouring translocation t(4;11) or t(11;19). 
Next, PCA was used to better visualize these different clusters, emphasizing the separation 
of the samples into the three expected groups characterized by t(4;11), t(11;19) or t(9;11) 
together with translocation-negative infant ALL (Figure 2b). When included, the normal 
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bone marrow samples remained within the cluster comprising samples carrying t(9;11) 
or wild-type MLL genes (Figure 2c). In concordance with this, no significant aberrant DNA 
methylation could be detected in t(9;11)-positive or untranslocated (wild-type MLL) infant 
ALL, when separately compared with normal bone marrow. 
Correlation between promoter methylation and gene expression
Given the aberrant methylation patterns in t(4;11)- and t(11;19)-positive infant ALL samples, 
we investigated the effects of promoter hypermethylation (Agilent platform) on gene 
expression (Affymetrix platform) of corresponding genes. Compared with normal bone 
marrow samples, infant ALL cells carrying t(4;11) displayed a total of 794 hypermethylated 
CpG island probes (FDR<0.01), and 75 probes were significantly hypermethylated in 
t(11;19)-positive infant ALL (FDR<0.01). From these analyses, the most significantly 
hypermethylated genes were selected. Gene names, log-fold changes in methylation, 
and p-values for these genes are listed in the Supplemental data (tables 4S and 5S). Next, 
DNA methylation array data was compared with gene expression profiles from the same 
samples, and visualized as heatmaps and PCA plots (Figure 3). Promoter hypermethylation 
and down-regulated gene expression correlated for ~90-95% of the genes in both t(4;11)-
positive and t(11;19)-positive infant ALL. However, for the remaining genes we observed 
the opposite; despite extensive hypermethylation, these genes were higher expressed in 
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Figure 2 - Infant ALL subtype-specific CpG island hypermethylation. a1-2. Heatmaps showing the 20 most 
significantly hypermethylated probes for each infant ALL subtype. Columns represent patient samples and 
rows represent genes. Relative DNA methylation levels are shown in red (high) and blue (low). Genes and 
samples were ordered using hierarchical cluster analysis (Euclidean distance, complete linkage), and gene 
identifiers are listed at the right. b1-2. Principal component analyses (PCA) separating t(4;11) (red), t(11;19) 
(orange), t(9;11) (yellow) and MLL wild-type infant ALL (green). c1-2. shows the PCA when normal pediatric 
bone marrow samples (blue) are included in the analysis. 2-1. shows data from the custom 9K CpG island 
microarray. 2-2. shows data from the commercially available 244K CpG island microarray (Agilent).
Chapter 5
98
The degree of methylation influences clinical outcome in MLL-rearranged infant 
ALL
In both the heatmaps and PCA plots that represent the most significantly hypermethylated 
genes among t(4;11)-positive and t(11;19)-positive infant ALL, a clustering of patient 
samples into two subgroups appeared. Ostensibly, one cluster represents patient samples 
that, at least for the selected genes, seem to be more densely hypermethylated than 
the samples in the other cluster. (Figure 3) To better visualize this difference in degree of 
methylation we plotted the normalized methylation log-ratios of the genes. This semi-
quantitative representation of the data indeed confirmed differences in the degree of 
methylation between both clusters (Figure 2S). To explore the clinical relevance of these 
subgroups, we computed risk of relapse statistics for these patient groups (Figure 3S). 
Four patients received bone marrow transplantation (BMT) in complete remission. For 
these patients data were censored at BMT. One patient died before the start of treatment 
(referred to as early death), and was excluded from further analyses. Twelve out of 16 (75%) 
patients from the “heavily” methylated subgroup had a relapse after achieving complete 
remission, whereas among the “lightly” methylated patients, relapses occurred in 5/12 
(42%) of the cases. The cumulative incidence of relapse at 1 year after diagnosis was 
significantly (p<0.05) different for the “heavily” and “lightly” methylated subgroups with 
incidences of 52.5 (SE: 13.7) and 35.7 (SE: 15.5) respectively. The number of patients that 
could be included in these analyses is not sufficient to evaluate the impact of the degree of 
DNA methylation adjusted for known prognostic factors (like age, white blood cell count 
and the in vivo response to prednisone) separately. Therefore we used the INTERFANT-06 
risk stratification which represents a combination of these factors (see: Supplemental 
Methods)2. Although these results must be interpreted with caution, the Cox regression 
model indicates that heavy methylation confers an increased risk of relapse (hazard ratio 
5.77, 95% CI 1.57-21.2, p=0.01) (table 6S). The separate clustering of these two patient 
groups, however, did not appear in the gene expression profiles (Figure 3). This implies that 
the grouping of these patients and the observed variance in relapse-free survival rather 
reflects progressive accumulation of genome-wide methylation, than direct differences in 
gene expression. In line with this hypothesis we show that the division into “heavy” and 
“light” methylation remains present when all significantly hypermethylated probes are 
used in a semi-quantitative representation (Figure 2S).





Methylation patterns in MLL-rearranged infants
99
Figure 3 - Correlation between CpG island methylation and gene expression. a. Heatmap and PCA showing 
the most significantly hypermethylated genes in t(4;11)-positive infant ALL (red dots) compared with normal 
bone marrows (blue dots). Relative DNA methylation levels are shown in red (high) and blue (low). b. Heatmap 
and PCA showing the corresponding gene expression levels from the same genes and samples as presented 
in Figure 3A. Relative gene expression values are shown in red (high) and green (low). Similarly, the c. CpG 
methylation data and d. gene expression data are presented for t(11;19)-positive infant ALL samples (orange 
dots) as compared with normal bone marrows (blue dots).
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MLL t(4;11)-positive cell lines as models for demethylation 
DNA methylation patterns of two t(4;11)-positive precursor B-cell ALL cell lines (i.e. RS4;11 
and SEMK2) were compared with the profiles from the t(4;11)-positive infant ALL samples. 
Nearly 50% of the 100 most significantly hypermethylated genes in t(4;11)-positive infant 
ALL were also hypermethylated in these cell lines (Figure 4a). Representing reasonable 
models for t(4;11)-positive infant ALL samples, we next studied the effects of demethylation 
on these genes by comparing DNA methylation profiles of these cell lines before and after 
a 10-day exposure to 100 µM of the demethylating agent zebularine. In the SEMK2 and 
RS4;11 cell lines, respectively 72% (33/46) and 59% (27/46) of the hypermethylated genes 
showed notable decreases in methylation upon exposure to zebularine. The genes display 
varying degrees of drug-induced demethylation (Figures 4b-c). For some of the genes 
the methylation status could be restored to nearly normal levels as observed in healthy 
hematopoietic cells. 
Specific zebularine sensitivity in MLL-rearranged ALL cells
To further investigate the sensitivity of ALL cells to in vitro demethylation, cytotoxicity 
assays were performed using escalating dosages of zebularine. Also two AML cell lines 
were added to the data set. AML cells (with or without an MLL translocation) seem to be 
less sensitive to the demethylating agent zebularine than MLL-rearranged ALL cells, but 
the MLL-rearranged AML cell line MV4-11 does appear more sensitive than the t(8;21)-
positive AML cell line Kasumi-1. Clearly, MLL-rearranged ALL cells were significantly more 
sensitive to zebularine than the other cell lines (p<0.01) (Figures 5A-B). As shown in figure 
5B, on average the IC50 value (i.e. the concentration inhibitory to 50% of the cells) in MLL-
rearranged ALL cells was ~50 µM, whereas zebularine failed to reach an IC50 value in other 
types of ALL cell lines.
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Figure 4 - ALL cell lines as models for (de)methylation a. Heatmap showing methylation levels in the t(4;11)-
positive B-ALL cell lines SEMK2 (light green dot) and RS4;11 (dark green dot) of genes most significantly 
methylated in t(4;11)-positive infant ALL patients (red dots) as compared with normal bone marrows (blue 
dots). b. Heatmaps showing methylation levels of these genes after exposure to zebularine. These methylation 
levels were compared with the average methylation levels as determined from normal bone marrow samples 
(n=7). b1 SEMK2 cell line and b2. RS4;11 cell line c1-6. Graphs displaying the mean and the standard error of 
the mean (SEM) of changes in methylation levels after zebularine exposure. Genes were divided into three 
groups for each cell line according to the degree of responsiveness to zebularine. c1-3. SEMK2 cell line and 
c4-6. RS4;11 cell line.
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Figure 5 - In vitro cytotoxicity to zebularine. a. Dose-response curves showing the in vitro cytotoxic response 
to zebularine in individual leukemia cell lines with or without MLL rearrangements, or b. the mean cytotoxic 
response for MLL-rearranged ALL cell lines (n=4) and for the other ALL cell lines (n=4). Error bars represent 
standard error of the mean (SEM). The differences between the means of the groups were statistically analyzed 
using the 2-tailed Student t test (p<0.01 for each concentration used).
Discussion
We here present the first global view of the DNA methylome in infant MLL-rearranged 
Acute Lymphoblastic Leukemia (ALL). MLL-rearranged infant ALL represents an aggressive 
and difficult to treat type of leukemia characterized by a unique gene expression profile, 
that clearly separates this malignancy from other ALL subtypes8, 9. Since epigenetic 
modifications directly influence gene expression patterns10, we hypothesized that specific 
DNA methylation patterns may underlie the characteristic gene signature as observed for 
MLL-rearranged infant ALL. Our data largely support this hypothesis, as the majority of 
MLL-rearranged infant ALL cases (i.e. those characterized by t(4;11) or t(11;19)) represent 
hypermethylated leukemias, whereas t(9;11)-positive and MLL translocation-negative 
(wild-type MLL) infant ALL display DNA methylation patterns that closely resemble that 
of normal bone marrow. Moreover, distinct leukemia-specific DNA methylation patterns 
could be identified for the different MLL-rearranged infant ALL subtypes as defined by the 
type of MLL translocation or absence of such translocations. Interference of non-leukemia 
related epigenetic differences in DNA methylation (such as age, sex-specific differences in 
methylation and differences related to B-cell maturation stages of leukemic cells) with our 
results could be excluded (Supplemental Results, tables 7S and 8S). 
Thus, the presence as well as the patterns of aberrant DNA methylation in infant ALL 
appear, at least to some extent, dependent on the presence and type of MLL fusion, 
which may reflect a mechanism proposed recently27. Apart from DNA methylation, a 
second component of the epigenetic code involves histone modifications28, shaping 
the chromatin in an open (transcriptionally active) or closed (inactive) conformation. An 
inactive chromatin state usually is associated with hypermethylated CpG promoter regions, 
whereas active chromatin marks, such as H3K4 trimethylation and H3K79 dimethylation, 
denote unmethylated promoters, allowing transcription. Interestingly, the MLL gene 
itself has specific histone methyltransferase activity29,30, which is lost during fusion of the 
MLL gene to one of its translocation partners. Therefore, MLL fusions can be expected to 
result in altered chromatin structures due to aberrant histone modifications. Recently, 
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Krivtsov and Armstrong (2007) proposed that the recruitment of different histone 
methyltransferases by different MLL fusion proteins, may indeed result in inappropriate 
histone modifications directed by the MLL fusion partner27. Given the sound interplay 
between histone modification and CpG island methylation, this proposed influence of 
different MLL fusion genes on histone modifications, and the apparent influence of the 
MLL fusion partner on DNA methylation as shown in the present study, are presumably 
linked. In addition, the paper by Krivtsov et al.(2007)27,as wells as the study by Mueller 
and co-workers (2007)31 demonstrated the recruitment of a transcriptional elongation 
complex to MLL target genes, resulting in gene activation (i.e. expression). These studies 
suggest that MLL fusion proteins trigger or maintain the leukemia by the activation of 
specific target genes. In contrast, our present study shows that, apart from specific gene 
activation, MLL-rearranged ALL is also characterized by severe gene inactivation, which 
may well be driven by the same MLL fusion. MLL-rearranged ALL cells typically mirror 
highly immature B-cells. Possibly, the MLL fusion ignores the activation of many genes 
that should have been activated (by wild-type MLL) at this stage of B-cell development, 
and necessary for proper differentiation towards mature and functional B-cells. This would 
suggest that our observed patterns of gross genome-wide DNA methylation is in favor 
of blocking B-cell differentiation, while simultaneously the MLL fusion activates several 
(proto-onco)genes in favor of uncontrolled cell proliferation and survival. Alternatively 
(or additionally), inappropriate activation of certain genes by the MLL fusion, may in turn 
induce abnormal inactivation (silencing) of several other genes. However, these proposed 
mechanisms are highly speculative and remain to be confirmed. 
Nonetheless, we can conclude from our data that MLL-AF4 and MLL-ENL represent MLL 
fusion proteins that both alter histone modifications that result in strongly altered DNA 
methylation patterns. The differences found in DNA methylation patterns between MLL-
AF9 and MLL-ENL may then seem surprising given the apparent common mechanism 
of transformation involving the recruitment of DOT1L as put forward by others 27,31. 
Surprisingly, the MLL-AF9 fusion did not lead to significant aberrant DNA methylation in 
infant ALL. This suggests that oncogenic transformation in t(4;11)- and t(11;19)-positive 
infant ALL patients may be facilitated or largely driven by gross epigenetic changes, 
whereas t(9;11)-positive infant ALL cells presumably transform via alternative mechanisms. 
In concordance with this is that t(9;11)-positive ALL patients characteristically seem to be 
different from other MLL-rearranged infant ALL patients. For example, t(9;11)-positive infant 
ALL is typically diagnosed at a later stage during infancy and usually is characterized by 
a more mature immunoglobulin gene rearrangement pattern (immunophenotype) than 
t(4;11)- and t(11;19)-positive infant ALL2,4. On the other hand, no significant differences in 
survival exist between infant ALL patients carrying either t(4;11) or t(11;19) and patients 
with t(9;11).2
Studying the genes most significantly hypermethylated in t(4;11)- and t(11;19)- positive 
infant ALL samples, we found that the expression of the vast majority of these genes 
(~90-95%) was indeed down-regulated. Among the hypermethylated genes we found 
genes that were previously described to be silenced due to DNA hypermethylation in 
MLL-rearranged ALL, such as the tumor suppressor gene FHIT13 and the DLX3 gene32, 
demonstrating the integrity of our data. Moreover, most of these genes responded well 
to exposure to the demethylating agent zebularine in t(4;11)-positive cell line models. 
Among the most significantly hypermethylated genes for either t(4;11)-positive or t(11;19)-
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positive infant ALL, a limited overlap was observed. Nevertheless, global gene ontology 
analysis showed that most of the down-regulated genes in both subgroups are involved 
in transcriptional regulation (table 9S). This pronounced epigenetic deregulation of the 
transcriptional machinery may indeed have contributed to the unique gene expression 
profile characteristic for MLL-rearranged ALL8,9. Yet, this would not be true for t(9;11)-positive 
infant ALL, as no aberrant promoter hypermethylation was observed in these samples. This 
apparent contradiction, however, is easily explained by the fact that most of the published 
MLL-specific gene expression signatures, including the signatures reported by Armstrong 
et al. (2002) are predominantly based on t(4;11)- and t(11;19)-positive samples8. Therefore 
gene expression profiling studies including t(9;11)-positive infant ALL samples may well 
come to demonstrate that profiles associated with t(9;11) are different from those obtained 
in t(4;11)- and t(11;19)-positive samples.
 Remarkably, about 5% of the most significantly hypermethylated genes in t(4;11)- and 
t(11;19)-positive infant ALL remained highly expressed. This observation controverts the 
dogma that promoter methylation per definition induces suppression of gene expression. 
However, Weber and co-workers recently nuanced this dogma by elegantly demonstrating 
the influence of promoter CpG density on the ability to induce transcriptional repression33. 
Therefore, these methylated but highly expressed genes may well exhibit promoters 
containing weak CpG islands (i.e. a low or intermediate CpG density), unable to repress 
transcription even when methylated. Another possible explanation for this would again 
be the involvement of the MLL fusion protein, which may have induced activating histone 
modifications on otherwise inactive regions in the chromatin associated with promoter 
methylation. In turn, this newly acquired open chromatin state may have overruled the 
relatively weak DNA methylation, allowing transcription despite earlier established 
epigenetic silencing. If so, this group of genes may well represent potential therapeutic 
targets directly influenced by the MLL fusion itself. 
Most of the genes that were methylated in t(9;11)-positive infant ALL and infant ALL carrying 
wild-type MLL genes were also methylated in normal bone marrow. Presumably, these 
represent genes that were already silenced in normal hematopoietic cells, but became 
hypomethylated in t(4;11) and t(11;19) positive infant ALL cells. Interestingly, among these 
were several genes with oncogenic potential, such as CDH3, TBX2, ERCC1 and NPR2 (figures 
2A-B), that have been reported to be involved in proliferation, tumor aggressiveness and 
prognosis in a wide range of human cancers34,35. Interestingly, among these hypomethylated 
genes also appeared the HOXA9 gene which was previously described to be protected 
from methylation by the MLL-fusion itself36. Thus, the present study not only characterizes 
epigenetically down-regulated genes, but also identifies proto-oncogenes that may be 
inappropriately expressed in t(4;11)- and t(11;19)-positive MLL-rearranged ALL in infants. 
Obviously, such genes represent yet another set of candidate target genes for future 
therapeutic intervention. 
Of main therapeutic interest is our finding that the degree of DNA methylation among 
t(4;11)- and t(11;19)-positive infant ALL patients is related to relapse-free survival, with 
patients presumably carrying heavily methylated genomes being at an increased risk 
of relapse. Therefore, these children in particular should be considered candidates for 
therapies including inhibitors of DNA methylation, especially since we here show that MLL-
rearranged ALL cells are highly sensitive to zebularine in vitro. The authors believe that 
this increased sensitivity to demethylation is rather based on the presence of a general 
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methylator phenotype (i.e. globally deregulated DNA methylation) than on the actual 
re-expresssion of a fixed number of hypermethylated genes. Apparently, genome-wide 
demethylation is sufficient to cause MLL-rearranged ALL cells to undergo apoptosis. This 
is in concordance with the identification of a heavily and a lightly methylated subgroup 
of MLL-rearranged infant ALL, which is also based on a widespread phenotype with more 
or less pronounced levels of DNA methylation that are in fact not visible at the gene-
expression level. In conclusion, the findings presented here urgently require gene per 
gene validation studies and mandate additional studies using demethylating agents 
in the currently only available genuine mouse model for MLL-rearranged ALL, recently 
described by Krivtsov et al.37
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supplemental results
Exclusion of non–leukemia-related epigenetic differences between subtypes of 
infant ALL
To test whether non–leukemia-related epigenetic differences were present among the 
sample population that may compromise our findings, we performed several comparisons 
deducting this possibility. Since leukemic samples were either obtained as peripheral 
blood or as bone marrow, we first compared DNA methylation patterns in bone marrow 
samples with samples derived from peripheral blood. No significant differences in 
promoter CpG island methylation were observed. From this, we concluded that samples 
of both sources could legitimately be used together in our analyses. 
Next, and similarly, sex differences were assessed. A female predominance (62% vs. 
38%) was identified among the MLL-rearranged infant ALL subgroups, whereas a male 
predominance (61% vs. 39%) was present in the translocation-negative (wild-type MLL) 
infant ALL group. 176 probes were differentially methylated between male and female 
patients (FDR<0.01) according to the Agilent microarray platform (Tables S7 and S8). 
The 121 probes corresponding to 75 genes, hypermethylated in females were all located 
on the X chromosome. Conversely, most of the 55 probes, corresponding to only 5 
genes hypermethylated in male individuals were located on the Y chromosome. None 
of these genes appeared to interfere with the infant ALL subtype-specific methylation 
signatures.  In general, infant ALL represents a highly immature type of 
precursor B-cell leukemia with t(4;11)- and t(11;19)-positive infant ALL most often 
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displaying the most immature phenotypes.1 We therefore investigated whether the 
identified DNA methylation profiles to some extent reflected different maturation stages of 
early B-cell development. For this, we compared samples with a pro–B-cell (CD34+, CD19+, 
(CD10−)) leukemia with the more mature pre–B-cell (CD34−, CD19+, CyIgµ+) leukemia within 
the group of samples carrying t(11;19), t(9;11) or wild-type MLL genes. Infant ALL samples 
carrying t(4;11) were excluded because they nearly all represented pro–B-cell leukemias 
and thus would strongly bias these analyses. No significant differences were found between 
pro-B and pre-B infant ALLs. 
 Finally, no significant differences in promoter CpG island methylation could be 
observed when DNA methylation patterns from infants diagnosed below 6 months of age 
were compared with those from infants diagnosed between 6 months and 1 year or age. 
 Taken together these comparisons indicate that the DNA methylation patterns 
as presented in this study represent leukemia-specific profiles that are unlikely to be 
influenced by differential CpG island methylation induced by non-leukemic factors. 
supplemental methods
Differential methylation hybridization using CpG island microarrays
Differential methylation hybridization (DMH) was performed as described by Yan et al.2 
Briefly, 0.5 ug of high-quality genomic DNA was digested using the restriction enzyme 
MseI (New England Biolabs). Next, unphosphorylated linkers were ligated to the digested 
fragments, which were then sequentially digested with two methylation-sensitive 
restriction enzymes (BstUI and HpaII, New England Biolabs). These second digestions 
eliminate unmethylated fragments, enriching the samples for methylated sequences. The 
digested linker-ligated DNA was then used as a template for polymerase chain reaction 
(PCR) amplification (20 cycles of 97°C for 1 min and 72°C for 3 min, final extension at 72°C 
for 10 min), generating methylated amplicons. Using the BioPrime Array-CGH Genomic 
Labeling kit (Invitrogen, Carlsbad, USA), amino-allyl dUTPs were incorporated into the 
amplicons, allowing the amplicons to be labeled with the fluorescent dyes Cy5 (patient 
samples) and Cy3 (common reference samples). The common reference for all samples 
was a commercially available genomic DNA pool derived from five healthy males and 
five healthy females (Promega Benelux BV, Leiden, the Netherlands). Hybridization and 
washing were performed according to DeRisi3 for the custom 9K microarray chips, and 
for the 244K microarray chips (Agilent), the Agilent ChIP-on-chip protocol version 9.0 was 
used. Hybridized slides were scanned with a 2565 AA DNA microarray scanner (Agilent 
Technologies), and the acquired images were analyzed using the GenePix Pro 6.0 software 
or the Agilent Feature Extraction 9.5.3 software. 
statistical analyses and software
Analyses of differential methylation
Differentially methylated CpG islands were identified using linear models for microarray 
data (limma).4 These models use an empirical Bayes approach to moderate the standard 
errors of the estimated standardized log-fold changes by borrowing information across 
genes. This results in more stable assumptions and enhanced power, especially when 
group sizes are small.5
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Permutation testing
As a measure of internal validation for the subtype-specific methylation signatures, 
permutation testing (global test) 6 was applied to evaluate whether genes were significantly 
associated with a certain type of MLL translocation. Therefore the tendency of repeated re-
assignment of individual samples to their original cluster was assessed. As a default 10.000 
permutations were used to calculate p-values. 
Gene expression
Gene expression values were calculated using Affymetrix Microarray Analysis Suite® (MAS) 
5.0.2 software. Unscaled expression signals were normalized using variance stabilization 
and normalization (vsn).7
Risk stratification according to the INTERFANT-06 treatment protocol
For the one-step Cox model patients were stratified as high-risk when aged <6 months (183 
days) and displaying white blood cell counts (WBC) >300 × 109/L at diagnosis. Alternatively, 
patients were classified as medium-risk when aged >6 months at presentation, or aged <6 
months with WBC <300 × 109 / L. 
(Statistical) software
We used the statistical environment R (R Development Core Team, 2007) version 
2.6.1 for the microarray analyses, including packages limma,4 global test,6 and 
vsn.7 Heatmaps were generated in GenePattern version 3.1.1 (Broad Institute, 
MIT, http://genepattern.broad.mit.edu), and PCA plots were produced using 
Genemath XT 1.6.1. software (Applied Maths, Inc., Austin TX, USA). SPSS 16.0 




supplementary Figure s1 - Heatmaps showing the top 20 most significantly hypermethylated probes for 
each infant ALL subtype (compared with the other subgroups). Additionally, normal bone marrow samples 
were added to the heatmaps. Columns represent patient samples and rows represent genes. Relative DNA 
methylation levels are then shown in red (high) and blue (low). Genes and samples were ordered using 
hierarchical cluster analysis (Euclidean distance, complete linkage) and gene identifiers are listed at the right. 
Samples are color-coded to indicate the genetic subtype of infant ALL: t(4;11) (red), t(11;19) (orange), t(9;11) 
(yellow), infant ALL with wild-type MLL genes (green) and normal bone marrow (blue). 1-1. Data are shown 
for the 9K chip and 1-2. the 244K chip (Agilent). Due to restricted availability of patient material, Agilent 
DNA methylation profiles were generated for 49 infant ALL patients (t(4;11)-positive (n=16), t(11;19)-positive 
(n=15), t(9;11)-positive (n=6), and MLL wild-type (n=12)) and 7 normal bone marrows. The 20 most significantly 
hypermethylated genes shared by t(9;11)-positive and wild-type MLL samples were also methylated in normal 
bone marrow samples, implying that these genes are normally methylated in healthy hematopoietic cells.
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supplementary Figure s2 - Semi-quantitative representation of the degree of methylation. Visualization of the 
normalized and sorted log-ratios (patient signal divided by common reference signal) of methylation (Y-axis) for 
the most significantly hypermethylated genes (X-axis) in A. t(4;11) and B. t(11;19)-positive infant ALL patients. 
Different patient groups represent either heavily or lightly methylated clusters (figure 3). C.  Visualization of the 
normalized and sorted log-ratios of methylation for all significantly hypermethylated genes in t(4;11)-positive 
infant ALL patients, compared with normal bone marrow samples. These data demonstrate that the observed 
separation of two patient groups with varying degrees of methylation as observed among both t(4;11) and 
t(11;19)- positive infant ALL, is not restricted to the most significantly methylated genes. As shown here, these 
differences remain present when all hypermethylated probes (n=794) are used for t(4;11) positive patients.
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supplementary Figure s3 - Relapse-free survival in t(4;11)-positive and t(11;19)-positive infant ALL patients 
divided by the degree of DNA methylation (figure 2S), based on hierarchical clustering as shown in figure 3. 
t(4;11)-positive and t(11;19)-positive patients were combined. Risk of relapse is presented on the Y-axis and 
the time of follow-up (in years) is presented on the X-axis. The p-value is from a log-rank test. Risk of relapse is 
significantly increased in the heavily methylated subgroup of infant ALL.
supplementary table s1. Patient characteristics. Available at: http://bloodjournal.hematologylibrary.org/
content/114/27/5490/suppl/DC1
supplementary table s2  - The top 20 of genes most significantly hypermethylated in each genetic subtype 
of infant ALL (compared with the other subgroups) are listed in order of decreasing statistical significance. Data 
are shown for the 9K CpG island microarray chip. The Gene ID, Gene Name, log- fold change (logFC), p-value, 
and p–value adjusted for multiple testing (adj.P.Val) are listed (limma analyses). Results of permutation testing 
are added for each subgroup (global test). This 9K chip is a custom spotted microarray, therefore no official 
probe IDs are included. Available at: http://bloodjournal.hematologylibrary.org/content/114/27/5490/suppl/
DC1
supplementary table s3 - The top 20 of genes most significantly hypermethylated in each genetic subtype 
of infant ALL (compared with the other subgroups) are listed in order of decreasing statistical significance. 
Data are shown for the 244K CpG island microarray chip. The probe ID (Agilent ProbeName), Entrez Gene ID, 
Gene Name, log- fold change (logFC), p–value, and  p–value adjusted for multiple testing (adj.P.Val) are shown 
(limma analyses). Results of permutation testing are added for each subgroup (global test). Available at: http://
bloodjournal.hematologylibrary.org/content/114/27/5490/suppl/DC1
supplementary table s4.  The top 100 of genes most significantly hypermethylated in t(4;11)-positive 
infant ALL (compared with normal bone marrow) are listed in order of decreasing statistical significance. The 
probe ID (Agilent ProbeName), Entrez Gene ID, Gene Name, log- fold change (logFC), p–value, and  p–value 
adjusted for multiple testing (adj.P.Val) are shown (limma analyses). The corresponding Affymetrix probe ID 
from the gene expression platform (Affymetrix ProbeName) is added for these genes as well as the adjusted 
p-value for differential gene expression (adj.P.Val expression) (limma model). Available at: http://bloodjournal.
hematologylibrary.org/content/114/27/5490/suppl/DC1
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coNclUDiNG remArKs AND FUtUre PersPectives
DNA methylation profiling: different techniques, different targets
The past decade has seen major advances in the methods for detecting DNA methylation 
on a genome-wide level. Enzyme-based (e.g., HELP1, MMASS2, DMH3 and CHARM4) and 
chromatin immunoprecipitation methods5 are most commonly used in combination with 
custom or commercial CpG island or promoter microarrays. Recently, captured methylated 
DNA6 and bisulfite-converted reduced representations7 were analyzed using high-
throughput sequencing strategies. Although bisulfite-converted reduced representation 
still relies on restriction enzymes, the combination of antibody-mediated pull-down 
techniques with sequencing (ChIP-seq) does not. Combining restriction site-independent 
techniques with high-throughput sequencing can help to approach a true genome-wide 
analysis of the methylome. However, these ChIP-seq analyses are not without a bias. An 
over-representation of high CpG content by these techniques can lead to a false negative 
result of less dense CpG-rich loci. Interestingly, studies using the enzyme-based technique 
CHARM have shown that conserved regions up to 2 kb from the promoter (CpG island 
shores) undergo more cancer-related differential methylation than traditional promoter 
CpG islands do8. Additionally, ChIP-on-chip experiments have shown that CpG islands of 
lower density (intermediate-CpG islands) also undergo more cancer-related differential 
methylation9. Because differential methylation of these regions is tightly correlated to 
altered gene expression, the importance of these regions might have been underestimated 
in previous studies. These findings highlight another bias in microarray methodology for 
detecting DNA methylation. Following the general focus on promoter CpG island regions, 
the use of arrays that contain only such sites has led to the aforementioned interesting sites 
being ignored. 
The DMH method was used in chapters 2, 4 and 5. This technique -particularly in 
combination with the home-spotted 8.5 k array (chapter 2)- can be regarded as a low-
resolution approach in comparison with ChIP-seq or set-ups using arrays that contain larger 
genomic coverage. Despite the low genomic representation on the 8.5-k home-spotted 
microarray, the represented loci were experimentally selected based on their ability to 
be methylated in vitro10, 11. Moreover, pre-selection fragmentation was performed using 
MseI. Because the MseI recognition site rarely occurs in GC-rich regions, this pre-digestion 
leaves intact most of the low- to high-density CpG island fragments. These aspects of our 
experimental set-up allowed the identification of colon tumor-specific methylation of 
the PTPRGint1 locus in chapter 2. Additionally, in chapters 4 and 5, we used the DMH 
method in combination with a commercial 244-k oligonucleotide microarray platform 
containing broader coverage of the genome. This increase in resolution allowed us to 
identify BRAF mutation-specific promoter methylation of SMO and FOXD3 (chapter 4) and 
MLL translocation-specific patterns of DNA methylation (chapter 5). 
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DNA methylation and early detection of colon cancer
chapter 2 described the colon tumor-specific methylation of a low CG-dense CpG island 
that is located in the first intron of the PTPRG gene (PTPRGint1). No direct biological 
implication of PTPRGint1 methylation on colon tumorigenesis could be given in this thesis 
despite a loss of CTCF binding to the region. However, in sporadic colon lesions ranging 
from early adenomas to carcinomas, high levels of PTPRGint1 methylation were observed 
(chapter 2). In addition, Lynch syndrome-associated colon lesions contained similar high 
levels of PTPRGint1 methylation (chapter 2).
As mentioned in the Introduction, early detection greatly increases the survival rate 
for patients with colorectal cancer. Given the long asymptomatic preclinical phase, 
population screening of the general public would greatly increase the early detection rate 
of sporadic colorectal cancer. The available screening tests that are most commonly used 
for the detection of colorectal cancer include colonoscopy and fecal occult blood tests. 
Although colonoscopy is a highly sensitive method, its high costs, invasiveness and risk of 
complications such as bowel perforation make it less applicable for screening the general 
population. However, it remains a valuable method for screening high-risk patients in 
Europe and other views on colonoscopy use pervade in the US. Fecal occult blood testing 
is relatively simple, and although it has low predictive value, several randomized trials12 
have shown a decrease in the mortality rate of colorectal cancer patients by up to 25%. 
According to published reports, tests using epi- and genetic biomarkers for screening 
serum and feces promise to hold high value in the development of accurate, non-invasive 
screening methods13, 14.
To date, a number of DNA methylation markers have been tested in both stool and serum 
samples (for an overview, see Table 2). The addition of even more specific and sensitive 
markers -and a combination of these markers- will provide a screening method that is more 
accurate, more cost effective and more comfortable than current screening methods. The 
possible addition of the PTPRGint1 locus to the current list of stool and/or serum markers will 
depend on the successful adaption of the locus to an applicable method for such testing. 
Currently, the use of (quantitative) methylation-specific PCR protocols is predominantly 
reported in the literature.
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ALX481 Stool 25/30 (83%) 16/52 (30%)
CDH482 Peripheral blood 32/46 (70%) 0/17(0%)
CDKN2A/p1683 Stool Adenomas 9/29 (31%) 3/19 (16%)
CDKN2A/p1684 Serum 12/17 (71%) 0/10(0%)
GATA485 Stool 20/28 (71%)
Cohort 2: 24/47 (51%)
7/45 (16%)
2/30 (7%)
HIC186 Stool 11/26 (42%)
Adenomas 4/13 (31%)
Hyperplastic polyps 0/9 (0%)
1/32 (3%)
HLTF87 Serum 16/49 (32.7%) 3/41(7%)
HLTF88 Serum 22/103(21%) 0/20(0%)
ITGA489 Stool 9/13(69%) 6/28(21%)
MGMT83 Stool Adenomas 14/29 (48%) 5/18 (27%)
MLH190 Peripheral blood 35/262 (13.4%)
MLH187 Serum 19/49 (39%) 1/41 (2%)
NDRG491 Stool 17/28 (61%)
Cohort 2: 25/47 (53%)
7/45 (16%)
0/30 (0%)
NGFR92 Plasma 68/133 (51%) 29/179 (16%)
OSMR93 Stool 26/69 (38%) 4/81 (5%)
PGR94 Stool 18/23 (78%) 8/26 (31%)
RUNX384 Serum 11/17 (65%) 0/10 (0%)
SEPT992 Plasma 92/133 (69%) 25/179 (14%)
SFRP294 Stool 19/23 (83%) 6/26 (26%)
SFRP594 Stool 18/23 (78%) 9/26 (35%)
TPEF/HPP192 Plasma 87/133 (65%) 56/179 (31%)
TPEF/HPP188 Serum 13/103 (13%) 0/20 (0%)
Vimentin95 Stool 43/94 (46%) 20/198 (10%)
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ctcF binding regulation by PTPRGint1 methylation
The methylation status of PTPRGint1 was not found to have a direct effect on the 
transcription level of the PTPRG gene (chapter 2). However, the annotation of PTPRGint1 
as a CTCF-binding locus suggests possible downstream effects on transcription and 
chromatin modifications through the varied functions of CTCF (chapter 2). Recently, an 
electrophoretic mobility shift assay was performed on the PTPRGint1 locus and validated 
this region as a methylation-dependent CTCF binding region (Barry Pepers, Leiden 
University Medical Center, personal communication).
The binding of CTCF to a region confers protection against DNA methylation; CTCF 
remains associated with specific chromosomal regions during mitosis, thereby suggesting 
a possible role in the maintenance of epigenetic marks throughout cell division15-18. 
Aberrant methylation of CTCF binding sites such as the ones that are associated with ARF19, 
20, Rb21, BRCA122, 23, p16,24 RASSF124 and CDH124 result in the spreading of DNA methylation 
to the promoters of these genes, as implicated previously in human cancers. CTCF can 
directly protect the binding sequence against DNA methylation; inhibition of CTCF 
binding -and consequently, its insulator function- putatively results in a boundary loss 
between euchromatin and heterochromatin with sequential spreading of inactivating 
epigenetic marks (Figure 8)24-26. 
In humans, the CTCF gene maps to the cancer-associated chromosomal locus 16q22.1 
(Ref. 27), which is a region that is often lost in primary breast carcinomas28-30, prostate 
adenocarcinomas31, ovarian cancer32 and Wilms’ tumors33. However, the biallelic loss 
of CTCF expression is not observed in human cancers. CTCF null mice exhibit early 
embryonic lethality; conditional knock-down of CTCF in cultured fibroblasts rapidly leads 
to apoptosis34, 35, thereby suggesting that a loss of CTCF is incompatible with cell survival. 
However, tumor-specific mutations in the third and seventh zinc fingers of the CTCF 11-
zinc finger coding domain have been found in breast, prostate and Wilms’ tumors36. All 
of the identified mutations were accompanied by the loss of the second CTCF allele and 
resulted in a missense codon at a position that is predicted to be critical for either zinc 
finger formation or DNA sequence recognition36. CTCF can use various combinations 
of zinc fingers to bind to a wide range of DNA sequences and proteins. Theoretically, 
the mutations that were identified in CTCF could confer a differential loss of binding to 
specific DNA recognition sites and/or proteins.
Such a model wherein specific CTCF functions are affected without interfering with other 
CTCF functions that are essential for cell viability is potentially interesting. However, 
mutations in CTCF are extremely rare and cannot account for the wide-scale DNA 
methylation differences that are observed in cancers33, 35-37. An alteration in the protein 
partners that CTCF requires to perform one or more of its many functions is an alternative 
explanation.
Although the spreading of heterochromatin marks can be a consequence of a loss of 
CTCF binding, evidence for the sequential progression between CTCF binding and 
DNA methylation of its own binding site remains elusive. Given that CTCF binding to a 
CpG-containing binding site has been shown to be sensitive to methylation, whether 
methylation of the CTCF binding site is caused by a loss of CTCF binding or whether 
aberrant methylation precedes CTCF binding loss remains an open question. 
Before tackling these important fundamental questions, the impact of losing CTCF 
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binding after methylation of the PTPRGint1 region must first be investigated. Mapping of 
CTCF binding sites in normal colon epithelium would serve as an essential validation of 
the region as a colon-specific CTCF binding site, as the PTPRGint1 region has only been 
described as such in a cell line model system (chapter 2). Applying the chromosome 
conformation capture technique to both normal colon epithelium and colon cancers with 
PTPRGint1 methylation might reveal putative differences in chromatin loop formation. 
An analysis of DNA/histone modifications, Lamina-associated domains and transcription 
changes with respect to these putative chromatin loop formation alterations might provide 
a clear view of the consequences of PTPRGint1 methylation. However, apart from assessing 
DNA methylation and mRNA levels, the aforementioned analyses are difficult to perform 
on tissues other than cultured cells due to the high numbers of cells that are required.
Figure 8 – Heterochromatin spreading caused by disassociation of CTCF binding. Upper panel: normal CTCF 
protein (pink) binding demarcates the boundaries between heterochromatin (green line) and euchromatin 
(light blue line). Middle panel: disassociation of CTCF protein (pink) binding causes spreading of lamina-
associated heterochromatic marks. Lower panel: spreading of non-lamina-associated heterochromatic marks 
by the regional loss of CTCF binding. Figure adapted from de Wit et al.25.
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Aberrant histone modification machinery: initiation of cancer 
specific DNA methylation?
In support of a direct link between histone modifications and DNA methylation, H3K4 
methylation was found to protect against DNA methylation38. In addition, binding of 
the PRC2 member EZH2 to a region recruits DNMTs39. Evidence for a developmental 
model (see Figure 4 in the General Introduction) resulted from the discovery that 
polycomb-mediated H3K27 methylation in ES cells pre-marks genes for de novo DNA 
methylation in colon cancer40-45. In this model, the balance between mediator binding of 
inactivating (Polycomb Repressive Complex 2 ; PRC2) and activating histone (Trithorax-
group ; TrxG) marks dictate the downstream DNA methylation and expression states of 
chromosomal regions (see Figure 4 in the General Introduction). This balance between 
the antagonistic histone modifications is most pronounced in ES cells in which almost all 
H3K27me3 bound promoters are bivalent46, 47. The loss of this bivalent binding in both adult 
differentiated colon tissue and colon cancer supports the conventional view that such 
histone modifications act as ‘plastic’ epigenetic switches for transcription and de novo 
methylation during development40-45. In this hypothesis, DNA methylation serves as a 
definitive epigenetic lock that is preceded by histone modifications and their associated 
machinery. 
Recent studies have reported a possible pre-marking of cancer-specific hypermethylated 
genes by H3K27me3 and binding of the PRC2 member SUZ12 in both ES cells and 
differentiated normal colon mucosa42-44. The presence of repressive histone modifications 
at promoters in normal colon epithelium suggests that the associated genes are in a 
transcriptionally silent state prior to tumor formation, thereby reducing the relevance of 
their promoter’s methylation on expression and thus tumorigenesis. To focus on genes 
that are silenced by tumor-specific promoter methylation (rather than lineage-specific 
methylation), we excluded from our analysis in Chapter 4 the loci with H3K27me3 in 
embryonic stem (ES) cells.
In model systems, abnormal TrxG or PRC2 function often results in aberrant gene 
expression that leads to tumor development, which suggests that dysregulation of these 
epigenetic programs can initiate tumorigenesis39, 48-50. Although there is no evidence 
of alterations in the balance between TrxG proteins and PRC2 in colon cancer, such an 
alteration exists in infant B-ALL. In Chapter 5, we described the translocation-based 
grouping of DNA methylation patterns from MLL-rearranged B-ALL patients. Although 
patients who contain the translocation t(4;11) or t(11;19) have comparable high levels of 
DNA methylation, patients with a t(9;11) translocation have DNA methylation patterns 
that are comparable to normal controls and B-ALL patients without MLL mutations. As 
the histone methyltransferase moiety of one copy of MLL is lost in all three translocation 
subtypes, their differing DNA methylation levels suggest that this loss has minimal impact 
on DNA methylation. In addition, 90% of all genes that are expressed in t(4;11) rearranged 
leukemia cells contain the H3K4me3 modification51. Therefore, perturbation of MLL H3K4 
methyltransferase activity by the alteration of one copy of MLL also has a low impact on 
H3K4 methylation levels52. Finally, recent studies have shown that a loss of the normal 
H3K4 histone methyltransferase activity in one copy of MLL is not sufficient to initiate 
leukemia53, 54. It is therefore likely that the combined functions of the reciprocal fusion 
partners facilitate both aberrant DNA methylation and tumorigenesis in infant B-ALL54, 55. 
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The fusion protein that results from the aforementioned translocations is a combination of 
a C-terminal transcriptional activation domain provided by the fusion partner (AF4, AF9 or 
ENL) fused with the DNA binding N terminus of MLL. Recruitment of DOT1L and sequential 
H3K79 methylation to regions that are bound by N-terminal MLL is contributed to these 
fusion proteins51, 52, 56-59. This addition of H3K79me -a modification that is associated with 
transcription elongation- could explain the high expression of MLL target genes that are 
associated with leukemogenesis such as MEIS1 and HOXA951, 52, 58. Co-occupancy of both 
the germline MLL protein and the MLL fusion protein could provide both the activating 
H3K4me3 histone mark and the transcription elongation mark H3K79me. The combination 
of both histone modifications might be sufficient to enable such aberrant high expression 
(Figure 9). However, the effect of the fusion proteins on the DNA hypermethylation that has 
been observed in infant B-ALL patients with t(4;11) and t(11;19) translocations (Chapter 5) 
remains unknown. 
Recent studies have shown that unlike the MLL-AF4 fusion protein, the t(4;11) reciprocal 
fusion protein AF4-MLL, which consists of N-terminal AF4 and C-terminal MLL, is sufficient 
to induce leukemogenesis in mouse models53. The N-terminal domain of AF4 has been 
suggested to retain its ability to bind RNA polymerase II while losing the ability to recruit 
DOT1L. However, the downstream effects of this reciprocal translocation protein and its 
importance in leukemogenesis warrant further investigation.
Our future understanding of the full impact of MLL rearrangements on histone modifications 
and their role in aberrant DNA methylation will require multi-dimensional studies that 
combine histone modification, DNA methylation, insulator binding, transcription and MLL 
fusion protein binding data. The involvement of the TrxG member MLL supports a direct 
link to the disrupted balance between the antagonistic histone modifiers PRC2 and TrxG in 
infant B-ALL. However, down-regulation of MLL histone-methyltransferase activity has little 
effect on H3K4 methylation levels52. Complete mapping of DNA and histone modifications 
-combined with transcription data from the various stages in hematopoiesis and MLL-
rearranged leukemogenesis- will provide a clearer understanding of the true identity of 
the oncogenic drivers. The identification of translocation-specific MLL binding sites might 
provide additional insight into the differences in DNA methylation that have been observed 
between infant B-ALL patients who harbor different types of translocations (Chapter 5). 
A sequential model for colon differentiation and tumorigenesis would provide similar insights 
and could reveal possible links between aberrant DNA methylation, histone modification and 
their modifier complexes. Linking this data to transcription and insulator binding data should 
help expand our understanding of the role of DNA methylation in the etiology of colon cancer. 
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Co-occupancy of germline MLL 
and the MLL fusion protein
Direct DOT1L 
recruitment
Loss of PCR2 binding and H3K27 
methylation
DOT1L recruitment
Loss of PCR2 binding and H3K27 
methylation
Normal activation of gene expression Aberrant activation of gene expression 
by co-occupancy
Figure 9 – Progression model showing normal and aberrant recruitment of the H3K79 histone 
methyltransferase DOT1L. Co-occupancy of both the unaffected MLL (red crescent) as well as the MLL fusion 
protein (large red crescent with gray stripes) recruits DOT1L (grey crescent). This direct recruitment of DOT1L 
and its histone (H3K79) mark (orange) for transcription elongation can aberrantly activate gene expression 
by circumventing the sequential progression and balance between the TrxG/MLL, PRC2 (yellow crescent) 
proteins and associated histone marks (H3K4 methylation in purple and H3K27 methylation in green).
the trxG family and BrAF, is there a connection?
The aforementioned enrichment of PRC2 components and H3K27me3 in targets for colon 
cancer-specific DNA methylation suggests a possible dysregulation of the balance 
between TrxG and PRC2 during colon tissue differentiation (chapter 4). Although this 
balance is perturbed by deregulation of the TrxG protein MLL in MLL-rearranged ALL, 
such an association has not been described in colon cancer. One study described a direct 
link between colon cancer and dysregulation of TrxG in both colon cancer cell lines 
and tumors. The TrxG member MLL2 was found to be overexpressed in colon tumors 
compared to corresponding adjacent tissue60. In addition, colon cancer cell lines that 
were derived from highly invasive, poorly differentiated tumors exhibited altered sub-
cellular distribution and proteolytic processing of MLL2 compared to non-tumor cell lines 
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and less invasive tumor cell lines60. In contrast to increased MLL2 expression, the altered 
sub-cellular distribution and proteolytic processing indicate a decrease in normal MLL2 
activity. Although the relationship between CIMP and MLL2 has not been investigated, 
CIMP is known to be associated with poor differentiation, thus indicating a possible 
association between CIMP and the proteolytic dysregulation or sub-cellular distribution 
of MLL2. Unfortunately, no distinction of CIMP, MSI or BRAF mutational status was made in 
the study in relation to the overexpression of MLL2 in colon tumors and cell lines. Grouping 
these factors would provide a clearer insight into the role of MLL2 in the etiology of tumors 
with aberrant DNA methylation. Interestingly, in chapter 4 we described an association 
of colon cancer DNA methylation with H3K27me3 targets in ES cells and showed that this 
enrichment is less pronounced in CIMP- and BRAF-associated DNA methylation.
An association between BRAF mutations and CIMP colon cancer has been documented61 
and was also described in chapter 3 for colon cancer patients up to 50 years of age. CIMP 
colon cancer with BRAF mutations and MSI may originate from sessile serrated polyps 
through a unique pathway. While BRAF mutations are present in sessile serrated polyps and 
serrated aberrant crypt foci, KRAS mutations are more closely associated with non-serrated 
polyps and non-serrated aberrant crypt foci62-67. Interestingly, 90% of all aberrant crypt foci 
with BRAF mutations were found to be microsatellite-stable , whereas ~70% of sporadic 
MSI colon cancers exhibit BRAF mutations. These observations led to the suggestion that 
BRAF mutations precede MLH1 methylation and that mutationally active BRAF might play 
an initiating role in the manifestation of aberrant DNA methylation in colon cancer62-64, 68-70. 
Although no direct interactions between members of the RAS-RAF pathway and either the 
TrxG, PRC2 or DNMT family have been described, the downstream transcription factors 
that are activated by the RAS-RAF pathway protein MAPK (for example, c-Fos, CREB and 
c-MYC) interact with DNMT3A and DNMT3B71. Additionally, it was shown that inhibiting the 
ERK/MAPK signaling pathway decreases the genomic DNA methylation content in cancer 
cells72. KRAS and BRAF are directly linked in the same pathway but associate differently 
with CIMP in colon cancer. Therefore, interactions between these shared transcription 
factors and the DNA methylation machinery should be investigated further. An alternate 
hypothesis regarding the association between BRAF mutations and DNA methylation 
suggests that promoter methylation and silencing of specific target genes could favor the 
selection of activating BRAF mutations. This hypothesis has been suggested for IGFBP7, a 
mediator of BRAF-induced cellular senescence73-75. Promoter methylation and the down-
regulation of IGFBP7 could provide a favorable context in which to obtain an activating 
BRAF mutation73-75. In chapter 4, we showed BRAF mutation-specific promoter methylation 
of FOXD3 after stringent filtering for pre-marking and copy number changes. FOXD3 is 
a mediator of p21Cip1- and p53-dependent cell cycle arrest, which is down-regulated by 
constitutively active BRAF in melanoma cells76. These findings suggest that FOXD3 might 
play a role in eluding BRAF-induced senescence in colon cancer through epigenetic 
inactivation. The augmented proliferation and high levels of senescence that are induced 
by constitutively active BRAF could favor the selection of cells that can escape senescence 
by the epigenetic inactivation of mediators, which might explain the link between BRAF 
mutations and aberrant DNA methylation in colon cancer.
In chapter 3, we described site-specific methylation of the MLH1 promoter in sporadic 
colon cancer patients with an age of diagnosis below 50 years, despite low levels of 
global methylation. In contrast, patients with a BRAF mutation who were either below 
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or above 50 years of age at diagnosis have significantly higher levels of CIMP marker 
methylation. The aforementioned BRAF mutation-driven selection for cells that can escape 
senescence suggests an accumulation of promoter methylation that ultimately results 
in MMR deficiency and/or escape from BRAF-induced senescence. Future studies of the 
interactions of activated RAS-RAF pathway proteins with histone and DNA modification 
machineries should yield a clearer understanding of the roles of KRAS and BRAF in the 
initiation of aberrant DNA methylation. The suggested interaction between RAS-RAF 
activated transcription factors and DNMT3A and DNMT3B in targeting specific promoter 
loci71 is particularly interesting. Identifying differential RAS-RAF-associated transcription 
factor binding sites in BRAF and KRAS mutated cancer models might point towards specific 
mediators of BRAF-initiated DNA methylation. However, the mechanisms that underlie the 
observed site-specific MLH1 promoter methylation in BRAF wild-type patients have been 
elusive. Polymorphisms such as the MLH1 -93G>A polymorphism that was discussed in 
chapter 3, when present in such a transcription factor binding site and thereby putatively 
altering binding, could provide an additional factor in site-specific DNA methylation.
The observation that promoter methylation of the Methylguanine-DNA methyltransferase 
(MGMT) gene can give rise to mutations in KRAS and the tumor suppressor gene TP5377 
is somewhat contradictory. A loss of MGMT expression can result in a G-to-A transition in 
TP53 and codons 12 and 13 of the KRAS gene78-81. These findings argue against a role for the 
RAS-RAF pathway in initiating aberrant DNA methylation; elucidating the precise cascade 
of events is required to determine the function of RAS-RAF pathway in this process. 
The role of epigenetics in the initiation of colon cancer and its association with KRAS and 
BRAF mutations is complex and requires additional research to unravel the molecular 
mechanisms that are involved. Although links between mutations in the RAS-RAF pathway 
and the DNA methylation machinery have been reported68, 71, these links are indirect. In 
addition, cellular model systems with constitutively active BRAF fail to induce CIMP73. 
Selective pressure on neoplastic cells that carry KRAS or BRAF mutations for the epigenetic 
inactivation of certain genes might be a more plausible explanation for the associations 
between the mutations and the increased levels of promoter DNA methylation in colon 
cancer. The absence of BRAF mutations and the relatively low levels of methylation that 
are observed in Lynch syndrome patients82, young sporadic colon cancer patients with 
site-specific MLH1 methylation and colon cancer patients with germline MLH1 methylation 
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The aim of the research that is described in this thesis was to identify DNA methylation 
that is specific to colon cancer and infant B cell acute lymphoblastic leukemia (B-ALL). To 
obtain these data, the differential methylation hybridization (DMH) technique was used. 
In addition, the association between DNA mutations and high levels of cancer-specific 
methylation was explored. 
chapter 1 provides a general introduction to epigenetics. The complex interplay 
between the various aspects of DNA methylation, histone modification, nuclear position 
and chromatin condensation is described. In cancer, aberrant hypomethylation of the 
genome is accompanied by regional hypermethylation of dense CpG dinucleotide clusters 
called CpG islands (CGIs). Hypermethylation of promoter CGIs can lead to transcriptional 
inactivation of the associated gene. This form of epigenetic down-regulation occurs for 
numerous tumor-suppressor genes in various types of cancer. In this study, the following 
two types of cancer that undergo cancer-specific DNA methylation changes were 
investigated: colorectal cancer (CRC) and infant acute lymphoblastic leukemia (ALL) with 
rearrangements involving the mixed-lineage leukemia (MLL) gene.
 
chapter 1 also provides a brief overview of CRC tumorigenesis. CRC is the third-most 
common type of cancer in males and the second-most common in females. The lifetime 
risk for developing CRC for both men and women is 6%, representing approximately one 
in 17 individuals within the Netherlands. CRC is one of the leading causes of cancer-related 
deaths in both Europe and the United States. Approximately half of all CRC patients develop 
either a localized recurrence or a distant metastasis during the course of their illness, and 
this dramatically decreases their chance of survival. Therefore, the ability to detect and treat 
CRC before metastasis occurs is extremely important. A recent decrease in the numbers 
of new CRC cases and reported deaths has been observed in developed countries, and 
this is possibly due to improved screening and a consequent increase in early diagnosis. 
chapter 1 also describes the various paths of CRC tumorigenesis and discusses how DNA 
methylation might affect these pathways. 
The second type of cancer that was studied with respect to DNA methylation is infant 
ALL. Infant patients (i.e., up to one year of age at diagnosis) with MLL-rearranged ALL only 
achieve a 5-year survival rate of approximately 50%. Approximately 80% of infants with ALL 
carry chromosomal translocations that involve the MLL gene, and these patients typically 
display an immature CD10-negative precursor B-lineage immunophenotype. The MLL 
gene is ubiquitously expressed both during development and in most adult tissues, and its 
expression is required for definitive hematopoiesis. chapter 1 provides both a brief general 
overview of infant ALL and the specific molecular implications of MLL rearrangements in 
ALL leukemogenesis. 
 
In chapter 2, the differential methylation hybridization (DMH) technique was used 
in combination with home-spotted arrays to measure DNA methylation in a set of 18 
right-sided colon tumor samples. The DMH technique uses three rounds of restriction 
enzyme digestion of genomic DNA as follows: the first round shears the DNA into CpG-







rich fragments, followed by two methylation-sensitive digestions. These three digestion 
rounds generate fragments that -upon amplification- can be hybridized to a microarray 
that contains DNA probes of interest. The microarrays that were used in this chapter were 
home-spotted arrays that were based on a CpG island clone library that was originally 
generated at the Sanger Centre from affinity-purified in vitro methylated DNA fragments. 
In this initial setup, we identified colon cancer-specific methylation of a CpG island in the 
first intron of the PTPRG gene (PTPRGint1). This methylation pattern on PTPRGint1 was 
confirmed by methylation-specific multiplex ligation-dependent probe amplification (MS-
MLPA) in a larger cohort consisting of the following samples: 18 sporadic adenomas, 67 
sporadic carcinomas, 63 Lynch syndrome-associated carcinomas and 119 corresponding 
normal colon tissue samples. High sensitivity (methylated tumor/total tumors) and 
high specificity (unmethylated normal/total normal samples) for colorectal cancer 
was observed during the assessment of PTPRGint1 methylation, which prompted us to 
propose the incorporation of this region into new and existing colon cancer screening 
panels. 
Methylation of PTPRGint1 did not influence the expression of the PTPRG gene. However, 
we found that the PTPRGint1 region is located in a CTCF binding site. CTCF has been linked 
to many nuclear mechanisms, including transcriptional regulation, insulation, chromatin 
condensation and chromosomal loop formation. DNA methylation had a negative effect 
on the binding of CTCF to this region, which suggests that PTPRGint1 methylation could 
alter chromatin density and/or conformation. Such changes in chromatin state could 
affect the expression of -thus far- unknown genes, thereby affecting colon tumorigenesis. 
Methylation of the MLH1 promoter leads to microsatellite instable (MSI-H) colon cancer 
which is generally associated with a high age of onset. In chapter 3, a cohort of relatively 
young colon cancer patients (under 50 years of age at diagnosis) with sporadic MLH1 
methylation was studied. The mutational status of GADD45A, BRAF and KRAS, as well as 
the presence of the MLH1 -93G>A polymorphism and germline MLH1 methylation, were 
investigated in an attempt to identify initiating factors for the observed DNA methylation. 
Two individuals exhibited germline MLH1 methylation; however, locus-specific somatic 
MLH1 hypermethylation explained the majority of the sporadic early-onset MSI-H colon 
cancer cases in our cohort. In this study, we were unable to identify an intrinsic tendency 
towards CpG island hypermethylation other than aberrant accumulation of CpG island 
methylation via a somatic mutation of BRAF. The site-specific MLH1 promoter methylation 
observed in the early-onset MSI-H tumors hints towards an unknown targeted methylation 
mechanism other than that which is associated with BRAF mutations. This hypothesis is 
discussed further in chapter 6.
The relationship between BRAF mutations and DNA methylation was explored further in 
chapter 4, which describes an improved study of DNA methylation in BRAF mutation-
associated colon cancer. The DMH technique that was introduced in chapter 2 was 
applied to an oligonucleotide microarray platform that provided broader coverage of 
genomic CpG islands. To focus on genes that are silenced in a tumor-specific rather than 
a lineage-specific manner, we excluded regions that exhibit both colon cancer-specific 
promoter methylation and the so-called histone pre-marking in ES cells. We describe 
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BRAF mutation-specific promoter methylation of the FOX transcription factor genes FOXB1, 
FOXB2 and FOXD3 and speculate that this methylation might help these tumors escape 
BRAF-induced senescence. 
chapter 5 describes a study in which the DMH technique was combined with 
oligonucleotide microarrays that contained high CpG island coverage to determine the 
methylation patterns of infant B-ALL patients. The majority of MLL-rearranged infant ALL 
cases (i.e., those who are characterized by a t(4;11) or t(11;19) translocation) represent 
hypermethylated leukemias. In contrast, infant ALL patients with a t(9;11) translocation and 
those without any MLL translocation (wild-type MLL) displayed DNA methylation patterns 
that closely resembled the pattern seen in normal bone marrow. In addition, distinct 
leukemia-specific DNA methylation patterns were identified in MLL-rearranged infant ALL 
subtypes that were defined by the type of MLL translocation or by an absence of such 
translocations. The majority (90-95%) of the most significantly hypermethylated genes 
in the t(4;11)- and t(11;19)-positive infant ALL patients were found to be down-regulated 
as measured at the mRNA level. The high levels of methylation -and its correlation with 
expression- suggest an epigenetic block of B cell differentiation in infant ALL patients with 
a t(4;11) or t(11;19) translocation. In addition, the t(4;11)-positive B-ALL cell lines were 
significantly more sensitive than other leukemia cell lines to the demethylating agent 
zebularine. This study indicates that patients with a t(4;11) or t(11;19) translocation who 
have high levels of DNA methylation might be promising candidates for therapies that 
inhibit DNA methylation. 
chapter 6 presents concluding remarks and provides implications for the future. 
The collective data that are presented in this thesis suggest that a non-invasive DNA 
methylation-based screening method using a combination of existing and novel DNA 
methylation markers (such as PTPRGint1) might be feasible for most types of colon cancers. 
In addition, the translocation-specific DNA methylation that is described in this thesis 
creates new possibilities for the screening and treatment of aberrant DNA methylation 
in infant ALL patients with an MLL translocation. In chapter 6, we discuss the possible 
downstream effects of losing CTCF binding after methylation of the PTPRGint1 region. 
Known published examples of CTCF binding loss are discussed, and future experiments 
that aim to gain further insight into the full effects of PTPRGint1 methylation are proposed. 
     
A link between mutations other than those that occur in BRAF and aberrant DNA methylation 
in CRC was not found in this study. The associations between a constitutively active RAS-RAF 
pathway and the epigenetics that are described in the literature are discussed in chapter 
6. The interplay between BRAF mutations and the hypermethylation of the promoters of 
mediators of oncogene-induced senescence is proposed and discussed. However, the 
mechanism that underlies the accumulation of aberrant promoter methylation -as can 
occur in BRAF-mutated colon cancer- remains unknown and merits further investigation.


















Dit proefschrift beschrijft het onderzoek naar veranderingen in de systemen die de 
werkzaamheid van ons DNA reguleren. Specifiek werd de rol van de zogenaamde 
epigenetische DNA veranderingen in dikkedarmkanker en acute lymfatische leukemie 
(ALL) onderzocht. Dit laatste bij kinderen jonger dan één jaar oud bij diagnose. 
 Epigenetica is een verzamelnaam voor de verschillende mechanismen die invloed kunnen 
hebben op het tot expressie komen van onze genen zonder een directe verandering van 
de DNA code. De best bestudeerde onderdelen van de epigenetica zijn “DNA methylatie” 
en “covalente modificaties van de histonen”. 
De menselijke DNA code is samengesteld uit 4 basen: Cytosine, Guanine, Adenine en 
Thymine. Een cytosine die voorgaat aan een guanine (een CpG-dinucleotide) kan een 
methylgroep binden aan het vijfde koolstofatoom waardoor er een 5-methyl-cytosine 
ontstaat. Deze CpG-dinucleotiden zijn vrij zeldzaam in het menselijke genoom en 
worden veelal in clusters gevonden. Deze clusters worden CpG eilanden genoemd en 
liggen vlak voor ongeveer 50% van onze genen. De methylatie status van deze CpG-
dinucleotide clusters komen in veel gevallen overeen met de transcriptie activiteit van 
het geassocieerde gen waardoor deze CpG eilanden ervan worden verdacht een rol te 
spelen in de regulatie van de desbetreffende genen. Dit is het geval bij verscheidene 
genen die een associatie met kanker hebben. De twee soorten kanker die bestudeerd zijn 
in dit proefschrift laten veel DNA methylatie verschillen zien ten opzichte van het weefsel 
waaruit ze ontstaan.
 
In Hoofdstuk 1 wordt er een overzicht gegeven over dikkedarmkanker. Dikkedarmkanker 
is de, op twee na, meest voorkomende soort kanker bij mannen en, op een na, bij 
vrouwen. De kans om deze kanker te ontwikkelen is ongeveer 6%, of 1 op 17, geldend 
voor beide seksen in Nederland. Het is een van de meest voorkomende oorzaken van 
kanker-gerelateerde morbiditeit in Europa en de Verenigde Staten. Bij ongeveer de helft 
van alle dikkedarmkanker patiënten treedt er een plaatselijke terugkeer van de tumor of 
een uitzaaiing elders op hetgeen de kans op overlijden doet toenemen. Vroege detectie 
en behandeling van dikkedarmkanker en haar voorstadia zal de overlevingskans sterk 
verbeteren. Invoering van presymptomatische screening  zou hierin een belangrijke stap 
kunnen zijn. Ook het gebruik van individuele risicoprofielen kan hierin een belangrijke 
stap zijn. Te denken valt aan het herkennen van erfelijkheidsfactoren en risicovolle 
levensstijlen. De moleculaire pathogenese van dikkedarmkanker en hoe DNA methylatie 
hier een rol in speelt wordt in Hoofdstuk 1 samengevat.
De tweede soort kanker besproken in dit proefschrift is acute lymfatische leukemie bij 
kinderen onder de één jaar oud. Deze patiëntengroep heeft, ten opzichte van oudere 
kinderen met deze ziekte, een opvallend slechte 5-jaar overlevingskans, namelijk 50%. 
Bij ongeveer 80% van deze kinderen wordt de ziekte veroorzaakt door een uitwisseling 
tussen chromosomen waarbij het MLL gen (gelegen op chromosoom 11), is aangedaan. 
Dit MLL gen is actief in elke cel van ons lichaam en is vooral noodzakelijk voor de 
ontwikkeling van de bloedcellen. In Hoofdstuk 1 wordt een kort overzicht van ALL en de 




In Hoofdstuk 2 wordt de differential methylation hybridization techniek (DMH) toegepast 
op dikkedarmkanker en normaal darmweefsel. Hiermee konden de DNA methylatie 
veranderingen in dikkedarmtumoren worden bestudeerd. Deze techniek is gebaseerd op 
fragmentatie van het DNA met behulp van enzymen die het DNA op specifieke sequenties 
doorknippen (endonucleases, of restrictie enzymen). Er zijn drie ronden van digestie nodig: 
één digestie ronde om het DNA in CG-rijke fragmenten te knippen, gevolgd door twee 
rondes van methylatie-gevoelige digestie. De methylatie-gevoelige restrictie enzymen 
knippen de ongemethyleerde fragmenten kapot waardoor fragmenten met variërende 
methylatie, na hybridisatie op een DNA microarray, kunnen worden geïdentificeerd.
Met behulp van deze DMH techniek toonden we dikkedarmkanker-specifieke methylatie 
aan van een gebied in het eerste intron van het PTPRG gen (PTPRGint1). Deze specifieke 
methylatie werd ook gevonden met een tweede techniek (methylation-specific ligation-
dependent probe amplification) in een groter cohort van 18 sporadische adenomas, 67 
sporadische carcinomas, 63 Lynch syndroom geassocieerde carcinomas en 119 normaal 
darm weefsel samples. 
Methylatie van PTPRGint1 had geen invloed op de expressie van het PTPRG gen. Echter, 
PTPRGint1 bleek een zogenaamd methylatiegevoelig CTCF bindingsgebied te zijn, als 
onderdeel van een mechanisme dat de spatiële organisatie van het DNA reguleert . 
Verstoring van CTCF binding kan grote implicaties hebben op het expressie patroon door 
middel van veranderingen in de DNA lusvorming of DNA chromatine status. De methylatie 
van PTPRGint1 kan dus, tot nog toe, onbekende gevolgen hebben op de tumorigenese van 
dikkedarmkanker. 
 
Een subtype van dikkedarmkanker toont zogenaamde microsatelliet instabiliteit (MSI). 
Hierbij worden repetitieve stukken DNA sequentie (microsatellieten) korter of langer 
(instabiliteit) door defecten in het DNA mismatch repair systeem. Dit fenotype van 
dikkedarmkanker wordt gevonden in een erfelijke context (het Lynch syndroom) en in 
15 % van niet erfelijke of sporadische darmkanker. Het laatste wordt veroorzaakt door 
promotor hypermethylatie van het MLH1 gen en komt vooral voor bij oudere patiënten. 
In Hoofdstuk 3 wordt een cohort bestaande uit relatief jonge patiënten met sporadisch 
MSI dikkedarmkanker beschreven. Verscheidene genetische aberraties (GADD45A, BRAF 
en KRAS mutaties alsmede het MLH1 -93G>A polymorfisme) en kiembaan methylatie van 
MLH1 werden bestudeerd bij deze patiënten in een poging de initiërende factoren van de 
MLH1 hypermethylatie te identificeren. Kiembaan methylering werd gevonden bij twee 
patiënten. Veelal was er een relatie met het voorkomen van de activerende BRAF mutatie 
met ook hypermethylering van andere target DNA gebieden. In andere gevallen was er 
sprake van een nog onverklaarde locus-specifieke hypermethylatie van MLH1. 
 
De mogelijke relatie tussen BRAF mutaties en verhoogde DNA methylatie in kanker wordt 
verder behandeld in Hoofdstuk 4. In dit hoofdstuk wordt de DNA methylatie in BRAF 
gemuteerde dikkedarm tumoren beschreven. De DMH techniek, die ook in Hoofdstuk 2 
wordt beschreven, werd toegepast op een DNA oligonucleotide microarray platform met 
een hogere genomische CpG eiland dekking. Om ons te concentreren op DNA methylatie 
met een functionele impact op dikkedarm-tumorigenese hebben we microarray probes 
met zogenaamde “histon pre-marking” in embryonale stam cellen geëxcludeerd. Kanker-
specifieke methylatie van promotoren met deze histon pre-marking lijkt geen tot weinig 
Nederlandse samenvatting 






effect te hebben op de expressie van een geassocieerd gen. Promotor hypermethylatie 
zonder histon pre-marking werd aangetoond bij de FOX transcriptie factoren FOXB1, 
FOXB2 en FOXD3. Deze transcriptie factoren zouden een rol kunnen spelen in het blokkeren 
van BRAF gedreven oncogenese. De epigenetische uitschakeling van deze factoren zou 
een manier van de woekerende cel kunnen zijn om deze blokkade te omzeilen. 
 
Hoofdstuk 5 beschrijft het gebruik van de DMH techniek in combinatie met het DNA 
oligonucleotide microarray platform uit Hoofdstuk 4 om de methylatiepatronen van 
kinderen jonger dan een jaar oud met ALL in kaart te brengen. Een meerderheid van 
de patiënten met een MLL-translocatie,   vooral met t(4;11) en t(11;19), liet een sterke 
verhoging van CpG eiland methylatie zien. Een minderheid,   vooral met t(9;11), liet 
echter CpG eiland methylatie niveaus zien die vergelijkbaar zijn met die van normaal 
beenmerg.  Een verdere stratificatie van de patiënten op basis van hun MLL-translocatie 
leidde tot de identificatie van methylatie patronen specifiek voor deze verschillende 
translocaties. Een merendeel  (90-95%) van de gehypermethyleerde genen bij patiënten 
met een t(4;11) en t(11;19) translocatie kwamen lager tot expressie. De hoge niveaus van 
methylatie en correlatie met expressie suggereerden een epigenetische blokkade van 
B-cel differentiatie bij patiënten met een t(4;11) en t(11;19) translocatie. Cellijnen met 
t(4;11) lieten ten opzichte van leukemie cellijnen zonder deze translocatie, een verhoogde 
mate van gevoeligheid zien voor het demethylerende middel zebularine. Deze studie 
toonde aan dat jonge kinderen met ALL en een t(4;11) en t(11;19) translocatie mogelijke 
kandidaten zijn voor behandeling met DNA methylatie inhiberende therapieën.
 
Hoofdstuk 6 bevat de conclusies van dit proefschrift en beschrijft mogelijke implicaties 
voor de toekomst. In dit hoofdstuk worden verder de mogelijke gevolgen van PTPRGint1 
methylatie besproken, vooral het verlies van CTCF binding in dit gebied. Bekende gevallen 
van verlies van CTCF binding uit de literatuur alsmede de benodigde experimenten om een 
beter inzicht te krijgen in de functie van PTPRGint1 worden besproken. De in de literatuur 
beschreven associatie tussen de constante activatie van de RAS-RAF signaalcascade door 
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